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ABSTRACT
PURPOSE
To determine the distribution of vascular endothelial growth factor (VEGF) isoforms, 
angiopoietins (Ang-1 and -2) and their receptors, tumour necrosis factor alpha (TNF-a), 
pigment epithelium-derived factor (PEDF), and caveolin family members (Cav-1, -2, and -3) 
in non-diabetic retinas and diabetic retinas at different stages of diabetic retinopathy.
METHODS
Human eyes, obtained at post-mortem, were divided into those without diabetes and those 
with diabetes. Diabetic retinas were examined by microscopy and categorised as either non- 
lasered with no obvious features of retinopathy, non-lasered with intraretinal changes 
(microaneurysms, exudates etc.) but no evidence of proliferative diabetic retinopathy (PDR), 
diabetic with proliferative retinopathy, and those which had received scatter laser 
photocoagulation therapy and who no longer had evidence of PDR. Immunohistochemistry 
was used to determine the localisation of growth factors and caveolins in diabetic and control 
retinas, as well as in excised PDR membranes.
RESULTS
There appeared to be both temporal and spatial changes in the staining pattern for each 
growth factor in diabetic retina which correlated with the stage of disease progression. Apart 
from Ang-2 and PEDF, immunostaining was raised in diabetic retina as compared to non­
diabetic retina. Immunostaining was apparent in endothelial cells and the perivascular cells of 
the vessels. Immunostaining was also apparent within specific retinal layers for VEGF-A, 
VEGF-C, VEGFR’s, Ang-2, Tie-2, TNF-a, PEDF, and caveolin 1, -2, and -3.
CONCLUSION
These data suggest a role for both angiogenic factors and anti-angiogenic factors and the 
caveolins in the pathogenesis of diabetic retinopathy, possibly by acting synergistically to 
mediate a wide range of cellular responses culminating in the formation of a fibrovascular 
membrane. Therapeutic intervention to the VEGF and Tie-2 receptor, and possibly 
stimulation of the PEDF signalling, pathways may prove useful for the treatment of PDR.
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CHAPTER 1. INTRODUCTION
1.1 GENERAL INTRODUCTION
Diabetes mellitus is a metabolic disorder characterised by hyperglycaemia and 
alterations in fat and protein metabolism and is associated with a specific set of long term 
microvascular and neurological complications (Nathan, 1996). World-wide it is estimated 
that over 2.5 million people in the 25-65 year age group are blind due to diabetes, which 
makes it the fourth leading cause of blindness and an increasing problem in developing 
nations (Foster, 1988). Typical ocular complications of diabetes include diabetic retinopathy, 
iris neovascularization, glaucoma, cataract and microvascular abnormalities of the optic 
nerve (Infeld et al., 1998). The most frequent complication is diabetic retinopathy in which 
retinal ischaemia, occurring as a consequence of widespread capillary non-perfusion, results 
in the production of vasoproliferative substances and the development of neovascularization 
(Infeld et al., 1998). Signs of retinopathy are not usually manifest before duration of 15 to 20 
years, at which time the prevalence can approach 80% to 100% in insulin-dependent 
diabetics (Frank, 1986).
1.2 DIABETES MELLITUS AND ITS COMPLICATIONS
Diabetes mellitus is associated with typical patterns of long term vascular 
complications which vary with the organ involved. The microvascular kidney disease 
(Olgemoller et al., 1993) is characterised by thickening of the capillary basement membranes 
and increased deposition of extracellular matrix components, while loss of microvessels with 
subsequent neovascularization is predominant in the eye and peripheral nerves (Pfeiffer et al., 
1995). Macrovascular disease is characterised by accelerated atherosclerosis. These 
complications are dependent on long term hyperglycaemia. Specific biochemical pathways 
linking hyperglycaemia to microvascular changes have been proposed: the polyol pathway 
(Greene et al., 1987), non-enzymatic glycation of proteins (Brownlee et al., 1988), glucose 
autooxidation and oxidative stress (Hunt et al., 1990), hyperglycaemic pseudohypoxia 
(Williamson et al., 1993), and enhanced activation of protein kinase C by synthesis of 
diacetyl glycerol (Lee et al., 1989; DeRubertis and Craven, 1994). These pathways are not 
mutually exclusive (Larkins and Dunlop, 1992; Pfeiffer and Schatz, 1992). They may be 
linked to alterations in the synthesis of growth factors particularly since atherosclerosis and 
angiogenesis are associated with increased proliferation of endothelial cells.
Diabetic retinopathy may be classified as nonproliferative (NPDR) or proliferative 
(PDR) [Neely et al., 1998]. NPDR may be graded as mild, moderate, or severe. The level of
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severity correlates with the probability of progression to PDR (Neely et al., 1998). NPDR is 
characterised by structural abnormalities of the retinal vessels (primarily capillaries but also 
venules and arterioles), varying degrees of retinal nonperfusion, retinal oedema, lipid 
exudates, and intraretinal haemorrhages. An important pathological event is the loss of 
capillary pericytes which are modified smooth muscle cells, which support the vascular 
endothelium of the retina (Kohner, 1993). This appears to be the initial event in NPDR. PDR 
may include any of the changes present in nonproliferative disease with additional findings of 
optic disc, retinal or iris neovascularization (Neely et al., 1998).
Both NPDR and PDR may cause visual loss with the major vision-threatening 
complications being macula oedema, macula ischaemia, neovascularization with preretinal or 
vitreous haemorrhage, traction retinal detachment, and neovascular glaucoma (Neely et al., 
1998). Before considering the pathogenesis of diabetic retinopathy in detail it is important to 
have a basic knowledge of retinal anatomy and physiology.
1.3 STRUCTURE AND FUNCTION OF THE NON-PATHOLOGICAL RETINA
The retina lines the posterior two-thirds of the eyeball (figure 1.1) and is separated 
from the sclera by the retinal pigment epithelium and the choroid (Naumann et al., 1986). 
The retina is firmly attached to the underlying pigment epithelium at the optic nerve head and 
the ora serrata.
Light rays, scattered from objects in the outside world, enter the eye and hit the retina. 
Some processing of images then occurs in the retina, from which electrical impulses are then 
transmitted through the optic nerve to the primary and secondary visual centres of the brain.
The eye is normally directed so that the image of an object falls upon the fovea 
centralis the central portion of the macula, a depression in the retina situated about a 
millimetre or so to the lateral side of the posterior pole of the eye formed by lateral 
displacement of the cells of the inner retinal layers (Emslie-Smith et al., 1988). It serves the 
function of central and colour vision and is therefore susceptible to many diseases of the 
retina such as diabetic retinopathy.
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Figure 1.1 Structure of the Eye (Google Images)
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At the microscopic level, the retina is a highly organised structure, consisting of 
alternate layers of cell bodies and synaptic processes. A single common pathway, mediated 
by the retinal ganglion cells, carries information from the retina to the brain (Miller, 1994). 
The retina can be classified into three systems, the neuronal system, the glial system and the 
vascular system (Blanks, 1994). These three systems are located within the 9 layers of the 
retina (figure 1.2) and are described below.
1.3.1 The Neuronal System of the Retina
The neuronal system traverses the entire thickness of the retina and consists of 
photoreceptor cells, intermediate neurones and ganglion cells (Naumann et al., 1986).
The photosensitive cells, the rods and cones, lie in the outermost layer of the retina 
next to the pigment epithelium and serve the function of light perception (Emslie-Smith et 
al., 1988). Light rays pass through the ganglion cells and inner retinal layers to reach the 
photoreceptor cells, where light is transformed into an electrochemical event (Blanks, 1994).
Each photoreceptor consists of an outer segment and an inner segment, both o f which 
lie external to the external limiting membrane (ELM). Each photoreceptor also
15
Figure 1.2 S tructu re  and organization of the retina (Google Images)
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contains a cell body, together which form the outer nuclear layer (ONL). The processes of 
both rods and cones interact with the axons of the bipolar cells and horizontal cells in the 
outer plexiform layer (Naumann et al., 1986). The rods are thin, cylindrical structures which 
are primarily responsible for peripheral vision and vision in low illumination (scotopic 
vision). The cones, which in histological sections are distinguished by their broader flask- 
shaped profiles, are primarily responsible for phototopic vision and for highly discriminatory 
central and colour vision.
The cell bodies of four cells can be distinguished in the inner nuclear layer (INL): the 
most numerous of these are the bipolar cells. Their processes synapse outwardly with the 
photoreceptors, forming the middle limiting "membrane," and inwardly with the dendrites of 
the ganglion cells (Naumann et al., 1986).
Three types of bipolar cells have been distinguished morphologically. One 
morphologic type exclusively relates to rods, and two types relate exclusively to cones. The 
two cone-related types o f bipolar cells make different kinds of synaptic connections with the 
cones, have axonal terminals that end in different parts of the inner plexiform layer, and 
appear to be involved in the generation of either ON or OFF responses to light in the retina. 
Rod-related bipolar cells extend their dendrites into invaginations of the rod terminals. The 
dendritic ends of the rod bipolar cells are considerably larger than those of the cone bipolar 
cells and allow a single rod bipolar cell to contact as many as 45 rod terminals.
The horizontal cells are located at the outer region of the INL. The horizontal cells 
(and amacrine cells which are discussed below) provide numerous "horizontal" neural
16
interconnections between groups or fields of retinal sensory neurones. In the retina, the 
processes of horizontal cells (and amacrine cells) modulate and transform visual information 
that is conveyed to the brain.
In the primate retina there are two morphologically distinct types of horizontal cells 
(Blanks, 1994). The type I  horizontal cell is characterised by stout dendrites that contact only 
cones, and a single, long axon ending with a terminus that contacts only rods. These dendritic 
terminals form the lateral elements of the rod synapse. The type II horizontal cell contacts 
only cones with its slim dendritic branches and short axon.
Amacrine cells are located primarily in the inner portion of the inner nuclear layer. 
They extend processes to adjacent amacrine or bipolar cells, and their axons synapse with 
ganglion cells within the inner plexiform layer. Displaced amacrine cells are also present 
within the ganglion cell layer (GCL). Amacrine cells are more diversified and numerous than 
horizontal cells.
Until recently, amacrine cells have been classified according to the degree of 
stratification of their processes, e.g., as unstratified, bistratified, or multistratified if many 
branches of the main processes ramify in one, two, or more levels, respectively, or as diffuse 
if the many branches ramify without stratification. In the last several years, classification of 
amacrine cells, based on their neurotransmitters, has changed dramatically because of the 
finding that there may be as many as 30 different types. It has been shown that amacrine cells 
with differently shaped dendritic trees can be matched with particular neurotransmitters
Interplexiform cells were recognised only 15 years ago as a distinct class of neurones 
in the vertebrate retina. This intemeurone has a cell body located at the innermost border of 
the INL, but its processes extend into both the inner and outer plexiform layers.
Nasally, the GCL consists of a single row of cells, which are separated by the 
processes of the Muller fibres (Naumann et al., 1986). They are closely grouped near the 
optic nerve but are widely separated in the periphery: they are only occasionally seen at the 
region of the ora serrata. Temporally from the nerve, the ganglion cells become multilayered, 
increasing to six to eight layers of cells in the macula region.
The axons of ganglion cells converge to form the nerve fibre layer and exit the eye as 
the optic nerve. Ganglion cells and to a lesser extent bipolar cells, can have quite extensively 
spreading dendrites so that each ganglion cell may be influenced by the activity of a large 
number of rods and cones. Further lateral interactions are mediated by the horizontal and 
amacrine cells. In all regions of the retina, except the central fovea, the ganglion cells can be 
seen to be connected, through intermediate bipolar cells, to rods as well as cones.
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1.3.2 The Glial System of the Retina
The glial system of the retina consists of Muller Cells, astrocytes and microglia. 
Muller cells are the most prominent of all retinal cells and they stretch from the internal 
limiting membrane (ILM) to beyond the ELM (Naumann et al., 1986). The Muller cell 
bodies lie in the inner two thirds of the INL, among the cell bodies of the amacrine and 
bipolar cells. Muller cell radial fibres are prominent in the inner retina, where the main 
ascending processes are thick and relatively straight. They pass directly through the inner 
plexiform layer, among the ganglion cells, and between the nerve fibre bundles where they 
terminate internally on the outer surface of the ILM by formation of basal foot processes. 
Many delicate horizontal processes extend laterally from these radial fibres, which are 
particularly prominent as the horizontal fibres of the nerve fibre, inner and outer plexiform 
layers. In the nuclear layers, these lateral processes form a honeycomb around the various 
cell bodies. Muller cell processes intervene between most smaller vascular elements and 
neuronal processes. In the outer retina the ELM is formed by a network of cell junctions 
between Muller cell processes and photoreceptors .
In contrast to most other elements of the retina, which possess either a photoreceptive 
or neurotransmission function, the Muller cell provides structural support and contributes to 
the metabolism of the sensory retina. The cytoplasm of Muller cells has a high content of 
glial fibrils, glycogen granules, and abundant smooth endoplasmic reticulum. It also contains 
abundant lactic acid dehydrogenase suggesting they have an important role in carbohydrate 
metabolism in the retina. Muller cells also may be active in the degradation of synaptic 
transmitters such as Gamma amino butyric acid (GABA) and in regulating extracellular 
levels of glutamine released during neuronal activity. Another important function of Muller 
cells concerns the maintenance of potassium homeostasis in the retina. Neuronal activity is 
associated with the release of potassium into the extracellular space. Potassium is removed 
from the outer retina, probably by an active pump located in the Muller cell villi, and leaves 
these cells most likely with the aid of an active pump located in the endfoot membrane.
Fibrous astrocytes, typical of those found elsewhere in the central nervous system 
(CNS), are common in the nerve fibre layer of the retina where their number is proportional 
to the thickness of the layer. There are 2 types of atrocytes present in the retina, elongate 
astrocytes and stellate astrocytes. Elongate astrocytes have multiple long slim processes that 
traverse the retina within the nerve fibre bundles. They have not been observed to contact 
blood vessels. Stellate astrocytes have many slender processes that cross the nerve fibres; 
some of these processes contact nearby blood vessels with a bulbous endfoot. Astrocytes are
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found occasionally at other locations in the inner half of the retina, but with much less 
frequency than the nerve fibre layer. Blood vessels never directly contact neuronal 
processes; intervening processes may be astrocytic but are most commonly derived from 
Muller cells.
Microglia contain an elongate nucleus and a slender cell body with two or more thick 
basal processes from which multiple coarse, short secondary processes may branch. The 
entire cell is covered with blunt spines from which slender hair-like extensions may continue 
10-25 microns from the cell. The cells tend to be flat and are most common in the inner 
plexiform layer but they also occur in the external plexiform layer. Microglia are mesodermal 
in origin and are thought to arise from pericytes of blood vessels. As in the brain, they are 
amoeboid, migrate freely, are phagocytic, and become activated under pathological 
conditions of the retina.
The retinal pigment epithelium (RPE) is composed of a single-layered cuboidal or 
cylindrical epithelium containing pigment granules, a nucleus, mitochondria, and other cell 
organelles that mediate the active metabolic, fluid exchange, and phagocytic functions of the 
cells. (Naumann et al., 1986). Because the sensory-pigment epithelium attachment is firm 
only at the ora serrata and optic nerve, the retina is susceptible to pathological separation 
from the underlying pigment epithelium.
1.4 VASCULAR SUPPLY TO THE RETINA
The primary arterial supply to the eye is the ophthalmic artery, which is the first 
branch of the internal carotid artery. The ophthalmic artery enters the orbit with the optic 
nerve through the optic canal and then divides into two major subdivisions: (1) the retinal 
system, in particular the central retinal artery, which supplies the inner one-half of the retina; 
and (2) the ciliary system, which supplies the uvea as well as the outer half of the sensory 
retina and optic nerve (Naumann et al., 1986).
The secondary and tertiary branches of the central retinal artery occurring on the optic 
nerve head, as well as more peripherally in the fundus, form the arterioles and the primary 
blood supply to the four quadrants of the fundus. In a small percentage of cases a cilioretinal 
artery is present. This vessel originates from the short posterior ciliary vessels (the circle of 
Zinn) and enters the superficial aspect of the retina at the margin of the optic nerve. The four 
primary fundus arterioles lie superficially in the nerve fibre layer. The arterioles can easily be 
distinguished from the venules- not only clinically by their colour differences and smaller 
diameter but also histologically by evaluation of the vessel wall thickness. The terminal
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fundus arterioles bend sharply and dip almost vertically into the retina, forming a rich 
capillary network. The capillaries extend as deeply as the outer aspect of the INL, sometimes 
extending just into the outer plexiform layer to the dividing line formed by the middle 
limiting "membrane".
The central fovea is almost totally devoid of blood vessels; however, the parafoveal 
and perifoveal zones or the more peripheral macula zones are richly vascularized by three 
arcades of capillaries within the inner half of the retina. Most of the extramacula and 
extrapapillary fundus is supported by two layers of capillaries: peripherally, this is reduced to 
a scanty single layer as the ora serrata is approached.
The branches of the retinal vein run alongside the arteries, the retinal vein passing out 
of the eye in the optic nerve (Emslie-Smith et al., 1988). A separate choroidal system of 
vessels lies between the pigment epithelium and the sclera and supplies the outer layers of the 
retina.
The retinal capillaries consist of two distinct cell types; the endothelial cell (EC) and 
the pericyte (PC) (Naumann et al., 1986). ECs line the lumen of the capillary and in turn are 
encircled by their basement membranes (BM) [figure 1.3].
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Figure 1.3 Normal Retinal Capillaries, a. Flat Preparation, b. Cross Section Showing 
The Nonfenestrated Endothelial Lining. (Copied from Naumann et al., 1986)
The ECs of a normal retinal capillary are closely bound together about the lumen by 
intercellular junctions of the zonula occludens type (tight junctions). These inter-cellular 
bridges render the vascular channels nonfenestrated and thus prohibit a free flow of fluids 
from the vascular lumen into the retinal interstitium outside the capillary. These junctions, in
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association with the astrocyte and Muller cell foot processes that encircle the retinal 
capillaries, probably contribute to the blood-retina barrier. Newly formed vessels (e.g. 
neovascularization in diabetic retinopathy) characteristically leak dye after fluorescein 
angiography, perhaps because of qualitatively and/or quantitatively incomplete intercellular 
tight junctions.
In addition to regulating vascular permeability ECs have a number of other functions. 
They are responsible for preserving vascular integrity with respect to maintaining 
uninterrupted blood flow by inducing platelet aggregation to plug injured sites and by 
triggering the extrinsic pathway of clotting. They are involved in the inhibition of 
intravascular thrombosis and lysis of established clots. They participate in the control of 
vascular tone, both vasodilator and vasoconstrictor substances are produced within the 
endothelium, e.g. nitric oxide (NO) [Gamer, 1994] being a potent mediator of the first of 
these functions and endothelin-1 an equally effective mediator of the second.
ECs also have an inflammatory role in terms of leukocyte binding through the 
expression of specific adhesion molecules. The endothelium also can express class II major 
histocompatibility complex antigens and function as an antigen-presenting tissue in 
immunological reactions. It is a source of BM constituents and other extracellular proteins, 
such as fibronectin and a source of growth factors involved in angiogenesis and wound 
repair.
The PCs form a "cap" around the outer aspects of the EC membrane. Each cell 
extends processes that envelop the capillary and are sandwiched between layers of BM; in the 
retina about 85% of the lining endothelium is covered in this way. Various diseases cause a 
relative decrease in the number of pericytes. The most important of these is diabetic 
retinopathy.
The basic component of vascular BM is type IV collagen, which acts as a structural 
backbone and binds to other membrane components; it also has an inhibitory effect on EC 
proliferation, such that BM dissolution is obligatory before new vessel formation can take 
place. Laminin is another major constituent relating primarily to cell attachment, whereas 
fibronectin has a wider range of binding capacity. Proteoglycans, with heparin sulphate 
proteoglycan being the major one present and, due to the presence of their anionic charges, 
are crucial to the selective barrier function of the membranes.
The retinal vessels are also surrounded by perivascular glial elements, consisting of 
astrocytic foot processes and Muller cell processes (Naumann et al., 1986).
21
1.5 DIABETIC RETINOPATHY
Angiogenesis, the formation of new capillary blood vessels by sprouting from 
existing micro vessels to promote neovascularization, plays a major role in the evolvement of 
a vascular supply in the normal processes of ovulation, placental development, and wound 
healing, as well as variously clinically significant pathological processes such as tumour 
growth and diabetic retinopathy (Ferrara, 1995a; Ferrara et al., 1995b). In contrast, the 
development of new vessels from blood islands, i.e., committed stem cells, in early 
embryogenesis is termed vasculogenesis. Although different in many respects, 
vasculogenesis shows some similarities to angiogenesis. However, vasculogenesis does not 
seem to contribute to repair and disease in postembryonic life (Battegay, 1995). In some of 
these processes the formation of new vessels contributes to necessary reparative processes 
involving tissue remodelling or preservation of vitally important ischaemic tissue. In other 
situations, such as in diabetic retinopathy, angiogenesis can significantly add to tissue 
destruction and promote disease (Battegay, 1995).
Many of the most sight-threatening ophthalmic disorders affecting patients 
throughout the world involve intraocular neovascularization as their major destructive 
component (Klein and Moorehead, 1970). Such disorders include not only the leading cause 
of blindness among infants (retinopathy of prematurity) [ROP], the leading cause of 
blindness among working age individuals (diabetic retinopathy), and the leading cause of 
blindness among the elderly (age-related macula degeneration), but other conditions such as 
central retinal vein occlusion, rubeosis iridis, sickle cell retinopathy, radiation retinopathy 
etc. (Klein and Klein, 1985).
Angiogenesis begins with the degradation of the parent vessel's BM followed by 
vascular EC migration outside the vessel wall, which results in vascular sprouts. The ECs of 
these sprouts proliferate, form lumina, and eventually generate new BM and recruit PCs 
(Folkman and Haudenschild, 1980).
Extracellular proteolysis is believed to be an essential component of the angiogenic 
process. Various elements of the angiogenic process may be mediated by extracellular 
proteolysis including degradation of the basement membrane of the parent vessel and 
invasion of the interstitial extracellular matrix by migrating ECs. Plasminogen activators 
(PAs) are key mediators of these processes and PA activity must be balanced by 
physiological inhibitors such as EC-derived Plasminogen activator inhibitor-1 (PAI-1) for 
normal capillary morphogenesis (Moscatelli and Rifkin, 1988; Pepper and Montesano, 1990).
22
During the stage of proliferative retinopathy, active proliferation of new vessels 
occurs on the retinal surface (Aiello, 1996). Although these vessels rarely cause visual loss, 
they are fragile and prone to bleed. As a result vitreous haemorrhage is a major component of 
visual loss during this period. Proliferating vessels are typically accompanied by a fibrous 
component containing glial tissue which can contract and may lead to traction on the retina. 
This traction can distort the retina, induce vitreous haemorrhage, or cause retinal detachment. 
The fibrovascular component often becomes prevalent as the retinopathy progresses. 
Fibrovascular proliferation in diabetic retinopathy typically proceeds from the disk along the 
major temporal vascular arcades to encircle the macula with increasing traction. This 
arrangement has led to the term wolf-jaw fibrovascular proliferation as the scar tissue slowly 
"bites down" on the macula. In the most severe final stages of diabetic retinopathy, this 
fibrous tissue creates a complete retinal detachment, contracting the retina into a funnel- 
shape. Untreated, these complications can lead to severe or total irreversible visual loss. The 
final stage of diabetic retinopathy is quiescence, which occurs both spontaneously over time 
or following laser photocoagulation. The final visual status of a person with diabetes is 
determined by whether this quiescence is reached without destruction of visually critical 
structures in the eye. Laser panretinal photocoagulation seems to accelerate this progression 
to quiescence therefore, more commonly resulting in inactive disease before the development 
of sight-threatening complications.
In severe cases, proliferation of new blood vessels may also occur in the anterior 
portion of the eye, especially on the iris and the anterior chamber angle. If these vessels 
obstruct the aqueous fluid outflow facilities of the eye, they can lead to neovascular 
glaucoma which is a severe sight-threatening disorder (Aiello, 1996).
PC loss is an early event in the pathogenesis of diabetic retinopathy. PCs are known 
to produce an inhibitor of EC growth which appears to be mediated through secretion of 
activated transforming growth factor-p (TGF-p). When the contact between ECs and PCs is 
lost, through PC dropout, ECs are free to proliferate (Orlidge and D’Amore, 1987).
Thickening of the extracellular matrix and alteration in its chemical composition is 
also probably of extreme importance. In diabetes, the documented changes in chemical 
composition of the BM include increased nonenzymatic glycosylation of collagen, decreased 
levels of heparan sulphate proteoglycans, and variable reports on changes in fibronectin and 
laminin. (Williamson et al., 1988). Such changes might alter cell-cell contact and perhaps
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allow cellular invasion and breakdown of the BM, one of the earliest features of 
angiogenesis.
The development of intraocular neovascularization is often correlated with areas of 
retinal capillary nonperfusion. During retinal development, the growing vessels are noted to 
invade areas of nonvascularized retina (Michaelson, 1948). In most of the ischaemic 
retinopathies, neovascularization of the retina or iris is preceded by increasing retinal 
capillary nonperfusion (Aiello, 1997). Often the neovascularization itself is located at the 
borders of perfused and nonperfused retina. Therapies which involve destruction of 
ischaemic retina such as laser photocoagulation or cryotherapy, often result in regression and 
quiescence of intraocular neovascularization (Aiello, 1997).
These observations suggest that the development and progression of 
neovascularization may be mediated by factors whose activity is induced by the onset of 
retinal ischaemia. As early as 1948, Michaelson used these clinical observations as support 
for the initial growth factor hypothesis concerning regulation of the developing retinal 
vasculature. This theory, known as the "Michaelson" hypothesis, was later refined by Ashton 
(1957). It was postulated that ischaemia of the retina produces a factor or factors capable of 
stimulating the growth of new vessels. To account for the clinical observations noted above, 
such a factor should be secreted and freely diffusible (accounting for neovascularization of 
adjacent retinal tissue or distant neovascularization of the iris), should be mitogenic for ECs 
(to account for proliferation of vessels), should be induced by retinal hypoxia, should have 
receptors located on retinal ECs (to permit stimulation of this cell type by the molecule), 
should be increased during periods of active intraocular neovascularization and diminished 
when neovascularization becomes quiescent either due to natural progression of the disease 
or successsful therapy.
It has now become widely accepted that growth factor release in retinopathy occurs as 
a consequence of hypoxia (Pfeiffer and Schatz, 1995). Hypoxia causes profound biochemical 
changes in cells and multiple systems within cells are effected by hypoxia. It is not yet 
known in detail how cells sense hypoxia, or how this translates into the secretion of 
angiogenic molecules. Possible mechanisms of hypoxia-sensing are similar to those of 
additional oxygen-responsive genes such as erythropoeitin (EPO) [Fisher et al, 1992; 
Goldberg et al., 1994; Minchenko et al., 1994a], endothelin-1, interleukin-la, ornithine 
decarboxylase (Goldberg et al., 1994), and glucose transporter (Loike et al., 1994). 
Erythropoeitin has recently been shown to induce angiogenesis (Anagnostou et al., 1994).
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Similar to erythropoeitin, hypoxia-induced VEGF gene expression depends on a haem- 
containing protein (Fisher et al., 1992; Goldberg et al., 1994; Minchenko et al., 1994a). 
Furthermore, induction of VEGF in response to hypoxia is due to transcriptional activation 
(Galis et al., 1994).
1.6 MODULATORS OF THE MICROVASCULAR COMPLICATIONS OF 
DIABETIC RETINOPATHY
1.6.1 INTRODUCTION
Proliferation of retinal blood vessels is one of the most striking features of advanced 
diabetic retinopathy. This feature has led to the conclusion that the normal balance of growth 
factors, which usually serves to keep angiogenesis in check, is disturbed in diabetic 
retinopathy (Sharp, 1995) and in ocular disorders such as ROP, leading to a devastating effect 
in the retina. PDR is one of the few examples of human pathological conditions in which 
abnormal growth of new vessels is one of the primary features. In normal ocular tissue, 
angiogenic homeostasis is controlled by the balance between angiogenic stimulators and 
angiogenic inhibitors
1.6.2 Angiogenic Modulators
Growth factors can be defined as multifunctional signals or mediators which modify 
cell growth or proliferation, alone or in concert, by binding to specific cell surface receptors 
(Spom et al., 1990). Their biological effects on cells include cell adhesion, migration, 
survival, differentiation, extracellullar matrix secretion, protease and protease inhibitor 
release, production of other growth activities, and angiogenesis. (Wiedemann, 1992).
A feature of growth factors is that, in most instances, they act locally within the 
tissues in which they are synthesised. This local action of growth factors has led to the 
concepts of 'paracrine' and 'autocrine' action. Paracrine action occurs when a growth factor is 
secreted by a cell and interacts with responsive cells in the immediate vicinity and autocrine 
action occurs when a growth factor is expressed, and acts upon, the same cells (McKay, 
1993).
One of the earliest candidates for a growth factor involved in retinal 
neovascularization was growth hormone (GH), based on clinical observations (Lundbaek et 
al., 1970), but latterly it has been thought that the retina itself produces the factors 
responsible for new vessel growth (Glaser et al., 1980). However, many years elapsed before 
techniques became available which permitted the in vitro demonstration of cell growth-
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promoting activity in soluble extracts of retinal tissue (Glaser et al., 1980). Since then, 
research in this area has progressed to the point where many growth factors and other 
cytokines with angiogenesis-modulating effects have been described. Some of these factors 
are stimulatory and some are inhibitory for one or more of the stages of the angiogenic 
response; others have no effect or have not been tested for a particular activity.
Numerous investigations, in an attempt to identify the factors involved in the 
neovascular response, have led to the characterisation of several molecules including insulin­
like growth factor (IGF) and basic fibroblast growth factor (bFGF). Both of these molecules 
have shown some association with intraocular neovascularization (Montesano et al., 1986), 
however, neither fulfils all of the criteria suggested by the Michaelson hypothesis. Although 
clearly an endothelial mitogen found in the eye (Klein et al., 1970), bFGF lacks a signal 
sequence necessary for secretion (Abraham et al., 1986). In addition, bFGF has not been 
consistently associated with active neovascularization in animal or human studies. IGF is a 
growth-promoting peptide with multiple biological effects (Le Roith and Roberts, 1993). 
IGF-1 is capable of inducing neovascularization, however, only at concentrations thought to 
be 10,000 times higher than the levels found in clinical disease (Grant et al., 1993) Therefore, 
although both FGF and IGF probably play a role in the overall angiogenic response, each has 
characteristics making them unlikely to be the primary ocular angiogenic growth factor.
Vascular endothelial growth factor (VEGF) appears to be the most promising as the 
major angiogenic factor of diabetic retinopathy. Even though other growth factors have been 
implicated in the process of intraocular vascular proliferation, these factors do not show a 
consistent increase as would be expected if they played a significant causative role 
(Hannehan et al., 1991; Meyer-Schwickerath et al., 1993).
The following sections will discuss in detail some of the growth factor families 
thought to be present in retinal neovascularization
1.6.2.1 The VEGF family
Several members of the VEGF family have been identified. VEGF-A was initially 
identified (Senger et al., 1983; Connolly et al., 1989; Ferrara et al., 1989; Levy et al., 1989; 
Plouet et al 1989; Conn et al., 1990). At least six different isoforms of VEGF-A polypeptides 
of different sizes (121,145,165,183,189 and 206 amino acid residues) are known to exist. 
These isoforms have distinct but overlapping functions in angiogenesis due to their 
differential binding to heparin sulphate (Leung et al., 1989; Houck et al., 1991; Tisher et al.,
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1991; Claffey et al., 1992; Ferrara et al, 2003; Tammela et al, 2005). Since the discovery of 
VEGF-A 5 other family members have been identified. VEGF-B, VEGF-C, VEGF-D, 
VEGF-E (viral) and VEGF-F (snake) [Lyttle DJ et al, 1994; Joukov et al, 1996; Rak et al, 
1995; Schmidt et al, 1997; Achen et al., 1998; Wise et al, 1999; Sheta et al, 2000; Veikkola 
et al, 2000; Shibuya, 2003; Suto et al, 2005]. Structurally, the VEGFs are related to the 
PDGF family of growth factors, with intrachain and interchain disulphide bonds between 
eight cysteine residues in conserved positions (Keck et al, 1989; Leung et al, 1989; Tischer 
et al, 1989; Claffey et al, 1992). The crystal structure of VEGF-A consists of two monomers 
that are organized in an anti-parallel fashion to form a dimer, with the receptor-binding sites 
located at each pole of the dimer
The VEGF receptors, VEGFR-1, VEGFR-2, AND VEGFR-3 belong to the receptor 
tyrosine kinase (RTK) gene family (Ullrich and Schlessinger, 1990). Each is a type III RTK 
containing seven extracellular immunoglobulin-like (IgL) domains (Shibuya et al., 1990; 
Matthews et al., 1991; Terman et a l, 1991). They also consist of a transmembrane domain, a 
juxtamembrane domain, a kinase domain interrupted by a 69 amino acid residue long insert, 
and a C-terminal tail (Shibuya et al., 1990; Matthews et al., 1991; Terman et a l,  1991; de 
Vries et al., 1992).
High expression of VEGF and its receptors is tightly controlled and restricted to 
developing microvessels and angioblasts during angiogenesis and vasculogenesis in 
developing mouse embryos. (Breier et al, 1992; Peters et al., 1993; Quinn et al., 1993; 
Yamaguchi et al., 1993).
In adults VEGF and its receptors are expressed in healthy organs with generally non­
proliferating vessels such as lung, kidney, adrenal gland, liver, stomach, and heart. (Ladoux 
and Frelin, 1993a; Olofsson et al, 1996) and in organs undergoing vascular remodelling such 
as in the female reproductive system. (Philips et al., 1990; Galland et al., 1992; Chamock 
Jones et al., 1993; Shweiki et al., 1993).
In tumours which contain hypoxic regions, VEGF is produced and secreted by blood 
vessels and tumour cells in the vicinity of tumours and acts on tumour ECs which express 
VEGF receptors. (Senger et al., 1986; Weindel et al, 1992; Brown et al., 1993a; Brown et 
al., 1993b; Shweiki et al., 1993; Weindel et al., 1994; Dvorak et al, 1995; Hatva et al., 1995; 
Leung et al., 1997; Yancopoulos et al, 2000; Padro et al, 2002; Pallares et al, 2006).
VEGF and its receptors are also increased in other pathological disorders 
characterised by hypoxia, microvascular permeability and neovascularization such as wound
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healing (Peters et al., 1993; Nissen et al., 1998), psoriasis (Detmar et al., 1994), and
rheumatoid arthritis (Fava et al., 1994; Koch et al., 1994).
During later stages of development and in adult tissues, VEGFR-3 mRNA becomes 
restricted to developing lymphatic vessels and high endothelial venules (Fournier et al., 1995; 
Kaipainen et al., 1995; Lymboissaki et al., 1998).
VEGF has been detected in neuronal cells, cardiac myocytes and cornea which are not 
directly associated with neovascularization (Breier et al., 1992; Plate et al., 1992; Ladoux 
and Frelin, 1993a).
VEGF and its receptors initiate signalling pathways that play a pivotal role during
embryonic development and pathological angiogenesis (Breier, 2000; Yancopulas et al.,
2000; Bates and Harper, 2002; Carmeliet and Storkebaum, 2002; Sun et al., 2003; Crol et al., 
2004). Heterozygous mutations inactivating the VEGF gene and the VEGFR-2 and VEGFR- 
1 genes in mice result in embryonic lethality and dramatic defects in angiogenesis and 
haematopoiesis (Carmeliet et al., 1996; Ferrara et al., 1996; Dumont et al., 1998).
VEGF activates a broad spectrum of biological responses in endothelial cells, 
including cell proliferation, migration, survival, differentiation and permeability to 
macromolecules (Senger et al., 1983; Senger et al., 1990; Ladoux et al., 1993a; Waltenberger 
et al., 1994; Rahimi et al., 2000; Suarez and Ballmer-Hofer, 2001; Yilmaz et al., 2003; Fu 
and Shen, 2004).
VEGFR-1 transmits only weak mitogenic signals in ECs, however VEGFR-1 may 
stimulate biological responses in ECs potentially by heterodimerizing with VEGFR-2 (Kanno 
et al,  2000; Rahimi et al., 2000; Autiero et al., 2003). VEGFR-1 activation in some non- 
endothelial cells, such as monocytes, is reported to stimulate cell migration and proliferation 
(Athanassiades et al., 1998). Recently VEGFR-1 was found to play a critical role in 
recruiting stem cell-differentiated endothelial cells into newly formed blood vessels (Eriksson 
et al, 2002; Carmeliet, 2003).
VEGFR-2 binds VEGF-A, VEGF-C, and VEGF-D (Wise et al, 1999; Zachary and 
Gliki, 2001). VEGFR-2 expression is low in quiescent endothelium (Ortega et al., 1997), 
however, the VEGFR-2 signalling pathway is crucial in bringing about the effects o f VEGFs 
in actively proliferating tissue, including vasodilatation, endothelial cell migration and 
proliferation (Dejana, 1996; Esser et al., 1998; Kroll and Waltenberger, 1998; Neufield et al., 
1999; Rahimi et al, 1999; Yang et al., 1999; Yancopoulos et al, 2000; Venkiteswaran et al, 
2002; Calera et al, 2004).
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VEGFR-3 binds VEGF-C and VEGF-D (Cao et al., 1998; Marconcini et al., 1999; 
Makinen et al., 2001; Stacker et al., 2001). VEGFR-3 is believed to play a critical role in the 
development of the embryonic vascular system but was originally believed to be restricted 
postnatally to the ECs o f lymphatic vessels and specialized fenestrated capillaries (Dumont et 
al, 1998; Karkkainen et al., 2000; Karkkainen et al., 2001). However, VEGFR-3 may also 
play a role in adult vascular endothelium. VEGFR-3 expression has been demonstrated to be 
associated with vascular endothelial cells in tumours and to play a role in vascular tubular 
morphogenesis (Valtola et al, 1999; Witmer et al,  2001; Clarijs et al, 2002; Persaud et al, 
2004). VEGF-D is mitogenic for endothelial cells and given that VEGF-D can activate 
VEGFR-3, it could be involved in the regulation and/or differentiation o f lymphatic and 
blood vessel endothelium just like VEGF-C (Jeltsch et a l,  1997).
1.6.2.2 The VEGF/VEGFR System and Diabetic Retinopathy
VEGF has been postulated to be one of the major retinal angiogenic factors for the 
following reasons. First, VEGF is known to promote increased vascular permeability and 
extravasation of plasma proteins (Keck et al., 1989; Ferrara et al 1992; Senger et al., 1993) 
resulting in the formation of an extravascular fibrin gel, a substrate for ECs (Dvorak et al.,
1995). Fibrin deposition in diabetic retinas has been demonstrated (Murata et al., 1995). 
Second, the production of VEGF is enhanced by ischaemia (Ferrara et al., 1992;
Shweiki et al., 1993; Senger et al., 1993; Minchenko et al.. 1994b; Dvorak et al., 1995) and 
ocular pathological angiogenesis is almost always associated with the occurrence o f capillary 
nonperfusion and regions of retinal ischaemia. The expression of VEGF, VEGFR-1 and 
VEGFR-2 occurs in numerous ocular cell types including RPE cells (Adamis et al., 1993; 
Aiello et al., 1995; Guerrin et al., 1995; Lutty et al.. 1996; Ohno- Schwesinger et al,  2000; 
Matsui et al. 2001; Grossniklaus et al,  2002), PCs (Aiello et al., 1995; Lutty et al., 1996; 
Takagi et al., 1996b; Darland et al, 2003), ganglion cells (Pierce et a l ,  1995; Dorey et al., 
1996; Murata et al., 1996), glial cells (Lutty et al., 1996; Pe'er et al., 1996; Sueishi et al.,
1996), choriocapillary endothelium (Lutty et al.. 1996; Amin et al., 1997), and microvascular 
ECs (Murata et al., 1995; Stone 1995; Dorey et al., 1996; Lutty et al., 1996; Pe'er et al, 
1996; Sueishi et al., 1996; Amin et al., 1997) and their production is dramatically increased 
in these cells when oxygen levels decrease (Adamis et al., 1993; Aiello et al., 1995; Shima et 
a l,  1995; Sueishi et a l ,  1996).
Third, the number of receptors for VEGF in retinal ECs is higher than that o f ECs in 
other tissues such as aorta, and cultures of BRECs can proliferate and migrate upon the 
addition of recombinant VEGF - two crucial steps of retinal angiogenesis (Simorre-Pinatel et
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al., 1994; Enaida et al., 1998; Rajah et al., 2002) and it increases in response to hypoxia 
(Thieme et al.. 1995). The higher level of VEGF receptor expression in retinal endothelial 
cells suggests that the retinal microcirculation may be more sensitive to the effects o f VEGF 
and this may contribute to the pathogenesis o f diabetic retinopathy.
Fourth, VEGF is diffusible, because it has the signal sequence needed for secretion 
and is water soluble (Ferrara et al., 1992; Senger et al., 1993). Other candidate growth factors 
such as the FGF's lack a classic signal peptide for secretion from the cell (Abraham et al., 
1986; Jaye et al., 1986).
VEGF is angiogenic in vivo and its expression, along with expression o f VEGFR-1 
and VEGFR-2 is temporally and spatially associated with the onset of ischaemia-induced 
intraocular neovascularization in several animal models (Miller et al., 1994; Pe'er et al., 
1995; Pierce et al., 1995; Stone et al., 1996; Aiello et al., 1997; Luna et al, 1997; Ozaki et 
al., 1997; Segawa et al., 1998; Suzuma et al., 1998; Alikacem et al., 2000; Wong et al, 2001; 
Tolentino et al., 2002). In diabetic rats increased levels o f VEGFR-1 and VEGFR-2 were 
expressed in vascular and non-vascular structures of the inner retinas, indicating that the 
VEGF/VEGFR system is upregulated in early diabetic retinopathy before neovascularization 
has occurred (Hammes et al., 1998). Inhibition o f VEGF reduces the formation and 
development of new vessels (Adamis et al.. 1994; Aiello et al., 1995; Adamis et al., 1996; 
Qaum et al., 2001; Tolentino et al, 2002).Increased expression of VEGF in the retina is 
sufficient to cause retinal and subretinal neovascularization (Okamoto et al, 1997; Tobe et 
al., 1998; Kinnunen et al., 2006) and signalling through VEGF receptors is necessary for 
retinal neovascularization (Adamis et al., 1996; Robinson et al., 1996; Tolentino et al., 1996; 
Ozaki et al, 2000; Ferrara et al.2003). Elevations of VEGF levels have been reported in the 
ocular fluid of eyes with active proliferative retinopathy as compared with non-diabetic 
patients, patients with nonproliferative diabetic retinopathy, and quiescent PDR (Adamis et 
al., 1994; Aiello et al., 1994; Malecaze et al., 1994; Kosano et al., 1999; Mitamura et al., 
2002; Ogata et al., 2002ab; Funatsu et al, 2003; Funatsu et al, 2004). Vitreous fluid 
containing measurable VEGF stimulated the growth of retinal ECs cells in vitro. This 
stimulation was inhibited by VEGF-neutralising antibodies (Aiello et al., 1994). Plasma 
levels of VEGF have also been shown to be higher in PDR patients than in non-diabetic 
controls (Lip et al, 2000).
In developing retinas VEGF expression has been shown to be temporally and spatially 
correlated with retinal vasculogenesis. VEGF mRNA and proteins are localised in the 
developing vessels and the angioblasts, i.e. endothelial precursors and to the nerve fibre and
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the GCL where the inner vascular network develops, and also in the INL where the outer 
vascular network develops (Stone, 1995; Dorey et al., 1996; Murata et al., 1996). Once 
vasculogenesis becomes inactive, VEGF mRNA expression is markedly decreased.
Immunohistochemical studies of rat and human retina have demonstrated that in 
diabetic retinas, VEGF immunoreactivity is markedly increased in the vascular endothelium 
and blood vessels walls and is observed in all layers of the retina (Murata et al., 1995; Lutty 
et a l 1996; Pe'er et al., 1996; Sueishi et al., 1996; Amin et al., 1997; Kunz Mathews et al., 
1997;; Ishihama et al., 2001; Famigletti et al., 2003).
In situ hybridisation of sections from whole globes which were enucleated at the 
time of ongoing neovascularization demonstrated that proliferation of vascular elements in 
PDR and neovascularization of the retina and/or iris secondary to central retinal vein 
occlusion, retinal detachment, and intraocular tumours were always accompanied by 
induction of retinal VEGF expression (Pe'er et al., 1995). In each case, expression o f VEGF 
was induced only in a particular layer o f the retina (either the ONL, the INL, or the GCL), 
matching the zones affected by impaired perfusion.
VEGF, VEGFR-2 and VEGFR-1 have also been detected in samples o f neovascular 
membranes from diabetic patients at vitrectomy (Malecaze et al., 1994; Chen et al., 1997; 
Armstrong et al., 1998a).
1.6.23 The Angiopoietin Family
Four members of the angiopoietin family have been identified. Ang-1 and Ang-2 
were initially isolated (Davies et al., 1996; Maisonpierre et al., 1997) followed by Ang-3 and 
Ang-4, which are probably interspecies homologs (Kim et al., 1999a; Valenzuela et al., 
1999). Angiopoietins contain an amino-terminal angiopoietin-specific domain followed by a 
coiled-coil domain, a linker peptide and a carboxy-terminal fibrinogen homology domain 
(Davies et al., 1996; Maisonpierre et al., 1997; Valenzuela et al., 1999). The fibrinogen 
homology domain is responsible for receptor binding, the coiled-coil domain is required for 
dimerization of angiopioietin monomers, and the short amino-terminal region forms ring-like 
structures that cluster dimers into variable sized multimers necessary for receptor activation 
(Procopio et al, 1999; Davies et al., 2003; Cho et al., 2004a). Ang-1, Ang-2 and Ang-4 bind 
to the receptor tyrosine kinase Tie-2. Tie-2 contains two IgL domains, flanking three EGF- 
like domains followed by three fibronectin type-III repeats in the extracellular region, a 
single hydrophobic transmembrane region and a split catalytic domain in the cytoplasmic
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region (Partanen et al., 1992; Dumont et al., 1993; Iwama et al., 1993; Sato et al., 1993; 
Schnurch ef a/., 1993).
Tie-2 expression appears to be mostly restricted to cells of the vascular system during 
embryogenesis (Sato et al., 1993; Korhonen et al., 1994). Its expression has also been shown 
to be localised to the endothelium of new vessels undergoing angiogenesis (Wong et al.,
1997). Tie-2 is also expressed in certain primitive haematopoietic stem cells (HSCs) and B 
lymphocytes but not in other lineage-committed cells.
Tie-2 and Ang-1 are co-expressed in quiescent arteries, veins and capillaries, in a 
wide range of adult tissues (Suri et al., 1996; Maisonpierre et al., 1997; Tsurumi et al., 1997; 
Stratmann et al., 1998; Audero et al., 2001; Nourhaghighi et al., 2003). Ang-1 is 
constitutively secreted by periendothelial cells (PCs/SMC's) in these quiescent vessels and in 
cultured SMC’s (Mandriata et al., 1998: Stratmann et al., 1998; Tanaka et al., 1999; Kim et 
al., 2000a; Loughna and Sato., 2001). This suggests a role for Tie-2 in the maintenance of 
quiescent vessels at all levels of the vasculature. Ang-1 mRNA expression has also been 
reported in neurons (Stratmann et al., 1998; Acker et al., 2001; Audero et al., 2001; 
Hashimoto et al., 2001).
Ang-2 is found only at sites of vascular remodelling including the ovary, placenta, 
and uterus and is selectively expressed in ECs and in some instances smooth muscle cells 
(Maisonpierre et al.y 1997; Gale et al., 2002). Ang-2 and Tie-2 expression are abundantly 
expressed in both tumour cells and in ECS of sprouting microvessels o f solid tumours 
(Stratmann et al., 1998; Bunone et al., 1999; Holash et al., 1999a; Takahama et al., 1999; 
Tanaka et al., 1999; Brown et al., 2000; Etoh et al., 2001; Yu et al., 2001; Nakayama et al, 
2004). In contrast to Ang-2, the expression o f Ang-1 is not high in most tumours (Hayes et 
al., 2000).
Tie-2 and Ang-1 appear to play a major role at later stages o f vascular development, 
i.e., during vascular maturation, maintenance of integrity and remodelling, unlike other 
angiogenic growth factors, such as VEGF, which function during the earliest stages of 
vascular development. (Keck et al., 1989; Dumont et al., 1994; Sato et al., 1995; Suri et al., 
1996; Witzenbichler et al., 1998). Tie-2 has been shown to recruit peri-endothelial cells 
(Dumont et al., 1994; Sato et al., 1995; Hanahan, 1997). Ang-1 secretion by periendothelial 
cells in normal quiescent vessels was shown to stabilise vessels by maintaining contacts 
between ECs and periendothelial cells (Stratmann et al., 1998; Tanaka et al ., 1999). 
However, more recently Uemura et al., 2002 showed that vessel stabalisation by Ang-1 
occurred in the absence of pericyte recruitment.
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In Ecs Ang-1 induces tube formation, sprouting, adherence, EC differentiation, and 
survival (Witzenbichler et al, 1998a; Koblizek et al.. 1998; Hayes et al., 1999; Kwak et al., 
1999; Papapetropoulos et al., 1999; Kim et al., 2000b; Kwak et al., 2000) but not migration 
(Witzenbichler et al., 1998; Ferrara et al., 1989). Ang-1 also decreases permeability, changes 
the distribution and activation of junctional adhesion molecules, and stabilizes cell-cell 
junctions (Gamble et al. 2000; Kim et al.. 2000b; Iizasa et al., 2002; Wang et al., 2004; 
Baffert et al., 2006). Ang-1 also has anti-inflammatory functions (Gamble et al., 2000; Kim 
et al., 2001a; 2002b; Joussen et al. 2002a; Pizurki et al, 2003; Lemieux et al., 2005).
Ang-2 has been shown to be a natural antagonist of Ang-1 by competitive binding to 
Tie-2 without stimulating autophosphorylation o f the receptor and is thought to play an 
earlier role at sites o f vessel invasion (Maisonpierre et al., 1997). Overexpression o f Ang-2 
produces vascular defects similar to those in Ang-1 or Tie-2 deficient mice (Keck et al 1989; 
Ferrara et al., 1991; Sato et al., 1995; Suri et al., 1996; Korpelainen et al., 1999). In tumours, 
Ang-2 expression exceeds Ang-1 expression and is specifically associated with small 
capillaries with few peri-endothelial support cells (Stratmann et al., 1998; Tanaka et al., 
1999). Inhibition of Ang-1 by Ang-2 promotes SMC/PC drop-off leading to loosening of the 
contacts between endothelial and peri-endothelial cells (Hanahan, 1997) which has been 
shown to be a requirement for rendering and maintaining ECs accessible to angiogenic 
inducers such as VEGF (Asahara et a l,  1998; Korff et al,  2001; Lobov et al,  2002; Visconti 
et al., 2002; Oshima et al, 2004; Oshima et al, 2005; Scharpfenecker et al, 2005). Down 
regulation of Ang-2 in quiescent ECs may permit physical interaction of ECs with peri­
endothelial cells, leading to inhibition o f endothelial proliferation and maturation of the 
vessel wall. However, in certain in vitro assays Ang-2 was shown to induce-Tie-2 
phosphorylation and MMP-9 expression, migration and sprouting, and tube formation of ECs 
(Maisonpierre et al, 1997; Kim et a l, 2000c; Korff et al, 2001; Teichert-Kuliszweska et al, 
2001; Mochizuki et al, 2002; Das et al, 2003). This suggests that Ang-2 can act as an 
agonist depending on cell type and experimental context. Also, overexpression of Ang-2 in 
cancer cells in mice promotes growth and vascularization of tumours (Tanaka et a l,  1999; 
Ahmad et al, 2001). In contrast, pharmacological inhibition specific to Ang-2 suppresses 
angiogenesis and growth of tumours (Oliner et al, 2004) and inhibits neovascularization in 
the rat cornea (White et al, 2003; Oliner et al, 2004).
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1.6.2.4 The Angiopoietin Family and Ocular Neovascularization
Ang-2 has been shown to be upregulated in the retinas o f diabetic rats, preceding the 
onset o f pericyte loss suggesting that upregulation of Ang-2 plays a critical role in the loss of 
pericytes in diabetic retina. (Hammes et a/. 2004).
Ang-1 was shown to suppress the development o f diabetic retinopathy and reduced 
both vascular endothelial injury and blood-retinal barrier breakdown (Holash et al,  1999a; b; 
Joussen et a l 2002a). This is consistent with the findings o f Thurston et a l,  1999 who 
showed that addition of Ang-1 was able to prevent diabetes-related vascular leakage and 
leukocyte adhesion and EC death. These effects were mediated in part via down-regulation of 
VEGF and VEGF has been shown to regulate vascular permeability through downregulation 
of the tight junction proteins occludin and zonula occluden 1 (Antonetti et al., 1998; 
Antonetti et al., 1999). In Ang-1-deficient mice ECs are poorly associated with the 
underlying matrix and do not properly recruit endothelial supporting cells (Suri et al., 1996). 
Leukocyte adhesion is thought to trigger the disorganization o f the EC zonula adherence and 
tight junctions (Del Maschio et al., 1996; Bolton et al., 1998). They therefore speculated that 
Ang-1 not only prevents leakage by stabilization o f the endothelial-pericyte interaction, but 
also via inhibition of leukocyte adhesion. The protective role o f Ang-1 in the mature 
vasculature therefore appears to act at several levels: a maturation signal during the 
development o f vessels; as an anti-inflammatory and anti-permeability agent that prevents 
leukocyte adherence and damage to the EC layer; and in the maintenance o f the blood-retina 
barrier.
Adult mice with induced expression o f Ang-1 ubiquitously, or specifically in the 
retina, appeared normal and had no identifiable changes in retinal or choroidal blood vessels 
or in retinal function as assessed by electroretinography (Nambu et a l 2004). This inhibition 
of ocular neovascularization is interesting because overexpression o f Ang-1 in skin 
stimulates neovascularization. Ang-1 also significantly reduced VEGF-induced retinal 
vascular permeability.
Ang-2 has been shown to be up-regulated in the retina during development o f the 
deep retinal capillaries by angiogenesis and during pathologic angiogenesis in diabetic retina 
(Adamis et al, 1996; Hackett et al., 2000; Lim et al, 2005; Patel et al, 2005). In human 
epiretinal membranes obtained from eyes with ischaemic retinal disorders, substantial 
upregulation of Ang-2 and tie-2 was found than in those from eyes with non-ischaemic 
diseases, whereas expression of Ang-1 was consistent in all membranes. Both Ang-1 and 
Ang-2 promoted tube-forming activity and enhanced the effects of VEGF in cultured BRECs
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(Takagi et al., 2003). Lim et al, 2005 showed that Ang-2 is raised in diabetes. In the absence 
of VEGF, Ang-2 induces vessel regression but facilitates EC migration and proliferation in 
concert with VEGF (Etoh et al, 2002; Lobov et al, 2002; Oshima et al., 2005). Therefore, 
selective up-regulation of VEGF and Ang-2 may lead to aberrant proliferation of leaky, 
friable vessels, which is characteristic off diabetic eye disease.
Ang-1 and Ang-2 have also been shown to be co-localised with VEGF in human 
choroidal neovascular membranes (Otani et al, 1999; Hangai et al, 2001). VEGF was shown 
to upregulate Ang-1 mRNA and protein levels in RPE cells by increasing mRNA stability. 
This suggests that VEGF may selectively modulate Ang expression during choroidal 
neovascularization (CNV).
1.6.2.5 TNF-a
Tumour necrosis factor alpha (TNF-a) was discovered as a serum protein released 
after systemic treatment of rodents with “bacilli Calmette-Guerin” and lipopolysaccaharide 
(Carswell et al, 1975). It was shown to beTNF belongs to a large family of structurally 
related proteins called the “TNF Ligand Superfamily”. The actions of these factors are 
diverse involving inflammation, apoptosis, cell proliferation and the stimulation of various 
aspects within the immune system (Pfeiffer, 2003; Goetz et al, 2004).
TNF-a is a 26-kDa transmembrane protein containing a C terminus that is external to 
the cell and cytoplasmic domain. In mammals, TNF can be released from the membrane by a 
protease of the metalloproteinase/disintegrin/cysteine-rich family called TACE (TNF-alpha 
converting enzyme), to produce a 17-kDa soluble protein (Black et al, 1997a,b; Blobel, 
1997; Ware, 1998). The overall structure of TNF is described as a ‘p-jellyrolT in which eight 
antiparallel p-strands form a sandwich 3D structure (Grass, 1996; Ware et al, 1998; Idriss 
and Naismith, 2000). The TNF-a gene contains four exons and three introns. The average 
size of mammalian TNF-a is 234 amino acids (Idriss and Naismith, 2000).
TNF-a is produced mainly from monocyte-macrophages but it has also been detected 
in astroyctes, microglia, smooth muscle cells, endothelial cells, neutrophils, and fibroblasts. 
(Frangogiannis et al, 1998; Meldrum, 1998; Meldrum et al, 1998). High levels of TNF-a in 
fluids and serum have been associated with inflammatory processes such as rheumatoid 
arthritis, Crohns disease, and multiple sclerosis (Brennan and Feldman, 1996; Rink and 
Kirchner, 1996). In addition, TNF-a is overexpressed in multiple myeloma cell lines and 
several reports have been associated with the detection of abnormally high levels of TNF-a 
protein in the blood of cancer patients with a wide range of tumour types (Partanen et al,
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1995; Leek et al, 1998; Karayiannakis et al., 2001; Yoshida et al., 2002). Within groups of 
patients with the same tumour type higher levels of TNF-a were correlated with advanced 
tumour stage, greater paraneoplastic complications and shorter survival time.
Upregulation of TNF-a and TNF-a receptor I mRNA and protein in glaucomatous 
retina has been demonstrated in the inner retinal layers predominantly in glial cells and 
ganglion cells and it was suggested that TNF-a-mediated cell death, through binding to 
TNFR-I, is involved in the neurodegeneration process of glaucoma (Tezel et al., 2001).
The biological responses to TNF-a are mediated by two types of TNF receptors, 
which can be differentiated by their molecular weight of ~ 55kDa (TNFR1) and 75 kDa 
(TNFRII). After binding to its receptors intracellular signal transduction pathways activated 
by TNF-a can be grouped into three general categories. TNF-mediated apoptotic cell death, 
which is mediated through a caspase cascade (Leong and Karsan, 2000; Petak and Houghton,
2001), TNF-a induced mitogenic, or TNF-a-induced inflammatory responses. TNF-a acts as 
an inflammatory factor by promoting leukocyte adhesion to vascular endothelium both in 
vitro and in vivo. Leukocyte adhesion is mediated by the complex interplay of adhesion 
receptors on both leukocytes and ECs. TNF-a induces the transcription of the leukocyte 
adhesion molecules ICAM1, VC AM, E-selectin, IL-6, IL-8, and cyclooxygenase (COX)-2, 
among others (Herz and Gerard, 1993; Rogers et al., 1996; Ridley et al., 1997; Bergstrom et 
al., 2000; Dunford et al., 2001; Gustin et al., 2004) by activating transcription factors like 
Activator Protein one (AP-1) and nuclear factor kappa B (NF-kB) [Leong and Karsan, 2000; 
Wajant and Scheurich, 2001; Hoefen and Berk, 2002; Paria et al., 2003; Viemann et al., 
2004; Trickier et al., 2005; Wang et al., 2006). Zhou et al., 2004 showed that TNF-a 
activates NFkB, PI3K, and MAPK with concomitant downstream expression of Bcl-2. Bcl-2 
is an anti-apoptotic factor whose expression is regulated in response to hypoxia.
TNF-a has also been shown to alter vascular tone (Hollenberg et al., 1991; Luckman 
et al., 1998) and increase micro vascular permeability in endothelial monolayers (Maruo et 
al., 1992; Brown and Robbins, 1999; Desai et al., 2002; Sedgwick et al., Vandamme et al., 
2003; Kerkar et al., 2006). In addition, TNF-a has also been shown to up-regulate the 
expression of growth factors such as PDGF, VEGF, and Ang-2 (Kim et al., 2000d; Yang et 
al., 2003; Wang et al., 2006) and to alter the expression of VEGFR-2 (Stadelmann and 
Lassmann., 2000).
Although originally identified as an endotoxin-induced protein which causes necrosis 
of tumours (Carswell et al., 1975), TNF-a has recently been shown to mediate tumour 
progression by causing the proliferation, invasion and metastasis of tumour cells (Balkwill,
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2002). When TNF-a is produced by tumours and tumour-associated macrophages or stromal 
cells at physiological levels, it promotes tumour growth and additional macrophage 
recruitment, stimulating the release of angiogenic and growth factors from infiltrating cells.
TNF-a has also been shown to modulate neuronal functions (Cunningham et al, 
1996; Pan et al., 1997), and to stimulate glial proliferation (Bama et al, 1990; Selmaj et al, 
1990; Dopp et al, 1997), and glial activation (Aloisi et al., 1992; Merrill, 1992; Panek et al, 
1994; Romero et al, 1996; Munoz-Femandez and Fresno, 1998).
1.6.2.6 TNF-a and Ocular Angiogenesis
TNF-a overexpresssion in diabetes is thought to contribute to several complications in 
diabetes, including retinopathy, nephropathy, neuropathy, and diabetes-enhanced periodontal 
disease (Nishimura et al, 2003; Satoh et al, 2003; Siragy et al, 2003; Gonzalez-Clemente et 
al. 2005; Krady et al., 2005). This may result from the effects of hyperglycaemia and 
advanced glycation end-products (AGES) as has been shown in HUVECs (Rashid et al, 
2004). Diabetic retinopathy has an underlying inflammatory component, involving leukocyte 
recruitment and adhesion to the retinal vasculature and up-regulation of inflammatory genes 
(Jousson, 2002). Jousson, 2002 showed that leukocyte adhesion in diabetic rat retinas was 
elevated two-fold more than levels in non-diabetic animals and treatment with the TNF-a 
receptor inhibitor etemacept reduced leukocyte adhesion in retinal vessels of treated vs. 
diabetic controls. Retinal neovascularization was also shown to be abrogated by other 
selective TNF-a blockers (Zhu et al, 2006).
TNF-a has also been shown to be the predominant pro-inflammatory cytokine 
observed within the extracellular matrix and luminal and abluminal surface of infiltrating 
vessels in PDR membranes and has also been demonstrated in PVR membranes (Limb et al., 
1996; Armstrong et al, 1998a). Increased levels of TNF-a and its receptors TNFR-I and II 
have also been detected in the vitreous of eyes with PVR, rhegmatogenous retinal detachment 
(RRD), and PDR compared with control eyes (Limb, 2001).
Retinal ischaemia has been shown to upregulate TNF, TNFR1 and TNFR2 (Fontaine, 
2002; Lahat et al ,2003). TNF-a mRNA was increased in mouse models of retinal 
neovascularization. (Majka, 2002; Yoshida et al, 2004) and was shown to be expressed by 
Muller glial cells, in the inner nuclear layer and outer nuclear layer. Yoshida et al., 2004 
showed that the TNF-a expression level was enhanced in macrophages/microglia 4 days after 
hypoxia.
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Zhao et al, 2006 showed that TNF-a upregulated VEGF-C and VEGFR-2 expression 
in retinal ECs. Flow cytometry results showed that VEGF-C prevented EC apoptosis induced 
by TNF-a and that the anti-apoptotic effect was mainly via VEGFR-2.
TNF-a has also been shown to colocalize with Ang-1, Ang-2 and VEGF in human 
CNV specimens (Hangai et al., 2006). It was shown to induce the sequential upregulation of 
Ang-2 and then Ang-1 and VEGF mRNA and protein expression in choroidal microvascular 
ECs in vitro.
TNF-a has also been shown to produce an angiogenic response in mouse cornea 
assays which was dramatically increased when Ang-1 or Ang-2 were added suggesting that 
Tie-2 signalling synergistically amplifies and participates in TNF-a-mediated angiogenesis 
(Nakoa et al., 2003; Chen et al, 2004).
1.6.3 Inhibitors of Angiogenesis
Numerous inhibitors of angiogenesis have been reported to counteract the effects of 
growth factors and endogenous angiogenic inhibitors are believed to be essential for 
maintaining the homeostasis of angiogenesis in the retina (Raymond, 1982). Extracts of 
cornea and vitreous contain substances that inhibit the proliferation and angiogenesis of 
endothelial cells.
1.6.3.1 PEDF
Among various molecules with antiangiogenic properties which have been reported to 
counteract the effects of growth factors, pigment epithelium-derived factor (PEDF) appears 
to play a prominent role (Mori et al, 2001; Stellmach et al, 2001). Recent studies suggest 
that the induction of angiogenesis in the eye requires not only an elevation of VEGF but also 
a decrease in PEDF (Tombran-Tink and Johnson, 1989).
PEDF is a glycoprotein of 50-kDa and a member of the serine protease inhibitors 
(serpine) superfamily related through their highly conserved folded conformation (Steele et 
al, 1993; Becerra et al, 1995). PEDF binds to heparin and other glycosaminoglycans in the 
ECM through lysine residues at a novel binding site for members of the serine family 
(Simonovic et al, 2001). It was first isolated based on its ability to convert dividing 
retinoblastoma cells into differentiated neurones, and was therefore characterized as a 
neurotropic factor (Tombran-Tink and Johnson, 1989; Tombran-Tink et al, 1991). Later, it 
was shown that besides its neurotropic functions, PEDF is a potent inhibitor of angiogenesis 
in the eye (Dawson et al, 1999), where it inhibits stimulatory activity of several
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proangiogenic factors. Subsequent workers also demonstrated that PEDF is associated with 
both the cell cycle and senescence (Pignolo et al, 1995; Palmieri et al., 1999; Tresini et al.,
1999).
The human PEDF gene spans approximately 16kb and contains eight relatively small 
exons and seven introns with the largest intron (intronl) approximately 4 kb in length 
(Tombran-Tink et al, 1996). The human PEDF gene contains an open reading frame 
encoding a 418-amino-acid protein with a hydrophobic signal that is characteristic of secreted 
proteins (Steel et al., 1993).
Whether or not PEDF exerts its actions trough a classical transmembrane receptor 
remains an open question. High affinity PEDF-binding sites and proteins have been shown to 
be present in plasma membranes of the retina, retinoblastoma, CNS, pericytes and ECs, 
consistent with a cell surface PEDF receptor protein (Wu et al., 1995; Alberdi et al., 1999; 
Aymerich et al., 2001; Bilak et al., 2002; Filleur et al., 2005). However, little is known about 
the identity of the receptor and molecular mechanism(s) by which PEDF functions to regulate 
neuronal and EC behaviour. Notari et al., 2006 found a novel RPE gene, which they termed 
PEDF-R. They demonstrated the expression of PEDF-R in the retina and showed it had a 
binding affinity for PEDF.
PEDF mRNA is found in many human foetal and adult tissues and the protein is 
secreted in primary cultures of various cell types including osteoblasts (Tombran-Tink et al., 
1996, 2004; Tombran-Tink and Barnstable. 2004). It is expressed not only in the retina, but 
also in the vitreous and aqueous humours, in association with fibroblasts, in ciliary 
epithelium, in cultured RPE, as well as in the adult human brain, the spinal cord, pineal 
gland, skeletal muscle, bone, heart, placenta liver, teeth, bone and cartilage matrix and human 
plasma. (Wu et al., 1995; Tombran-Tink et al., 1996 ; Bilak et al., 1999; Karakousis et al., 
2001; Behling et al, 2002; Kunci et al., 2002; Peterson et al., 2003; Tombran-Tink and 
Barnstable, 2003).
PEDF is among the most potent known natural antiangiogenic factors and it is even 
more active than angiostatin, thrombospondin-1, and endostatin (Dawson et al., 1999). It 
plays a role in preventing neovascularization by excluding vessels from invading the retina, 
vitreous, and cornea (Dawson et al., 1999; Stellmach et al., 2001). PEDF inhibits endothelial 
cell migration towards many angiogenic factors including platelet-derived growth factor 
(PDGF), VEGF, IL-8, fibroblast growth factor (FGF), and lysophosphatidic acid (Dawson et 
al., 1999). PEDF has been shown to inhibit VEGF-induced vascular permeability in mice 
(Liu et al, 2004) and the inhibitory effect of PEDF on VEGF-induced angiogenesis was
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shown to result from the enhanced y-secretase-dependent cleavage of the C terminus of 
VEGFR-1, which in turn inhibited VEGFR-2-induced angiogenesis (Cai et al, 2006). In 
addition, PEDF was also able to regulate the phosphorylation of VEGFR-1, which itself can 
regulate VEGFR-2 signalling. This identifies two novel pathways by which PEDF inhibits 
VEGF-induced angiogenesis: regulated intramembrane proteolysis and inhibition of 
VEGFR-1 phosphorylation.
The antiangiogenic effects of PEDF are associated with induction of endothelial cell 
apoptosis/cell death (Becerra, 2006). PEDF discriminates between ECs forming new vessels 
(cells that it destroys) and those that are part of pre-existing vessels (cells that it does not 
harm) by making use of the same Fas ligand-Fas receptor system that the immune system 
uses to apoptopically eliminate unwanted lymphocytes (Volpert et al, 2002). In apoptosis, 
Fas ligand and its receptor, Fas/CD95 sire tightly linked to the cell death cascade. When ECs 
are treated with PEDF Fas ligand expression increases and the Fas/FasL transduction cascade 
becomes activated which has been shown to lead to cell death of ECs (Volpert et al., 2002). 
However, it is still unclear whether other pathways are involved in PEDF signalling of 
apoptopic events since PEDF can still inhibit neovascularization of mice lacking either Fas or 
FasL (Barreiro et al., 2003). Chen et al., 2006 provide strong evidence that PEDF induces 
death of ECs through activation of both receptor-mediated and mitochondria-mediated 
pathways of caspase activation and that activation of these pathways is p3 8-dependent.
Overexpression of PEDF has been shown to inhibit tumour growth and progression 
(Crawford et al., 2001; Abe et al., 2004; Matsumoto et al., 2004). The inhibition of tumour 
growth was shown to occur via PEDF’s anti-proliferative and anti-apoptopic effects and it 
was shown to suppress VEGF expression in osteoscarcoma cells. Its transcription was shown 
to decrease with increasing grade of glioma tumour and it was absent in the most aggressive 
ones (Guan et al., 2003).
PEDF also has neurotrophic, neuronotrophic, nueroprotective and gliastatic properties 
and acts in neuronal survival and differentiation of photoreceptor and retina cells as well as 
neurons of the central nervous system (Araki et al., 1994; Cayouette et al., 1999; Cao et al., 
2001; Jablonski et al., 2001; Bilak et al., 2002; Kunci et al., 2002).
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1.6.3.2 PEDF and Ocular Angiogenesis
Several groups have suggested that shifts in the balance between pro-angiogenic 
factors such as VEGF and anti-angiogenic factors such as PEDF may be responsible for the 
pathology seen in choroidal and inner-retinal neovascularization (Gao, 2001; Ogata, 2001a; 
Ohno-Matsui, 2001; Gao et al., 2002; Gao and Ma, 2002; Ogata, 2002abc). To initiate 
angiogenesis, the balance between the positive and negative regulators is likely to be shifted 
such that angiogenic factors are up-regulated or inhibitory factors are decreased.
In foetal and adult human eye tissue, PEDF is expressed by the cornea, ciliary body, 
the RPE and cells of the inner and outer retina and ganglion cell layer (Karakoisis, 2001; 
Behling, 2002; Ogata et al, 2002bc; Eichler et al., 2004;). It is thought that PEDF secreted 
by these cells accumulates in avascular spaces of the eye such as the aqueous and vitreous 
humour and the interphotoreceptor matrix where it acts as a major inhibitor of angiogenesis 
(Karakousis, 2001; Behling, 2002).
PEDF is reported to inhibit retinal endothelial cell growth, migration and suppress 
ischaemia-induced retinal neovascularization (Mori 2001; Stellmach et al., 2001; Duh et al., 
2002; Stellmach et al., 2002; Yamagishi et al., 2002, 2003; Duh et al., 2003). In diabetic 
patients the levels of PEDF has been reported to be lower in the vitreous of patients with 
PDR (where new vessels are actively forming) than in healthy individuals or in diabetic 
patients whose vessels are quiescent (Ogata et al, 2001a; 2002a,b,c; Colombo, 2002; 
Holekamp et al, 2002). Retinal neovascularization, which was induced by hypoxia, was 
shown to stimulate a reduction in retinal PEDF and increases in VEGF protein and mRNA 
levels (Gao et al, 2002; Eichler et al, 2004).
AAV-mediated intraocular PEDF gene transfer has been found to increase cell 
survival after ischaemia-reperfusion injury of the rat retina and cause vessel regression in 
established neovascularization (Mori, 2001; Stellmach, 2001; Auricchio, 2002; Duh, 2002; 
Mori et al, 2002ab; Raisler, 2002; Takita, 2003).
PEDF mRNA and protein have shown to be significantly upregulated in RPE cells 
and the retina after photocoagulation therapy (Ogata, 2001b; Schmidt-Erfurth et al, 2002; 
Hattenbach et al 2005). Choroidal neovascular tissues, induced experimentally by panretinal 
laser photocoagulation, contain significant amounts of PEDF mRNA and protein (Ogata et 
al, 2002c; Martin et al, 2002). The expression of PEDF in these membranes is specifically 
localized to the proliferating RPE cells that cover the membranes. One reason that may 
account for the success of panretinal treatment is reducing neovascularization may be, in part, 
due to an upregulation of PEDF in proliferating RPE cells and its inhibitory effects on
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VEGF-induced vessel outgrowth (Ogata et al., 2001b). Matsuoka et al, 2004 showed that 
PEDF and VEGF were strongly expressed in the vascular ECs and RPE cells in the CNVMs 
where numerous new vessels were prominent (Clinically active CNVMs). On the other hand, 
immunoreactivity for PEDF and VEGF was weak in the new vessels where fibrosis was 
prominent (clinically quiescent CNVMs). However, the RPE cells were still positive for 
PEDF and VEGF.
It has been suggested that PEDF prevents retinal endothelial cells from responding to 
ischaemic signals by an apoptopic mechanism (Bouck et al., 2002). Addition of PEDF to the 
endothelial cultures markedly increased the number of apoptopic cells and apoptopic 
endothelial cells were more common in retina of hyperoxic animals treated with PEDF than 
those not receiving PEDF. Mori, 2002c showed that increased expression of PEDF causes 
regression of ocular neovascularization by promoting apoptosis of cells within neovascular 
lesions by use of AAV-mediated gene transfer of PEDF in a murine model of choroidal 
neovascularization. In the cornea, this apoptosis can be shown to be essential because PEDF 
fails to inhibit angiogenesis as the caspase enzymes required for apoptosis are prevented from 
functioning (Volpert, 2001).
Zhang et al., 2005 hypothesized that the inhibition of retinal NV and permeability by 
PEDF is mediated by its anti-inflammatory activity. They showed that retinal and plasma 
PEDF levels were drastically decreased in rats with endotoxin-induced uveitis (EIU), which 
suggests that PEDF is a negative acute-phase protein. Intravitreal injection of PEDF 
significantly reduced vascular hyperpermeablity in rat models of diabetes and oxygen- 
induced retinopathy, correlating with decreased levels of retinal inflammatory factors, 
including VEGF, VEGFR-2, MCP-1, TNF-a, and ICAM-1. In cultured retinal capillary 
endothelial cells, PEDF significantly decreased TNF-a and ICAM-1 expression under 
hypoxia. Moreover, down-regulation of PEDF expression by siRNA resulted in significant 
increases of VEGF and TNF-a secretion in retinal Muller cells. These findings suggest that 
PEDF is a novel endogenous anti-inflammatory factor in the eye. The decrease of ocular 
PEDF levels may contribute to inflammation and vascular leakage in the eye.
Yamagishi et al., 2006 showed that PEDF could inhibit the AGE-induced retinal 
vascular hyperpermeability and the mechanism by which it might achieve this beneficial 
effect. AGEs decreased retinal PEDF levels in rats. Treatment with PEDF inhibited the AGE- 
elicited VEGF-mediated permeability by down-regulating mRNA levels of p22phox and 
gp91phox, membrane components of NADPH oxidase, and subsequently decreasing retinal 
levels of an oxidative stress marker. PEDF also inhibited the AGE-induced vascular
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hyperpermeablity evaluated by transendothelial electrical distance by suppressing VEGF 
expression. PEDF decreased reactive oxygen species (ROS) generation in AGE-exposed 
endothelial cells by suppressing NADPH oxidase activity via down-regulation of 
mRNAMevels of p22PHOX and gp91PHOX. This led to blockade of the AGE-elicited RAS 
activation and NF-icB-dependent VEGF gene induction in ECs. These results indicate that the 
central mechanism for PEDF inhibition of the AGE signalling to vascular permeability is by 
suppression of NADPH oxidase-mediated ROS generation and subsequent VEGF expression.
Gao, 2002 showed that intravitreal injection of plasminogen kringle 5 (K5), a potent 
inhibitor of ischaemia-induced retinal neovascularization (Zhang, 2001) downregulates 
VEGF, and upregulates PEDF in a dose-dependent manner in cultured retinal vascular cells 
and in the rat retina. Retinal RNA levels of VEGF and PEDF were also changed by K5.
1.7 THE CAVEOLAE SYSTEM
1.7.1 Introduction
Caveolae (or ‘little caves’) are 50-100 nm plasma membrane invaginations and were 
originally identified in the 1950’s by electron microscopy (Palade, 1953, Yamada, 1955). 
They have a very unique lipid composition enriched in cholesterol and sphingolipids (Razani 
et al, 2002. In many cell types, caveolae occur singularly or in chains or grape-like clusters. 
(Predescu et al, 1994).
Caveolin (cav), a 21-24 kDa integral membrane protein, is a major protein component 
of caveolae and is necessary for the formation of invaginated caveolae (Rothberg, 1992; Van 
Deurs, 2003). Multiple members of the caveolin gene family have been identified (cav-1, 
cav-2, and -3) that differ in molecular structure and in tissue distribution (Razani et al,
2002). Cav-1 has two isoforms: cav-la and cav-lp which are translated from a different 
mRNA. Cav-2 has also been found to have multiple isoforms (a,p,y) that were discovered in 
adipocytes (Fra, 1999; Fra, 2000). Among the three caveolins, cav-1 and -3 show high 
homology (Tang et al, 1996) and either is sufficient for the formation of caveolae 
invaginations (Fra et al, 1995; Li et a l, 1998; Park et al., 2002). Cav-2 requires the presence 
of cav-1. It has to heterologomerize with cav-1, otherwise it remains trapped within the Golgi 
complex and is also degraded by cav-1 (Monier, 1995; Sargiocomeo, 1995; Scherer, 1997).
Caveolin is composed of cytoplasmic N and C termini and a central intramembrane 
domain (Carman et al, 1999). The N-terminal region contains the caveolin scaffolding 
domain, which is essential for both the formation of caveolin oligomers and the interaction of 
caveolin with a range of other proteins (van Deurs, 2003). The membrane-spanning domain
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(MS) forms a hairpin-like loop into the membrane but does not penetrate it. In addition, 
caveolin is attached to the lipid bilayer by three palmitoyl anchors in the C-terminal region.
Cav-1 null mice are viable but they lack cav-1 protein expression and plasmalemmal 
caveolae suggesting that cav-1 plays a vital role in caveolae biogenesis (Razani et al., 2001; 
Razani and Lisanti, 2001). Also analysis of cultured fibroblasts from cav-1 null embryos 
showed a loss of cav-2 protein expression. Therefore cav-1 expression is required to stabilize 
the cav-2 protein product.
Caveolae play a role in the internalization and transendothelial trafficking of solutes 
(Predescu et al, 1994). Caveolar release from the plasma membrane is an important mode of 
endocytosis in ECs (Predescue et al, 1993), and is the first step in migration of vesicles to 
the basal membrane (Schnitzer et al, 1996; Oh et al, 1998; Niles et al, 1999; Minshall et 
al, 2000). The vesicles detach from the plasmalemmal shuttle to the basal membrane where 
they fuse and release their contents, a process termed transcytosis (Predescu et al, 1994; 
Ghitescu et al, 1996; Milici et al, 1997; Minshall et al, 2000; Vogel et al, 2001). Caveolae- 
mediated transcytosis is an important mechanism of transendothelial transport of albumin and 
delivery of albumin-conjugated nutrients, fatty acids, and hormones across the endothelial 
barrier (Anderson, 1998).
Caveolin-1 contains a so-called scaffolding domain that is thought to concentrate 
signalling molecules in caveolae and which binds to and inhibits the activity of several 
signalling molecules. This allows cav-1 to organize proteins in caveolae through protein- 
protein interactions, enabling finely tuned regulation of physiological responses (for example, 
Ca2+entry and eNOS activation) [Drab, 2001].
Many signalling molecules present in caveolae play a role in adhesion, migration, and 
invasion. They include G-proteins, tyrosine kinases (src, Fyn), receptors for TGF-p type II, 
insulin, IGF-1, EGF, PDGF and VEGF, Angiopoietin, eNOS, and some components of the 
MAPK pathway. (Li et al, 1995; Liu et al, 1996; Mineo et al., 1996; Liu et al, 1997; 
Yamamoto et al, 1998; Feng et al., 1999a; Puyraimond 2001; Razani et al 2002; Huo et al, 
2003; Yoon et al., 2003; Schwartz et a l,2005).
A large variety of in vitro and in vivo studies have implicated caveolae and caveolin 
in the pathogenesis of cancer, atherosclerosis and vasoproliferative diseases, 
cardiachypertrophy and heart failure, degenerative muscle dystrophies and diabetes mellitus 
(Schwencke et al, 2006). Several studies have suggested that cav-1 plays a central role in 
angiogenesis (Liu et al, 1999; Griffoni et al, 2000;; Brouet et al, 2001; Woodman et al, 
2003; Sonveaux et al, 2004). However, it appears that a bimodal type of regulation seems to
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characterise the role of cav-1 in angiogenesis. Cav-1 has been shown to mediate cell 
transformation, proliferation and capillary tubule formation (Kim et al, 2002b; Griffoni,
2000). Increased expression of cav-1 and microvessel density was shown to correlate with 
metastasis and poor prognosis in renal cell carcinoma (Joo et al, 2004) Conversely, other 
workers have shown that Cav-1 inhibits cellular proliferation (Hulit et al, 2000; Razani et 
al, 2000; Galbiati et al, 2001) and prevents cell transformation (Engelman et al, 1997; 
Galbiati et al, 1998) and promotes cell-cycle arrest as well as senescence (Galbiati et al., 
2001; Volonte et al, 2002). Caveolin-1 has also been shown to function as a tumour 
suppressor protein in a large variety of cellular settings (Quest et al, 2004; Williams and 
Lisanti, 2005).
Endothelial-specific overexpression of cav-1 was shown to impair VEGF 
microvascular permeability and angiogenesis and inhibited the VEGFR-2-mediated 
angiogenic signalling cascade (Liu et al, 1999). These defects were associated with negative 
regulation of the PI-3K/Akt/eNOS signalling module, consistent with the established 
inhibitory action of cav-1 on eNOS (Bucci et al, 2000) and PI-3K activity (Zundel et al., 
2000).
Liu et al, 2002 showed that cav-1 is down-regulated by endothelial growth factors 
(VEGF, PDGF, bFGF, HGF) that stimulate the initial proliferative stage of angiogenesis. 
This is consistent with the above studies showing that cav-1 is a negative regulator of cell 
proliferation and cell cycle progression. They also showed that cav-1 expression stimulated 
EC differentiation and tubule formation.
1.7.2 Systemic Expression of Caveolae and Caveolins
Caveolae can occur at different surface densities in different cell types and they exist 
most abundantly in terminally differentiated cells including endothelium, adipocytes, type I 
pneumocytes, fibroblasts, and smooth muscle cells (Kogo et al, 2006) Caveolae and cav-1 
are particularly abundant in ECs and comprise 95% of cell surface vesicles and -15%  of EC 
volume (Predescu et al., 1993). There is a marked variation in caveolar surface density within 
a given cellular type, which is best exemplified in the case of the different types of 
endothelium (Simionescu et al, 1974) or mesothelia (Von Ruhland et al, 2004). In the 
endothelium, the largest population of caveolae occurs in the continuous type, while their 
numbers are much lower in the fenestrated to occasional caveolae in the endothelium of the 
discontinuous type (Simionescu et al, 1974).
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Cav-1 and cav-2 are co-expressed in most cell types (van Deurs et al., 2002). Cav-1 
and cav-2 are usually co-expressed and assembled into hetero-oligomers in the ER and Golgi 
complex (Scheiffele et al, 1998) and these hetero-oligomeric complexes eventually reach the 
plasma membrane for caveolae biogenesis (Scherer et al., 1997; Li et al., 1998; Das et al., 
1999; Mora et al., 1999; Parolini et al., 1999; Lahtinen et al., 2003; Sowa et al., 2003). Cav-1 
is expressed by ECs and pericytes in brain microvessels and in astrocytes surrounding 
microvessels where it may be involved in blood-brain barrier functioning and also supports 
coordinated activities between these cells (Virgintino, 2002).
Cav-3 (Way et al., 1996) is expressed in skeletal muscle and myocardium where it is 
essential for the formation of caveolae (Hagiwara et al., 2000; Galbiati et al., 2001). It was 
also shown to be expressed in smooth muscle cells (Song et al., 1996), astrocytes (Camero, 
1997; Ikezu, 1998), chondrocytes (Nishiyama et al., 1999; Schwab et al., 1999) and sinus 
ECs (Uehara et al., 2002).
1.7.3 Expression of Caveolae and Caveolins within the Eye
In the eye caveolae were shown to be associated with retinal ECS (Feng et al., 1999b; 
Kim et al., 2006) and cav-1 has been localized to the RPE (Bridges, 2001). In addition, 
ROS-derived detergent-resistant membranes (DRMS), and photoreceptor synaptic ribbons 
(Kachi 2001; Elliot et al., 2003; Martin et al., 2005) were shown to be enriched in cav-1 
where it was suggested that it may participate in phototransduction (Seno et al., 2001). 
Caveolae, cav-1 and cav-2 have also been demonstrated in the lens (Lo and Zhang, 1989; Lo 
et al., 1998, Lo et al., 2003; Lin et al., 2003; Rujoi et al., 2003; Lo et al., 2004; Sexton et al., 
2004). It was shown to co-immunprecipitate with PKCy and connexins 46 and 50 and was 
suggested to protect against oxidative stress which can trigger cataractogenesis. Sexton et al., 
2004 also suggested that in the lens cav-1 may play possible roles in cholesterol trafficking, 
cell to cell communication and signal transduction. Cav-3 expression was shown in the 
papillary sphincter smooth muscle cells but not the ciliary muscle and papillary dilator 
muscle (Kogo et al., 2006). Cav-1 was detected in the ciliary smooth muscle cells and the 
papillary sphincter muscle cell, but not in the papillary dilator and ciliary muscle. The 
localisation of caveolin at the cell membrane of corneal epithelium has previously been 
reported in the context of wound healing (Amino et al., 1997).
Western blot analysis showed that cav-1 and -2 are present in the rat retina (Kim et 
al., 2006). Immnohistochemistry indicated that cav-1 was expressed in the majority of the 
retinal layers, including the GCL, IPL, OPL, and vascular endothelial cells of the retina. Cav-
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2 was primarily immunostained in the vessels, but in a few other elements as well. This was 
the first demonstration of caveolin differential expression in the retina of rats, and suggests 
that caveolin plays an important role in signal transduction in glial cells and neuronal cells. 
Russelakis-Cameiro et al., 2004 demonstrated cav-1 expression in the neuronal cell bodies of 
the retina and in axons of the optic nerve in mice.
Stitt, 2000 showed that AGES bind to receptors in caveolin-rich membrane fractions 
and are internalized within caveolae organelles in retinal microvascular ECs. In a human 
retinal endothelial cell line, ECV 304, exposure to VEGF, and other growth factors resulted 
in a reduced endothelial cell expression of cav-1 which was mediated by a negative feedback 
mechanism through the VEGFR-2 receptor and subsequent downstream p4/44 MAP kinase 
pathway (Liu et al., 1999). It can therefore be proposed that cav-1 protein contributes in a 
unique manner to the angiogenic process in PDR, i.e. growth factors stimulate relaxation of 
cav-l’s action as a ‘molecular brake’ allowing growth-factor-induced endothelial cell 
proliferation.
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1.8 AIMS
The hypothesis of this study is that spatial and temporal differences in angiogenic growth 
factors and associated mediators are critical in the progressive stages that result in diabetic 
retinopathy. Although it has long been established that VEGF is a primary candidate in the 
pathology of diabetic retinopathy, limited information is available on the exact cellular 
location of VEGF, VEGF-C and the VEGF receptors in diabetic retina. Furthermore the role, 
if any, of the angiopoietins and PEDF in diabetic retinopathy needs to be further investigated. 
Caveolae play an important role in the compartmentalization of growth factor signalling 
molecules. Consequently, the following studies were undertaken to define these issues.
1) To examine diabetic retinas and categorize the tissue, by clinical and histological 
examination, into groups relating to the different stages of diabetic retinopathy
2) To perform immunohistochemistry on non-diabetic retinas, diabetic retinas and 
fibrovascular membranes for:
a) VEGF and VEGF-C;
b) The receptors which bind VEGF and VEGF-C;
c) Ang-1 and Ang-2;
d) Tie-2, the receptor for Ang-1 and Ang-2.
e) TNF-a
f) PEDF
g) Caveolins-1, -2, and -3
3) Examine the immunostained retinas and fibrovascular membranes by light microscopy and 
evaluate the intensity of staining semi-quantitatively.
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CHAPTER 2. MATERIALS AND METHODS
2.1 MATERIALS AND SOLUTIONS
2.1.1 Chemical Reagents and Solutions
All chemical reagents and antibodies are listed in appendix I together with their 
source. The constituents of solutions are provided in appendix II.
2.1.2 Human Tissue
Fifty Nine human eyes enucleated and fixed in 10% Neutral buffered formalin (NBF- 
see Appendix II) within 12 hr post-mortem, were obtained from the National Disease 
Research Interchange (NDRI), Philadelphia, USA. All eyes, unless stated, were normal and 
had no known pathological disease.
2.2 METHODS
2.2.1 Clinical assessment of donor eyes
The anterior segment was removed and examination of the posterior segment was 
performed by Professor David McLeod, a Consultant Ophthalmologist at the Manchester 
Royal Eye Hospital, using a Zeiss Stemi SV8 zoom dissecting microscope with Schott light 
source a) to note overt features of retinopathy (e.g. the presence of pre-retinal membranes, 
cotton wool spots, microaneurysms etc.) and b) to determine the extent of any scatter 
photocoagulation.
2.2.2 Categorisation of donor eyes
Donor eyes were divided into those with no obvious signs of diabetic abnormalities 
and those with diabetes. Based on the medical records available and on clinical assessment 
by stereomicroscopy the diabetic eyes were further divided into four groups. They were 
categorised as either diabetic with no overt retinopathy, diabetic with intra-retinal changes 
but no evidence of PDR, diabetic with active proliferative retinopathy or diabetic with scatter 
laser photocoagulation but no evidence of residual PDR.
2.2.2.1 Non-diabetic eyes
This group contained fourteen human eyes with no known ophthalmic disease, no 
history of diabetes and no abnormalities on stereomicroscopy. Donors ranged in age from 20 
to 92 years (mean 56 years).
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22.2.2 Diabetic with no overt retinopathy
This group contained twelve human eyes from diabetic donors with no clinical history 
and no overt macroscopic features of retinopathy or retinal photocoagulation. Donors ranged 
in age from 44 to 89 years (mean 74 years). A complete medical history was unavailable for 
all donors but, in those where medical histories were known, the duration of diabetes was 
between 6 and 25 years.
2 .2 2 3  Diabetic with intra-retinal changes but no evidence of PDR
This group contained ten human eyes from diabetic donors with intra-retinal changes 
on stereomicroscopy but no clinical history and no overt macroscopic features of PDR or 
retinal photocoagulation. Retinas exhibited cotton wool spots and/or obvious 
microaneurysms or haemorrhages. Donors ranged in age from 55-96 years (mean 71 years). 
A complete medical history was unavailable for all donors but, in those where medical 
histories were known the duration of diabetes was between 3 and 21 years.
2.2.2.4 Diabetic with preretinal PDR
This group contained nine human eyes from diabetic donors defined clinically as 
having PDR and exhibiting preretinal membranes when examined by stereomicroscopy. All 
eyes had previously received laser photocoagulation. Donors ranged in age from 37-76 years 
(mean 58 years). Duration of diabetes ranged from 3-18 years (mean 9 years).
2.2.2.5 Diabetic with scatter laser photocoagulation but no evidence of residual PDR
This group contained fourteen human eyes from diabetic donors defined clinically as 
having had PDR and having received scatter laser photocoagulation (no details were 
available as to time post laser). No preretinal membranes could be observed when retinas 
were examined by stereomicroscopy. Donors ranged in age from 41-82 years (mean 63 
years). The duration of diabetes ranged from 3 to 35 years (mean 17 years).
2.2.3 Dissection of donor eyes
The posterior segment of each eye was cut in the saggital plane through the centre of 
the optic nerve head. Cuts were then made perpendicular to this line a) on the horizontal 
midline on the nasal side and b) at approximately 5mm above and below the midline on the 
temporal side. A final vertical cut was made parallel to the initial cut and approximately 3mm 
lateral to the macula. For this study tissue was selected from a portion of retina/choroid/sclera
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approximately 3mm lateral to the macula and perpendicular to the horizontal plane (this 
region was chosen owing to its susceptibility to retinal changes associated with diabetes). 
Tissue was also selected from an area adjacent to the macula region in one eye where a pre­
retinal membrane was observed by stereomicroscopy.
2.2.4 Fibrovascular membranes
Seventeen fibrovascular pre-retinal membranes, which had been excised at vitreous 
surgery from eyes with PDR, were obtained from the Manchester Royal Eye Hospital. 
Membranes were fixed in 10% NBF immediately upon removal for a minimum of 12 hr 
before wax embedding.
2.2.5 Preparation of retinal tissue for wax sectioning
Retinal tissue which had been fixed for a minimum of 24 hr in 10% NBF was 
dehydrated through a graded series of alcohol concentrations (v/v distilled H2 O) as follows: 
50% alcohol for 30 min, 70% alcohol for 1 hr, 90% alcohol for 1 hr, 2 changes of 100% 
alcohol for 1 hr each. Dehydrated tissue was then immersed in 50% chloroform (v/v alcohol) 
for 30 min, 100% chloroform for 1 hr followed by 100% chloroform for 30 min and then 
embedded in wax for 1.5 hr, using a wax embedding system. The wax blocks were trimmed 
and 200 serial sections of 7pm thickness were cut on a Microm HM330 microtome. Every 
th50 section was placed into a warm water bath, allowed to flatten at 47-50°C and then 
transferred onto microscope slides. The slides were dried in an oven at 56°C overnight to 
allow the sections to adhere to the slides.
2.2.6 Preparation of fibrovascular membranes for wax sectioning
Fibrovascular membranes which had been fixed for a minimum of 12 hr in 10% NBF 
were dehydrated through a graded series of alcohol concentrations (v/v distilled H2 O) as
follows: 25% alcohol for 15 min, 33% alcohol for 15 min, 50% alcohol for 15 min, 63% 
alcohol for 15 min, 70 % alcohol for 30 min, 80% alcohol for 30 min, 90% alcohol for 30 
min, 2 changes of 100% alcohol for 30 min each. Dehydrated tissue was then immersed in 
25% chloroform (v/v alcohol) for 15 min, 33% chloroform for 15 min, 50% chloroform for 
30 min followed by 2 changes of 100% chloroform for 30 min and then immersed in wax for 
20 min. The wax blocks were trimmed and serial sections, throughout the whole block, of
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til5 ^ im thickness were cut. Every 20 section was placed into a warm water bath, allowed to 
flatten at 47-50°C and then transferred onto microscope slides. The slides were dried in an 
oven at 56°C overnight to allow the sections to adhere to the slides.
2.2.7 Haematoxylin and eosin staining of wax sections
Sections of retina, and fibrovascular membrane which had been mounted on slides 
were dewaxed by immersion in two baths of xylene and rehydrated through a graded series of 
alcohol concentrations (v/v distilled H2 O), 5 min in each of 100% alcohol (twice), 90% 
alcohol, 70% alcohol and 50% alcohol, followed by immersion in cold running water. After 
excess alcohol had been removed the slides were submerged in a solution of Harris 
haematoxylin for 3 min then washed in cold running H2 O until the dye turned blue. Sections 
were then submerged in eosin for 1 min, briefly washed in cold running H2 O and then 
dehydrated by immersing them quickly through an alcohol series (the reverse order of that 
above) followed by two washes with xylene. A coverslip was secured onto each section using 
Practamount adhesive which was allowed to set by drying overnight in a 60°C oven.
2.2.8 Immunohistochemical studies
2.2.8.1 Selection of sections for immunostaining
Once the sections of retina, and fibrovascular membranes had been stained by 
haematoxylin and eosin (H and E) they were examined by light microscopy. Non-diabetic 
retinal sections and diabetic retinal sections showing no overt signs of retinopathy and 
sections which had overt features of retinopathy, such as pre-retinal membranes, exudates 
and haemorrhages, were mounted onto 1% Aminopropyltriethoxysilane (APES-see appendix
II) coated slides in preparation for immunostaining (sections were selected which were 
adjacent to the corresponding H and E stained section). Sections of fibrovascular membranes 
were examined by light microscopy and where blood vessels and a large area of tissue were 
present adjacent sections were mounted onto 1% Apes coated slides in preparation for 
immunostaining.
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2.2.8.2 General protocol for immunostaining of sections
Sections were dewaxed and rehydrated as previously described (section 2.2.7). 
Sections were exposed to proteolytic pre-digestion, dependent upon the primary antibody to 
be used, for between 20 minutes and 30 minutes at 37°C/or in the pressure cooker for 3 
minutes (see table 1 and appendix II). Sections were covered for between 20 min and 1 hr at 
room temperature with the appropriate blocking agent (containing serum from the 
appropriate secondary antibody host) to block non-specific binding. Sections were washed 
three times in Tris buffered saline (TBS) [see appendix II]. Primary antibodies were diluted 
to an appropriate dilution in TBS with 0.2% serum (dilution determined by a dilution series 
experiment), and added to all the sections, except the negative controls (which received TBS 
with 0.2% serum) and incubated at 4°C overnight. Slides were washed three times in TBS 
before addition of the appropriate secondary antibody (biotin conjugated) for 1 hour. After 
washing three times in TBS, an avidin/biotin complex (ABC) [see appendix II] was applied 
for 30 min to enhance the antibody signal. After washing the slides three times in TBS a Fast 
Red substrate or diaminobenzidine (caveolin-1) (see appendix II) for the avidin/biotin 
complex was filtered and added to the sections to visualise the sites of antibody binding. 
After washing in running water to quench the substrate reaction slides were counterstained by 
immersion in a standard solution of Mayers haematoxylin for 10 seconds. Sections were 
placed in running cold water, air-dried, and coverslips applied using Loctite 358 ultra violet 
(UV) curing adhesive, which was then sealed by exposure to UV light for 3min.
53
Primary Ab Host Pre-treatment Blocking
Agent
Secondary Ab
VEGF165
(1/20)
Goat 0.1%
chymotrypsin
10% Milk 
proteins/10% 
Rabbit serum
Rabbit anti-goat 
biotin conjugate
VEGF-C
(1/100)
Goat 0.1%
Chymotrypsin
10% Milk 
proteins/10% 
Rabbit serum
Rabbit anti-goat 
biotin conjugate
Ang-1
(1/50)
Goat 0.1%
Chymotrypsin
Rabbit serum Rabbit anti-goat 
biotin conjugate
Ang-2
(1/50)
Goat 0.1%
Chymotrypsin
Rabbit serum Rabbit anti-goat 
biotin conjugate
VEGFR-1
(1/100)
Rabbit None 10% Milk 
proteins/10% 
Goat serum
Goat anti-rabbit 
biotin conjugate
VEGFR-2
(1/50)
Rabbit None 10% Milk 
proteins/10% 
Goat serum
Goat anti-rabbit 
biotin conjugate
VEGFR-3
(1/100)
Rabbit None 10% Milk 
proteins/10% 
Goat serum
Goat anti-rabbit 
biotin conjugate
Tie-2
(1/50)
Rabbit 0.1%
Chymotrypsin
Goat serum Goat anti-rabbit 
biotin conjugate
TNF-a
(1/25)
Goat Pressure
Cooker
Rabbit serum Rabbit anti-goat 
biotin conjugate
PEDF
(1/300)
Rabbit None Pig serum Pig anti-rabbit 
biotin conjugate
Caveolin-1
(1/10)
Mouse 0.2%
Triton X-100
Goat serum Goat anti-mouse 
biotin conjugate
Caveolin-2
(1/10)
Mouse 0.2%
Triton X-100
Goat serum Goat anti-mouse 
biotin conjugate
Caveolin-3
(1/10)
Mouse 0.2%
Triton X-100
Goat serum Goat anti-mouse 
biotin conjugate
Table 2.1 The pre-treatments, blocking agents and secondary antibodies used in the 
immunostaining for growth factors and their receptors, PEDF, TNF-a, Caveolin-1, -2, 
and-3
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2.2.8.3 Assessment of immunostaining
The degree and pattern of immunostaining both within and between specimens, as 
observed by standard light microscopy, was assessed by two independent observers (both of 
which obtained similar results - see appendix V). The intensity of staining was graded 
qualitatively as background (corresponding to the level of staining seen in the negative 
controls), weak, moderate, or intense (corresponding to the highest level of immunoreactivity 
observed). These intensities were recorded as 0, 1 ,2 , and 3 respectively. For each retinal 
specimen staining intensity was recorded for photoreceptors, outer retina, inner retina, GCL 
and retinal vessels. For the fibrovascular membranes staining intensity was recorded for the 
vessels and the surrounding matrix. An average score was then calculated for each retinal 
layer within each group.
2.2.8.4 Statistical Analysis
Differences between the retinal layers across tissue catagories was assessed using CHI 
squared statistical analysis (SPSS 12). Values of less than 0.05 were taken to be significant.
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CHAPTER 3 HISTOLOGICAL CATEGORIZATION OF NON-DIABETIC AND 
DIABETIC HUMAN RETINAS AND FIBROVASCULAR MEMBRANES
3.1 INTRODUCTION
59 retinas were stained with haematoxylin and eosin and examined by light 
microscopy. Each retina was put into a category depending upon whether they were non­
diabetic (see table 3.1) or whether they were diabetic and showed any intraretinal 
microvascular abnormalities associated with diabetic retinopathy (see tables 3.2 to 3.5). The 
retinas were categorized as either, non-diabetic, unlasered diabetic retinas with no obvious 
microvascular abnormalities, unlasered diabetic retina with obvious microvascular 
abnormalities, diabetic retina with PDR or lasered retinas without any obvious microvascular 
abnormalities. 17 excised fibrovascular membranes were also stained with haematoxylin and 
eosin to determine if neovessels were absent or present (see table 3.6).
3.2 Haematoxylin and Eosin Staining of Non-diabetic Retinas
None (14/14) of the non-diabetic retinas showed any microvascular changes 
associated with NPDR or any neovascular membranes associated with PDR (see figure 3.1). 
None of the retinas examined showed any indication of having previously received 
photocoagulation treatment. Donor details and the results from haematoxylin and eosin 
staining are shown below (see table 3.1).
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Table 3.1 Non-diabetic Retinas
Donor
Number
Sex Age Time
Post-
Mortem
(hours)
Findings
On
Stereomicroscopy
Findings
On
H andE
1 M 79 1 No microvascular 
Abnormalities
No
microvascular
abnormalities
2 M 88 2 No microvascular 
Abnormalities
No
microvascular
abnormalities
3 F 75 3 No microvascular 
Abnormalities
No
microvascular
abnormalities
4 M 82 2 No microvascular 
Abnormalities
No
microvascular
abnormalities
5 F 63 10.5 No microvascular 
Abnormalities
No
microvascular
abnormalities
6 F 20 9 No microvascular 
Abnormalities
No
microvascular
abnormalities
7 F 89 1 No microvascular 
Abnormalities
No
microvascular
abnormalities
8 F 92 6 No microvascular 
Abnormalities
No
microvascular
abnormalities
9 M 49 12 No microvascular 
Abnormalities
No
microvascular
abnormalities
10 M 22 5 No microvascular 
Abnormalities
No
microvascular
abnormalities
11 M 34 23 No microvascular 
Abnormalities
No
microvascular
abnormalities
12 F 57 6 No microvascular 
Abnormalities
No
microvascular
abnormalities
13 M 78 4 No microvascular 
Abnormalities
No
microvascular
abnormalities
14 F 27 8.25 No microvascular 
Abnormalities
No
microvascular
abnormalities
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Figure 3.1. H and E Staining of Non-Diabetic Retinas
3.3 Haematoxylin and Eosin Staining of Diabetic Retinas
12/45 of the diabetic retinas examined by light microscopy had no obvious signs of diabetic 
retinopathy and no indication of having previously received photocoagulation treatment and 
were placed into the category of unlasered diabetic retinas with no obvious microvascular 
abnormalities (see table 3.2; figure 3.2). 10/45 of the diabetic retinas examined by light 
microscopy had microvascular changes associated with NPDR, such as the presence of 
exudates and gross basement membrane thickening, and were placed into the category of 
unlasered diabetic retinas with obvious microvascular abnormalities (see table 3.3; figure 
3.3). 9/45 of the diabetic retinas had neovascular membranes on their surfaces and were 
placed into the category of diabetic retinas with PDR (see table 3.4; figure 3.4). 14/45 of the 
diabetic retinas which had previously had PDR showed evidence of laser treatment but no 
evidence of NPDR or PDR and were placed into the category of lasered retinas without any 
obvious microvascular abnormalities (see table 3.5; figure 3.5).
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Table 3.2 Unlasered Diabetic Retinas with No Obvious Microvascular Abnormalities
Donor
Number
Sex Age Time
Post-
Mortem
(hours)
Type
Of
Diabetes
Duration
Of
Diabetes
(years)
Lasered Findings
On
Stereomicroscopy
Findings
On
H and E
15 M 77 5 Type 2 9 No No microvascular 
Abnormalities
No
microvascular
abnormalities
16 F 82 4 Type2 10 No No microvascular 
Abnormalities
No
microvascular
abnormalities
17 F 89 3 Type 2 6 No No microvascular 
Abnormalities
No
microvascular
abnormalities
18 M 57 11 Type 2 5 No No microvascular 
Abnormalities
No
microvascular
abnormalities
19 M 57 11 Type 2 5 No No microvascular 
Abnormalities
No
microvascular
abnormalities
20 F 76 12 Type 1 8 No No microvascular 
Abnormalities
No
microvascular
abnormalities
21 M 88 2 Type 1 10 No No microvascular 
Abnormalities
No
microvascular
abnormalities
22 M 75 6 Type 2 6 No No microvascular 
Abnormalities
No
microvascular
abnormalities
23 F 82 3 Type 2 6 No No microvascular 
Abnormalities
No
microvascular
abnormalities
24 M 69 3.5 Type 1 5 No No microvascular 
Abnormalities
No
microvascular
Abnormalities
25 F 75 10 Type 1 7 No No microvascular 
Abnormalities
No
microvascular
Abnormalities
26 M 74 3 Type 2 5 No No microvascular 
Abnormalities
No
microvascular
Abnormalities
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Table 3.3 Unlasered Diabetic Retinas with Obvious Microvascular Abnormalities
Donor
Number
Sex Age Time
Post-
Mortem
(hours)
Type
Of
Diabetes
Duration
Of
Diabetes
(years)
Lasered Findings
On
Stereomicroscopy
Findings
On
H and E
27 F 96 3 Type 1 8 No Cotton wool 
Spots
Exudates,
basement
membrane
thickening
28 M 84 11 Type 2 6 No No
microvascular
abnormalities
Haemorrhages
exudates,
basement
membrane
thickening
29 M 68 5 Type 2 3 No Cotton wool 
spots
Basement
membrane
thickening
30 F 62 4.5 Type 1 15 No Haemorrhages Haemorrhages
31 F 62 6 Type 1 21 No White lesions Haemorrhages
exudates,
basement
membrane
thickening
32 F 48 3 Type 1 10 No No microvascular 
Abnormalities
Exudates,
basement
membrane
thickening
33 M 83 2.5 Type 1 30 No No
microvascular
abnormalities
Basement
membrane
thickening
34 M 33 10 Type 1 23 No No
microvascular
abnormalities
Basement
membrane
thickening
35 M 33 10 Type 1 23 No No
microvascular
abnormalities
Basement
membrane
thickening
36 F 50 12 Type 1 40 No No microvascular 
Abnormalities
Basement
membrane
thickening
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Table 3.4 Diabetic Retinas with Proliferative Diabetic Retinopathy
Donor
Number
Sex Age Time
Post-
Mortem
(hours)
Type
Of
Diabetes
Duration
Of
Diabetes
(years)
Lasered Findings
On
Stereomicroscopy
Findings
On
H and E
37 M 53 2 Type 2 10 No Pre-retinal
vessels
Pre-retinal
vessels
38 F 73 5 Type 2 6 No Pre-retina
vessels,
microaneurysms
Pre-retinal
vessels
39 F 76 8 Type 1 3 No Haemorrhages,
pre-retinal
vessels
Pre-retinal
vessels
40 M 37 6 Type 1 5 No Exudates,
haemorrhages,
pre-retinal
Vessels
Pre-retinal
vessels
41 F 47 3.25 Type 1 18 No Oedema, cotton 
wool spots
Pre-retinal
vessels
42 M 55 2.5 Type 1 21 No Exudates, pre­
retinal vessels
Exudates,
pre-retinal
vessels
43 M 55 2.5 Type 1 21 No Exudates, pre­
retinal vessels
Exudates,
pre-retinal
vessels
44 M 41 26 Type 1 23 No Pre-retinal
vessels
Exudates,
basement
membrane
thickening,
pre-retinal
vessels
45 M 81 16.5 Type 1 30 No No microvascular 
Abnormalities
Pre-retinal
vessels
62
Table 3.5 Lasered Retinas Without Any Obvious Microvascular Abnormalities
Donor
Number
Sex Age Time
Post-
Mortem
(hours)
Type
Of
Diabetes
Duration
Of
Diabetes
(years)
Lasered Findings
On
Stereomicroscopy
Findings
On
H andE
46 M 55 4 Type 2 35 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
47 M 76 7 Type 1 25 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
48 M 55 12 Type 1 24 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
49 F 41 4 Type 1 29 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
50 F 41 4 Type 1 29 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
51 F 47 8 Type 1 16 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
52 F 66 5 Type 2 12 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
53 F 66 5 Type 2 12 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
54 F 55 18 Type 1 15 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
55 M 61 14 Type 2 20 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
56 M 82 12 Type 1 8 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
57 F 40 19 Type 2 20 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
58 M 55 2 Type 1 12 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
59 M 53 2 Type 2 10 Yes No microvascular 
Abnormalities
No
microvascular
abnormalities
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Figure 3.2. H and E staining of Unlasered Diabetic Retinas 
with No Obvious Microvascular Abnormalities
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Figure 3.3. H and E Staining of Diabetic Retinas With NPDR
Intraretinal haemorrhages (A, B), exudates (C,D) and BM 
thickening were observed (E,F). Arrows show location of 
microvascular abnormalities
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Figure 3.4 H and E Staining of Diabetic Retinas With PDR
Arrows show localisation of preretinal membranes
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Figure 3.5 H and E Staining of Lasered retinas. Arrows show 
area of laser burns
3.4 Haematoxylin and Eosin Staining of Fibrovascular Membranes
All (17/17) of the fibrovascular membranes contained blood vessels (see figure 3.6). Donor 
details are shown below. Medical histories for some donors were not provided (see table 3.6).
Table 3.6 Fibrovascular Membranes
Donor
Number
Sex Age Neovessels
Present
B la F 44 Yes
Bib F 44 Yes
B2a M 46 Yes
B2b M 46 Yes
B6 M 27 Yes
B8 M 61 Yes
B9 M 59 Yes
BIO M 23 Yes
B lla M 36 Yes
B llb M 36 Yes
B12 M 39 Yes
B13 M 45 Yes
1447 N/A N/A Yes
1448 N/A N/A Yes
1450 N/A N/A Yes
1451 N/A N/A Yes
1552 N/A N/A Yes
1519 N/A N/A Yes
1520 N/A N/A Yes
2254 N/A N/A Yes
2255 N/A N/A Yes
2256 N/A N/A Yes
1454 N/A N/A Yes
N/A = No Medical Histories Available
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Figure 3.6 H and E Staining of Fibrovascular Membranes
3.5 DISCUSSION
Damage to the retinal microvasculature is a feature of many eye diseases including 
diabetic retinopathy and some degree of retinopathy occurs in nearly all patients with 
diabetes of greater than 20 years duration (Klein et al., 1984). Whether retinopathy appears 
or not depends mainly on the duration of the disease and the degree of metabolic control the 
patient maintains. Glycaemia-related vascular damage has been hypothesized to be mediated 
through various biochemical pathways including the hexosamine pathway, the advanced 
glycation end-product formation pathway, and the diacylglycerol (DAG)-protein kinase C 
(PKC) pathway (Jawa et al., 2004).
In this study it was important that donors who had previously not been diagnosed with 
diabetes in their lifetime, be examined for signs of microvascular abnormalities associated 
with diabetes. This is because it has become increasingly recognized that typical lesions of 
DR (microaneurysms and haemorrhages) are commonly seen in individuals without clinically 
diagnosed diabetes (Nguyen and Wong, 2006). However the findings from this study, from 
stereomicroscopy and from examination of H and E sections, demonstrated that none of the 
‘non-diabetic’ donors showed signs of retinopathy.
I then examined diabetic donors whose medical histories indicated that they had been 
diagnosed with diabetes but not with DR and whose retinas showed no obvious 
microvascular abnormalities when viewed by stereomicroscopy. Examination of the H and E 
sections was consistent with these findings. However, only a small sample of the retina from 
the macula region was examined by H and E staining as I only stained every 50th section 
from a total of 200 serial sections. Therefore to get a true picture of what is happening in 
each retina, it would have been more beneficial to examine every section throughout the 
macula sample and to take serial sections through all other regions of the retina (the same 
could apply to the non-diabetic retinas too). Tang et al., 2003 showed that microaneurysms, 
acellular capillaries and pericyte ghosts were more numerous in the temporal retina than the 
nasal retina in retinal whole mounts of diabetic patients. However, this does not rule out the 
presence of microvascular abnormalities in regions other than the macula.
NPDR is characterized by loss of pericytes around capillaries in the retina. This is 
followed by development of weakness in the capillary wall that leads to capillary aneurysm 
formation (microaneurysm) and fluid leakage and haemorrhages from capillaries as their 
walls become more permeable. An increase in the number of microaneurysms is considered a 
risk sign for progression of retinopathy as well as excessive permeability of the retinal 
vessels. (Kohner and Sleightholm, 1986; Klein et al., 1995; Ferris et a l, 1999). Fluid leakage
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can range from microexudates and infiltrating protein or lipid exudates (Davis, 1992; Chew 
et al., 1996) to the most severe form, macular oedema, which can seriously reduce vision 
(Ferris and Patz, 1984). Cotton wool spots are also seen which represent stasis of axoplasmic 
flow due to ischaemia of the nerve fibre layer (Palmberg, 1977; Early Treatment Diabetic 
Retinopathy Study Research Group, 1991).
In this study I demonstrated that microvascular abnormalities that were present in H 
and E sections were not always obvious by stereomicroscopy. This emphasises the 
importance of undertaking H and E staining and the examination of the sections by 
microscopy. Cotton wool spots and haemorrhages were seen by stereomicroscopy but only 
basement membrane thickening and exudates could be observed by light microscopy. I also 
observed haemorrhages with H and E staining.
Histological analysis has also demonstrated the presence of intraretinal haemorrhages, 
and exudates in several animal models of NPDR (Tolentino et al., 1996; Kim et al., 2004; 
Kakehashi et al., 2006; Van Eden et al., 2006). Electron, confocal and light microscopy 
techniques have shown increased BM thickening in numerous diabetic animal models 
(Fischer et al., 1981; Itabashi et al., 1981; Altshuler and Omey, 1986; Chakrabarti and Sima, 
1987; Cuthbertson and Mandel, 1987; Diani et al., 1987; Robinson et al., 1988; Marion and 
Carlson, 1989; Copeland et al., 1990; Carlson et al., 1997; Miyamura et al., 1999; 
Hainsworth et al., 2002; Carlson et al, 2003; Gardiner et al., 2003; Joussen et al., 2004; 
Yatoh et al., 2006). BM thickness was shown to increase at longer duration of diabetes 
compared with age-matched controls (Feit-Leichman et al., 2005). In addition, ultrastructural 
comparisons of BMs in a variety of tissues from diabetic and normal human subjects have 
been carried out (Danowski et al., 1972; Kilo et al., 1972; Dunn et al., 1979; Fischer et al., 
1979; Jackson et al., 1982; Johnson et al., 1982; Raskin et al., 1983; Sosenko et al., 1984; 
Feingold et al., 1986, 1989; Osterby, 1990; Osterby et al., 1998, 2001; Bangstad et al., 1999).
PDR typically develops in patients with type 1 diabetes which I have shown in this 
study as most of the donors with PDR had type 1 diabetes (Klein et al, 1984a,b; Frank, 
2004). In all but 2 of the retinas in this study pre-retinal membranes were observed both by 
stereomicroscopy and on microscopic examination of H and E sections. It is known that pre­
retinal neovascularization may be difficult to detect clinically in the fundus periphery 
(Tolentino et al., 2002). Therefore the examination of H and E sections was important in this 
study rather than just viewing the retinas by stereomicroscopy. In rat and mouse models of 
PDR neovascular membranes were seen in retinas when examined using haematoxylin and 
eosin staining (Lai et al., 2005; Kakehashi et al., 2006). Tolentino et al., 2002 also
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demonstrated the presence of preretinal neovascularization histologically using flat- 
embedded nonhuman primate retinas.
Studies of histopathology and immunohistochemistry demonstrated that epiretinal 
membranes (ERMs) consist of complex fibrocellular tissue mainly composed of RPE, 
macrophages, glial cells, fibroblast-like cells and various amounts of extracellular matrix 
components and vascular elements (Yamamoto et al., 1989; Hai et al., 1998). I showed that 
neovessels were present in all the fibrovascular membranes stained by H and E. This is 
consistent with the findings of Tsanou et al., 2005 who demonstrated that all ERMs 
surgically removed at vitrectomy had microvessels, with some vessels staining positively for 
Ki67 which is a marker of proliferation.
Panretinal photocoagulation is the treatment of choice for high-risk retinopathy (The 
Diabetic Retinopathy Study Research Group, 1979; Whiteside and Thompson, 1989; The 
Early Treatment Diabetic Retinopathy Study Research Group (ETDRS), 1995). The aim of 
laser photocoagulation is to eliminate areas of ischaemia, induce the regression of new 
vessels, and close leaking vessels leading to a decrease in exudates and macula oedema 
(Petrovic and Bhisitkul, 1999; De La Cruz et al., 2004). Laser treatment of clinically 
significant macular oedema in patients with diabetic retinopathy is beneficial and reduces the 
overall risk of visual loss by about 50% (ETDRS No 9, 1991). In some cases, however visual 
acuity deteriorates (Agardh et al., 1993), which could be due to either a rapid progress of 
oedema with hard exudates and subretinal fibrosis (ETDRS No23, 1997) or subretinal 
neovascularization membranes (Lewen, 1988; Varley et al., 1988). However in this study 
none of the lasered retinas showed signs of exudates or neovascular membranes, when 
examined by stereomicroscopy and on examination of H and E sections, suggesting that the 
treatment had been successful.
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CHAPTER 4 EXPRESSION OF PRO-ANGIOGENIC GROWTH FACTORS AND 
THEIR RECEPTORS IN THE NORMAL AND DIABETIC RETINA
4.1 INTRODUCTION
Sections were stained to localise and assess the extent of VEGF-A1 6 5 , VEGF-C and
their receptors VEGFR-1, VEGFR-2 and VEGFR-3 presence in the retina and preretinal 
membranes. Sections were also stained to localise and assess the extent of angiopoietin-1, 
angiopoietin-2 and their receptor Tie-2 presence in the retina and preretinal membranes. 
Finally, sections were stained to localise and assess the extent of TNF alpha presence in the 
retina and preretinal membranes.
Immunostained sections of retina were examined by light microscopy to determine if 
there was a temporal and spatial relationship between staining intensity and the various 
pathological changes associated with diabetic retinopathy.
4.2 CONTROL STAINING
To confirm specificity of the immunostaining control sections were processed with 
0.2% non-immune serum in place of the primary antibodies. Staining was negative on all the 
control sections (see figure 4.1).
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Table 4.1 Transverse Sections Showing Negative Control Staining for VEGF-A165 
(A), VEGF-C (B), VEGFR-1 (C), VEGFR-2 (D), VEGFR-3 (E), Ang-1 (F), Ang-2 
(G), Tie-2 (H), and TNF-a (I).
4.3 IMMUNOLOCALISATION OF PRO-ANGIOGENIC GROWTH FACTORS
4.3.1 VEGF-A165, and VEGF-C immunostaining of retinal sections and fibrovascular 
membranes
When examined by light microscopy, VEGF-A165 staining was apparent in most 
diabetic tissue but generally absent or weak in the non-diabetic tissue. VEGF-A165 
immunoreactivity was generally confined to endothelial cells and perivascular regions. 
Variability of staining was observed for each retina within each category, which is 
represented by the standard deviations in table 4.1, but this did not correlate with either donor 
age, post-mortem time, or duration of diabetes. Statistical analysis demonstrated that 
significant differences were observed within the retinal vessels across the tissue categories (P 
= <0.05%) but not within the retinal layers.
The average scores and standard deviations for VEGF-A1 6 5  immunostaining are 
represented in table 4.1. Although staining for VEGF-A1 6 5  was generally absent in the non­
diabetic retinas, weak staining was associated with the retinal vessels in 7/15 of the 
specimens. Staining was absent or minimal within the photoreceptors, and the cell bodies in 
the inner and outer retina and GCL (Fig. 4.2).
In the diabetic retinas with no overt retinopathy VEGF-A1 6 5  was absent or minimal 
within the photoreceptors, and the cell bodies in the inner and outer retina and GCL. Staining 
was raised in the retinal vessels as compared to the non-diabetic retinas and was observed in 
12/19 specimens (Fig. 4.3).
In the diabetic retinas showing vascular changes but no evidence of PDR VEGF- 
Ai65 immunostaining was increased within the retinal vessels and the GCL compared to that 
observed in normal retinas and diabetic retinas with no overt retinopathy. Staining of the 
photoreceptors, and in the cell bodies in the outer and inner retina was not significantly 
elevated above that observed in the normal retinas and the diabetic retinas with no overt 
retinopathy (Fig. 4.4).
Moderate to intense staining of the retinal vessels for VEGF-A1 6 5  was observed in 
all the diabetic retinas (6/6) with active neovascular PDR membranes on their surfaces. 
Intense staining was also observed within the membranes (Fig. 4.5). Staining was absent 
within the photoreceptors, within cell bodies in the outer retina, inner retina, and the GCL.
VEGF-A165 immunostaining in diabetic retinas that had undergone apparently 
successful laser therapy (that is, those with no preretinal neovascularization) showed a
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similar staining pattern to that observed for non-diabetic retina (Fig. 4.6). Minimal 
immunoreactivity was observed within the inner retinal vessels. Staining was absent within 
the photoreceptors, and the cell bodies of the outer retina, and inner retina. Weak staining 
was also observed within the GCL.
VEGF-A immunoreactivity was moderate to intense within the preretinal vessels of 
the excised membranes. Weak to moderate staining was observed within the non-vascular 
components of most (8/11) of the membranes (Fig. 4.7).
The average scores and standard deviations for VEGF-C immunostaining are 
represented in table 4.2. When examined by light microscopy, VEGF-C staining was 
apparent in most non-diabetic and diabetic vascular tissue which was confined to retinal 
endothelial cells and the perivascular region. Increased immunostaining was observed within 
intra-retinal vessels of diabetic tissue as compared to non-diabetic tissue. Variable staining of 
the vessels within each retina was observed with some staining positive and some staining 
negative. Staining was also associated with extravascular regions of the retina. Variability of 
staining was observed for each retina within each category, which is represented by the 
standard deviations in table 4.2, but this did not correlate with either donor age, time post 
mortem, or duration of diabetes. Statistical analysis demonstrated that significant differences 
were observed within the GCL across the tissue categories (P = <0.05%) but not within the 
other retinal layers and the retinal vessels.
In the non-diabetic retinas staining intensity for VEGF-C was generally absent or 
minimal within the photoreceptors, the cell bodies of the outer retina, the inner retina and the 
GCL. Weak staining was observed within the retinal vessels of 7/14 non-diabetic retinas (Fig. 
4.8).
In the diabetic retinas with no overt retinopathy weak to moderate immunoreactivity 
for VEGF-C was observed within the GCL (8/12), and the retinal vessels (9/12), which was 
increased as compared with the non-diabetic retinas. Staining intensity was again absent or 
minimal within the photoreceptors, and the cell bodies of the outer retina and inner retina 
(Fig. 4.9).
In the diabetic retinas showing vascular changes but no evidence of PDR moderate to 
intense immunoreactivity for VEGF-C was demonstrated within the retinal vessels (5/5) 
which was increased, as compared to the retinas with no overt retinopathy (Fig. 4.10). 
Staining intensity was again weak to moderate within the GCL and absent or minimal within 
the photoreceptors and the cell bodies of the outer retina and inner retina.
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In the diabetic retinas with active neovascular PDR membranes on their surfaces 
moderate to intense VEGF-C immunostaining of the retinal vessels was observed in all of the 
sections (6/6) [Fig. 4.11]. However, only minimal staining was observed within the preretinal 
vessels (2/6) and weak staining was observed within the extravascular matrix (4/6). Staining 
intensity was also reduced to minimal levels in the GCL (2/6) as compared to the previous 
categories of diabetic retinas. Staining intensity was minimal within the photoreceptors, and 
the cell bodies of the outer retina and inner retina.
In those diabetic retinas which had undergone successful laser therapy, staining 
intensity for VEGF-C was weak within the retinal vessels. Staining was absent or minimal 
within the photoreceptors, the cell bodies of the outer retina, the inner retina and the GCL 
(Fig. 4.12).
VEGF-C immunoreactivity was minimal within the preretinal vessels of the excised 
membranes. Weak staining was observed within the non-vascular components of most (8/11) 
of the membranes (Fig. 4.13).
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TABLE 4.1. MEAN INTENSITY OF VEGF-A165 IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non­ 0 0 0.2 0.8 1.0
diabetic
(n=14)
(0) (0) (0.1) (0.3) (0.2)
No Overt 0.1 0 0.2 0.4 1.2
Retinopathy
(n=12)
(0.1) (0) (0.2) (0.3) (0.2)
Intraretinal 0 0 0 1.4 2.2
Changes
(n=10)
(0) (0) (0) (0.4) (0.5)
PDR 0 0 0 0.3 2.5 2.5 0.6
(n=9) (0) (0) (0) (0.2) (0)
Laser-No
Residual 0 0 0 1.1 0.6
PDR
(n=14)
(0) (0) (0) (0.3) (0.3)
Excised 2.6 1.7
Membranes
(n=17)
(0.3) (0.2)
GCL = ganglion cell layer
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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TABLE 4.2 MEAN INTENSITY OF VEGF-C STAINING
Tissue
Category
Retina Layer Retinal Mem Drane
Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non­
diabetic
(n=14)
0.4
(0.8)
0
(0)
0.1
(0.4)
0.3
(0.4)
1.1
(1.2)
No Overt
Retinopathy
(n=12)
0.3
(0.7)
0
(0)
0.1
(0.3)
1.2
(1.0)
1.6
(1.1)
Intraretinal
Changes
(n=10)
0.6
(0.9)
0.2
(0.5)
0.6
(0.9)
1.2
(1.1)
2.4
(0.9)
PDR
(n=9)
0.3
(0.5)
0.2
(0.4)
0.3
(0.5)
0.3
(0.5)
2.5
(0.5)
0.7
(1.0)
1.2
(1.0)
Laser-No
Residual
PDR
(n=14)
0.4
(0.6)
0.4
(0.9)
0.3
(0.5)
0.4
(0.5)
0.8
(1.2)
Excised
Membranes
(n=17)
0.3
(0.9)
1.1
(0.8)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.2 Transverse Sections Showing the Immunolocalisation (Arrows) of 
VEGF-A in Non-Diabetic Retinas
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Figure 4.3 Transverse Section Showing the Immunolocalisation of VEGF-A 
(Arrows) in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities.
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Figure 4.4 Transverse Sections Showing the Immunolocalisation of VEGF-A
(Arrows) in Unlasered Diabetic Retinas with NPDR.
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Figure 4.5 Transverse Sections Showing the Immunolocalisation of VEGF-A in 
Diabetic Retinas with PDR.
Arrows show location of staining in the retinal vessels and the preretinal
membranes
Figure 4.6 Transverse Sections Showing the Immunolocalisation of VEGF-A in 
Lasered Diabetic Retinas
Weak staining was seen in the GCL of some (arrows) of the retinas
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Figure 4.7 Transverse Sections Showing the Immunolocalisation of VEGF-A
(Arrows) in Fibrovascular M embranes
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Figure 4.8 Transverse Sections Showing the Immunolocalisation of VEGF-C
(Arrows) in Non-Diabetic Retinas.
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Figure 4.9 Transverse Sections Showing the Immunolocalisation of VEGF-C 
(Arrows) in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities.
Figure 4.10 Transverse Sections Showing the Immunolocalisation of VEGF-C
(Arrows) in Unlasered Diabetic Retinas with NPDR.
Figure 4.11 Transverse Sections Showing the Immunolocalisation of VEGF-C 
in Diabetic Retinas with PDR.
Arrows show location of staining in the retinal vessels and the preretinal 
membranes
Figure 4.12 Transverse Sections Showing the Immunolocalisation of VEGF-C 
(Arrows) in Lasered Diabetic Retinas.
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Figure 4.13 Transverse Sections Showing the Immunolocalisation of VEGF-C
(Arrows) in Fibrovascular M embranes
4.3.2 VEGF receptor immunostaining of retinal sections and fibrovascular membranes
When examined by light microscopy immunostaining for all three receptors was 
observed in both non-diabetic and diabetic vascular and extravascular tissue. The staining 
pattern depended upon the specificity of the antibody being used and the category of tissue. 
Increased immunostaining was observed in preretinal and intra-retinal blood vessels of 
diabetic tissue as compared to non-diabetic tissue. For all the receptors variable staining of 
the vessels within each retina was observed with some staining positive and some staining 
negative. In some instances staining was associated with both endothelial cells and the 
perivascular region of the vessels. Variability of staining was observed for each retina within 
each category, which is represented by the standard deviations in tables 4.3 to 4.5, but this 
did not correlate with either donor age, or time post mortem.
The average scores and standard deviations for VEGFR-1 immunostaining are 
represented in table 4.3. Statistical analysis demonstrated that significant differences were 
observed within the photoreceptors and the cell bodies of the outer retina across the tissue 
categories (P = <0.05%) but not within the other retinal layers or the retinal vessels.
In the non-diabetic retinas staining intensity for VEGFR-1 was generally minimal or 
weak within the photoreceptors, and the cell bodies of the outer retina. Weak to moderate 
staining was observed within the cell bodies of the inner retina (11/14), the GCL (11/14), and 
the retinal vessels (9/14) [Fig. 4.14].
In all the diabetic retinas with no overt retinopathy weak to moderate 
immunoreactivity for VEGFR-1 was associated with the cell bodies of the inner retina 
(12/12), the GCL (11/12), and the retinal vessels (8/12) [Fig. 4.15]. Immunoreactivity was 
slightly raised as compared to non-diabetic retinas. Staining within the other retinal layers 
was generally minimal or weak.
In the diabetic retinas showing vascular changes but no evidence of PDR staining for 
VEGFR-1 was raised, as compared with the non-diabetic and diabetic retinas with no overt 
retinopathy, within the cell bodies of the outer retina (3/5), the inner retina (5/5), the GCL 
(5/5), and the retinal vessels (4/5) [Fig. 4.16]. The most intense staining was observed within 
the GCL. Staining was again minimal or weak within the photoreceptors.
In the diabetic retinas with active neovascular PDR membranes on their surfaces 
intensity of staining for VEGFR-1 was similar within the cell bodies of the outer retina (4/6), 
the inner retina (5/6), the GCL (6/6), and within the retinal vessels (5/6) as compared to the 
retinas with vascular changes but no PDR (Fig. 4.17). The most intense immunoreactivity for 
VEGFR-1 was observed within the preretinal vessels of the membranes with all of them
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demonstrating positive staining (6/6). In this tissue category staining of the intra-retinal 
vessels was associated both with the membranes and across the retina. Staining was weak 
within the non-vascular components of the membranes. Staining was absent from 
photoreceptors.
In those diabetic retinas which had undergone successful laser therapy staining was 
weak to moderate within the cell bodies of the inner retina (13/14), the outer retina (14/14), 
the GCL (14/14), and the retinal vessels (14/14). Staining was again generally minimal 
within the photoreceptors (Fig. 4.18).
VEGFR-1 immunostaining was weak to moderate within the preretinal vessels of 
10/11 of the excised membranes but staining tended to be confined to a proportion of the 
vessels within each membrane with 4/11 of the membranes demonstrating staining both 
around the vessels and in the adjacent matrix. Weak staining was associated with the non- 
vascular components of the membranes (Fig. 4.19).
The average scores and standard deviations for VEGFR-2 immunostaining are 
represented in table 4.4. Statistical analysis demonstrated that significant differences were 
observed within the inner retina, the GCL, and the retinal vessels across the tissue categories 
(P = <0.05%) but not within the other retinal layers.
In the non-diabetic retinas and the diabetic retinas with no obvious retinopathy 
VEGFR-2 immunoreactivity was absent or minimal within all the retinal layers and within 
the retinal vessels (Fig. 4.20; Fig. 4.21).
In the diabetic retinas showing vascular changes but no evidence of PDR increased 
staining was observed within the cell bodies of the inner retina (3/5) and the GCL (4/5) 
compared to the non-diabetic retinas and the diabetic retinas with no overt retinopathy. 
Staining was particularly apparent within the Muller cell endfeet in the GCL (Fig. 4.22). 
VEGFR-2 immunoreactivity was again absent or minimal in all the other retinal layers and 
within the retinal vessels.
In the diabetic retinas with active neovascular membranes on their surfaces VEGFR-2 
immunoreactivity was reduced to minimal levels within the cell bodies of the inner retinal 
layer and the GCL as compared to the diabetic retinas with vascular changes. Staining was 
absent or minimal within the other retinal layers. In all retinas moderate to intense staining 
was observed within the retinal vessels (Fig. 4.23). Moderate staining was also observed 
within the preretinal vessels of most (5/6) of the membranes. In 4/6 diabetic retinas staining 
of the intra-retinal vessels was associated with the membranes but in 2/4 of these staining
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was also observed in vessels across the retina. Minimal staining was associated with the non- 
vascular components of the membranes.
In those diabetic retinas which had undergone successful laser therapy staining was 
reduced to minimal levels within the retinal vessels in comparison to the diabetic retinas with 
PDR membranes on their surfaces (Fig. 4.24). Staining was again absent or minimal within 
the retinal layers.
VEGFR-2 staining was weak to moderate within the preretinal vessels of 7/11 of the 
excised membranes but staining tended to be confined to a proportion of the vessels within 
each membrane with 2/11 of the membranes demonstrating staining both around the vessels 
and in the adjacent matrix. Minimal staining was associated with the non-vascular 
components of the membranes (Fig. 4.25).
The average scores and standard deviations for VEGFR-3 immunostaining are 
represented in table 4.5. Statistical analysis demonstrated that significant differences were 
observed within the GCL and the retinal vessels across the tissue categories (P = <0.05%) but 
not within the other retinal layers.
In the non-diabetic retinas VEGFR-3 immunostaining was generally absent or 
minimal within all the layers and within the retinal vessels (Fig. 4.26).
In the diabetic retinas with no overt retinopathy all the retinas (12/12) demonstrated 
increased immunoreactivity for VEGFR-3 within the GCL as compared with the non-diabetic 
retinas, with most (11/12) also demonstrating increased immunoreactivity for VEGFR-3 
within the cell bodies of the inner retina. Staining within the retinal vessels was generally 
weak with 9/12 retinas showing positive immunoreactivity to VEGFR-3. Staining within the 
other retinal layers was generally absent or minimal (Fig. 4.27).
In the diabetic retinas showing vascular changes but no evidence of PDR the intensity 
of staining for VEGFR-3 was similar to that observed for the eyes with no overt retinopathy. 
Again staining was weak to moderate within the cell bodies of the inner retina (4/5) and the 
GCL (4/5). Staining was particularly apparent within the Muller cell endfeet in the GCL (Fig. 
4.28). Staining within the retinal vessels was weak (2/5). Staining within the other retinal 
layers was absent or minimal.
In the diabetic retinas with active neovascular PDR membranes on their surfaces the 
intensity of staining for VEGFR-3 was generally absent or minimal within the photoreceptors 
and the cell bodies of the outer retina. Staining intensity within the cell bodies of the inner 
retina was reduced to minimal levels as compared to the unlasered diabetic retinas. Staining 
intensity within the GCL was weak and so was also reduced compared to the unlasered
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diabetic retinas. Weak to moderate staining intensity was observed within the retinal vessels 
with 5/6 showing positive immunoreactivity for VEGFR-3; staining was slightly raised as 
compared with that observed in the unlasered diabetic retinas with obvious vascular changes. 
Weak to moderate staining was also observed within the pre-retinal vessels of the membranes 
with 5/6 showing positive immunoreactivity for VEGFR-3 (Fig 4.29). In this tissue category 
staining of the intra-retinal vessels was associated with the membranes in 3/6 retinas but 
staining in 2/3 of these was also observed in vessels across the retina. Minimal staining was 
associated with the non-vascular components of the membranes.
In those diabetic retinas which had undergone successful laser therapy staining was 
minimal or weak and was generally reduced to the levels observed within the non-diabetic 
retinas (Fig. 4.30).
VEGFR-3 immunostaining was weak to moderate within the pre-retinal vessels of 
10/11 of the excised membranes but staining tended to be confined to a proportion of vessels 
within each membrane with 2/11 of the membranes demonstrating staining both around the 
vessels and in the adjacent matrix. Minimal staining was associated with the non-vascular 
components of the membranes (Fig. 4.31).
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TABLE 4.3 MEAN INTENSITY OF VEGFR-1 IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non­ 0.6 0.2 1.2 1.6 1.1
diabetic
(n=14)
(0.8) (0.4) (0.9) (1.1) (1.0)
No Overt 0.4 0.3 1.4 1.9 1.3
Retinopathy
(n=12)
(0.5) (0.5) (0.5) (0.9) (0.9)
Intraretinal 0.8 1.2 1.6 2.2 1.6
Changes
(n=10)
(1.2) (1.2) (0.8) (0.8) (1.0)
PDR 0 1.0 1.3 2.0 1.5 2.5 1.2
(n=9) (0) (0.8) (0.7) (0.8) ( i.i) (0.5) (0.4)
Laser-No
Residual 0.2 1.5 1.5 1.9 1.7
PDR
(n=14)
(0.6) (0.6) (0.6) (0.7) (0.4)
Excised
Membranes 1.6 1.1
(n=17) (0.8) (0.8)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
96
Figure 4.14 Transverse Sections Showing the Immunolocalisation of 
VEGFR-1 (Arrows) in Non-Diabetic Retinas.
Figure 4.15 Transverse Sections Showing the Immunolocalisation of 
VEGFR-1 (Arrows) in Unlasered Diabetic Retinas with No obvious 
M icrovascular Abnormalities.
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Figure 4.16 Transverse Sections Showing the Immunolocalisation of 
VEGFR-1 (Arrows) in Unlasered Diabetic Retinas with NPDR.
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Figure 4.17 Transverse Sections Showing the Immunolocalisation of 
VEGFR-1 in Diabetic Retinas with PDR.
Arrows show location of staining in the retinal vessels and the preretinal 
membranes, and also in retinal layers where positive staining was observed
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Figure 4.18 Transverse Sections Showing the Immunolocalisation of 
VEGFR-1 (Arrows) in Lasered Diabetic Retinas.
Figure 4.19 Transverse Sections Showing the Immunolocalisation of VEGFR- 
1 (Arrows) in Fibrovascular M embranes
TABLE 4.4 MEAN INTENSITY OF VEGFR-2 IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo-
Receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non-diabetic 0.1 0.1 0.5 0.3 0.4
(n=14) (0.3) (0.3) (0.7) (0.5) (0.4)
No Overt 0.3 0 0.8 0.8 0.8
Retinopathy
(n=12)
(0.4) (0) (0.6) (0.4) (1.0)
Intraretinal 0.4 0 1.4 1.4 0.4
Changes
(n=10)
(0.9) (0) (1.3) (0.9) (0-6)
PDR 0 0 0.5 0.2 2.3 2.0 0.7
(n=6) (0) (0) (1.1) (0.4) (0.8) (1.2) (1.1)
Laser-No
Residual 0.1 0 0.7 0.3 0.5
PDR
(n=9)
(0.3) (0) (0.5) (0.5) (0.9)
Excised
Membranes 1.6 0.6
(n=17) (1.2) (0.7)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.20 Transverse Sections Showing the Immunolocalisation of 
VEGFR-2 in Non-Diabetic Retinas.
Staining was absent or minimal.
Figure 4.21 Transverse sections showing the immunolocalisation of VEGFR-2 in 
Unlasered Diabetic Retinas with No obvious Microvascular Abnormalities.
Staining was absent or minimal.
100 pm 100 pin
/  /
'
/
100 Mm 100 M»n
/
/
100 Mm
/
100 Mm
/
/
* . • • •* .V  ■> • •Lg* .1Bf? r i ' ■ m
Figure 4.22 Transverse Sections Showing the Immunolocalisation of VEGFR 
2 (Arrows) in Unlasered Diabetic Retinas with NPDR.
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Figure 4.23 Transverse Sections Showing the Immunolocalisation of VEGFR-2
in Diabetic Retinas with PDR.
Arrows show staining around the retinal vessels and in the preretinal membranes.
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Figure 4.24 Transverse Sections Showing the Immunolocalisation of VEGFR- 
2 in Lasered Diabetic Retinas.
Staining was absent or minimal.
Figure 4.25 Transverse Sections Showing the Immunolocalisation of 
VEGFR-2 (Arrows) in Fibrovascular Membranes
TABLE 4.5 MEAN INTENSITY OF VEGFR-3 IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non­ 0 0.1 0.9 0.6 0.8 (0.9)
diabetic
(n=14)
(0) (0.3) (0.9) (0.7)
No Overt 0.3 (0.8) 0 1.5 1.8 1.0
Retinopathy
(n=12)
(0) (0.8) (0.8) (0.7)
Intraretinal 0.6 0 1.8 2.0 1.2
Changes
(n=10
(0.8) (0) (1.2) (1.1) (1.5)
PDR 0 0 0.3 1.0 1.5 1.5 0.3
(n=9 (0) (0) (0.5) (0.8) (1.1) (1.3) (0.5)
Laser-No
Residual 0.2 0.2 0.9 0.8 0.9
PDR
(n=14)
(0.6) (0.4) (0.6) (0.6) (0.8)
Excised
Membranes 1.7 0.2
(n=17) (1.0) (0-4)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.26 Transverse Sections Showing the Immunolocalisation of VEGFR-3
in Non Diabetic Retinas
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Figure 4.27 Transverse Sections Showing the Immunolocalisation of VEGFR-3
in Unlasered Diabetic Retinas with No obvious Microvascular Abnormalities
Figure 4.28 Transverse Sections Showing the Immunolocalisation of VEGFR-3 
in Unlasered Diabetic Retinas with NPDR.
Figure 4.29 Transverse Sections Showing the Immunolocalisation of
VEGFR-3 in Diabetic Retinas with PDR.
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Figure 4.30 Transverse Sections Showing the Immunolocalisation of VEGFR-3
in Lasered Diabetic Retinas.
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Figure 4.31 Transverse Sections Showing the Immunolocalisation of VEGFR-3
in Fibrovascular M embranes
4.3 Angiopoietin immunostaining of retinal sections and fibrovascular membranes
When examined by light microscopy, Ang-1 and Ang-2 staining was apparent in both 
non-diabetic and diabetic tissue. The staining pattern depended upon the specificity of the 
antibody being used and the category of tissue. Ang-1 immunoreactivity was generally 
confined to the vessels of the retina but not to the preretinal vessels of the membranes. Ang-2 
immunoreactivity was confined to the preretinal vessels undergoing active neovascularization 
but only appeared to be associated with the retinal vessels of the non-diabetic retinas and 
diabetic retinas with no overt retinopathy. Variable staining of the vessels within each retina 
was observed with some staining positive and some staining negative. Ang-2 
immunoreactivity was also observed within the GCL. Variability of staining was observed 
for each retina within each category, which is represented by the standard deviations in tables 
4.6 and 4.7, but this did not correlate with donor age, post-mortem time, or duration of 
diabetes.
The average scores and standard deviations for Ang-1 immunostaining are 
represented in table 4.6. Statistical analysis demonstrated that significant differences were 
observed within the retinal vessels across the tissue categories (P = <0.05%) but not within 
the retinal layers.
In the non-diabetic retinas staining intensity for Ang-1 was generally absent or 
minimal within the photoreceptors, the cell bodies of the outer retina, the inner retina, and the 
GCL. Weak to moderate staining was observed within the retinal vessels of 10/14 of the non­
diabetic retinas (Fig. 4.32).
In the diabetic retinas with no overt retinopathy Ang-1 staining intensity was reduced 
to weak levels within the retinal vessels as compared to the non-diabetic retinas. Staining was 
again absent or minimal within the photoreceptors, the cell bodies of the outer retina, the 
inner retina and the GCL (Fig. 4.33).
In the diabetic retinas showing vascular changes but no evidence of PDR, Ang-1 
immunostaining was increased within the retinal vessels of 4/5 of the retinas, compared to 
that observed in the diabetic eyes with no overt retinopathy. Staining was again absent or 
minimal within the photoreceptors, and the cell bodies of the outer retina, inner retina, and 
GCL (4.34).
In the diabetic retinas with active neovascular PDR membranes on their surfaces 
staining was increased to moderate levels within the retinal vessels (5/6) compared to the 
retinas with intraretinal changes. Minimal staining was observed within the preretinal vessels 
of the membranes and no staining was apparent within the non-vasculr components of the
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membranes. Staining was absent or minimal within the photoreceptors and the cell bodies of 
the outer retina, the inner retina, and the GCL.
In those diabetic retinas which had undergone successful laser therapy the staining 
intensity was reduced to weak to moderate levels within the retinal vessels. Staining was 
again absent or minimal within the photoreceptors, the cell bodies of the inner retina, the 
outer retina, and the GCL (Fig. 4.35).
Minimal staining was observed within the preretinal vessels of the excised 
membranes. Weak to moderate staining was associated with the non vascular components of 
most (9/11) of the membranes (Fig. 4.37).
The average scores and standard deviations for Ang-2 staining are represented in table 
4.7. Statistical analysis demonstrated that no significant differences were observed within the 
retinal layers and the retinal vessels across the tissue categories.
In the non-diabetic retinas weak to moderate staining was observed within the GCL 
(11/14) and the retinal vessels (10/14). Minimal staining was demonstrated within the 
photoreceptors (6/14), and the cell bodies of the outer retina and the inner retina (Fig. 4.38).
In the diabetic retinas with no overt retinopathy, Ang-2 immunostaining was again 
weak to moderate within GCL (10/12), and the retinal vessels (8/12). Minimal staining was 
demonstrated within the photoreceptors and the cell bodies of the outer and inner retina (Fig. 
4.39).
In the diabetic retinas showing vascular changes but no evidence of PDR, Ang-2 
staining was reduced to minimal levels within the retinal vessels (2/5) as compared to the 
non-diabetic retinas and the retinas with no overt retinopathy. Ang-2 staining intensity was 
weak to moderate within the GCL (4/5). Minimal staining was demonstrated within the 
photoreceptors and the cell bodies of the outer retina and inner retina (Fig. 4.40).
In the diabetic retinas with active neovascular PDR membranes on their surfaces 4/6 
retinas demonstrated increased immunoreactivity for Ang-2 within the cell bodies of the 
inner retina as compared with the other categories of tissue. Ang-2 staining intensity was 
again weak to moderate within the GCL (5/6). Minimal staining was demonstrated within the 
photoreceptors, the cell bodies of the outer and inner retina and the retinal vessels. The 
staining intensity was weak to moderate within the preretinal vessels of the membranes. In 
this tissue category staining of the intraretinal vessels was associated both with the 
membranes and across the retina. (Fig. 4.41).
In those diabetic retinas which had undergone successful laser therapy Ang-2 
staining was again weak to moderate within the GCL (14/14). Minimal staining was
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demonstrated within the photoreceptors, the cell bodies of the outer retina, and the inner 
retina, and the retinal vessels (Fig. 4.42).
Minimal staining was observed within the preretinal vessels and the non-vascular 
components of the membranes (Fig. 4.43).
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TABLE 4.6 MEAN INTENSITY OF ANG-1 IMMUNOSTAINING
Tissue Retinal Layer Retinal Membrane
Category Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non­ 0.5 0.1 0.1 0.4 1.6
diabetic
(n=14)
(0.8) (0.3) (0.4) (0.6) (1.2)
No Overt 0.3 0 0 0.3 0.9
Retinopathy
(n=12)
(0.4) (0) (0) (0.6) (1.0)
Intraretinal 0.4 0 0.2 0.2 1.4
Changes
(n=10)
(0.9) (0) (0.5) (0.5) (1.1)
PDR 0 0 0.2 0.2 2.2 0.4 0
(n=9) (0) (0) (0.4) (0.4) (1.3) (0.9) (0)
Laser-No
Residual 0.1 0 0.1 0.1 1.2
PDR
(n=14)
(0.3) (0) (0.3) (0.3) (1.0)
Excised
Membranes 0.5 1.6
(n=17) (1.0) (1.0)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.32 Transverse Sections Showing the Immunolocalisation of Ang-1
(Arrows) in Non-Diabetic Retinas.
Figure 4.33 Transverse Sections Showing the Immunolocalisation of Ang-1 
(Arrows) in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities.
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Figure 4.34 Transverse Sections Showing the Immunolocalisation of Ang-1 
(where present) [Arrows] in Unlasered Diabetic Retinas with NPDR.
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Figure 4.35 Transverse Sections Showing the Immunolocalisation of Ang-1 in 
Diabetic Retinas with PDR.
Photographs from sections with minimal antibody precipitates present are shown.
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Figure 4.36 Transverse Sections Showing the Immunolocalisation of Ang-1
(Arrows) in Lasered Diabetic Retinas
Figure 4.37 Transverse Sections Showing the Immunolocalisation of Ang-1 in
Fibrovascular M embranes
TABLE 4.7 MEAN INTENSITY OF ANG-2IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo­
receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non-diabetic 0.6 0.2 0.1 1.5 1.6
(n=14) (0.9) (0.6) (0.4) (1.0) (1.2)
No Overt 0.8 0.3 0.2 1.8 1.5
Retinopathy
(n=12)
(0.6) (0.5) (0.4) (1.1) (1.2)
Intraretinal 0.6 0.2 0.4 1.6 0.6
Changes
(n=10)
(0.9) (0.5) (0-6) (1.1) (0.9)
PDR 0.3 0.3 1.0 1.5 0.7 1.5 0.3
(n=6) (0.5) (0.8) (1.1) (1.1) (1.2) (1.6) (0.5)
Laser-No
Residual 0.6 0.4 0.6 1.6 0.9
PDR
(n=14)
(0.7) (0.6) (0.8) (0.6) (1.0)
Excised
Membranes 0.7 0.9
(n=17) (1.3) (0.9)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.38 Transverse Sections Showing the Immunolocalisation of Ang-2
(Arrows) in Non-Diabetic Retinas
Figure 4.39 Transverse Sections Showing the Immunolocalisation of Ang-2 
(Arrows) in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities
100 um
Figure 4.40 Transverse Sections Showing the Immunolocalisation of Ang-2
(Arrows) in Unlasered Diabetic Retinas with NPDR.
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Figure 4.41 Transverse Sections Showing the Immunolocalisation of Ang-2
(Arrows) in Diabetic Retinas with PDR.
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Figure 4.42 Transverse Sections Showing the Immunolocalisation of Ang-2
(Arrows) in Lasered Diabetic Retinas
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Figure 4.43 Transverse Sections Showing the Immunolocalisation of Ang-2 in 
Fibrovascular M embranes.
Staining was absent or minimal.
4.3.4 Tie-2 immimostaining of retinal sections and fibrovascular membranes
The average scores and standard deviations for Tie-2 immunostaining are represented 
in table 4.8. When examined by light microscopy, Tie-2 staining was apparent in most of the 
non-diabetic and diabetic vascular tissue which was confined to retinal endothelial cells and 
the perivascular region. Increased immunostaining was observed within the intraretinal 
vessels of diabetic tissue as compared to non-diabetic tissue. Variable staining of the vessels 
within each retina was observed with some staining positive and some staining negative. 
Staining was also associated with extravascular regions of the retina. Variability of staining 
was observed for each retina within each category, which is represented by the standard 
deviations in table 4.8, but this did not correlate with either donor age, post-mortem time, or 
duration of diabetes. Statistical analysis demonstrated that significant differences were 
observed within the photoreceptors across all the tissue categories (P = <0.05%) but not 
within the retinal layers or the retinal vessels.
In the non-diabetic retinas weak staining for Tie-2 was observed within the retinal 
vessels (5/14). Weak to moderate staining was observed within the photoreceptors (11/14) 
and the cell bodies of the outer retina (13/14), the inner retina (12/14), and the GCL (13/14) 
[Fig. 4.44].
In the diabetic retinas with no overt retinopathy weak staining was demonstrated 
within the retinal vessels (6/12). Moderate staining was observed within the photoreceptors 
(10/12), and the cell bodies of the outer retina (11/12), and the GCL (11/12). However 
staining intensity was slightly reduced to weak to moderate levels within the cell bodies of 
the inner retina as compared to the non-diabetic retinas (11/12) [Fig. 4.45].
In the diabetic retinas showing vascular changes but no evidence of PDR the staining 
intensity was raised to weak to moderate levels within the retinal vessels (4/5) and to 
moderate levels within the cell bodies of the inner retina (5/5) as compared to the non­
diabetic retinas and the retinas with no overt retinopathy. Staining intensity was reduced to 
weak to moderate levels within the photoreceptors (3/5) and the cell bodies of the outer retina 
(3/5) as compared to the non-diabetic retinas and the retinas with no overt retinopathy. 
Staining within the GCL was intense in all (5/5) of the retinas (Fig. 4.46).
In the diabetic retinas with active neovascular PDR membranes on their surfaces the 
staining intensity was increased to moderate to intense levels within the photoreceptors (6/6) 
and the cell bodies of the outer retina (6/6) as compared to the retinas with intraretinal 
changes. Staining intensity was again moderate within the cell bodies of the inner retina (4/6) 
and weak to moderate within the retinal vessels (3/6). In this tissue category staining of the
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intra-retinal vessels was not specifically associated with the membranes. Weak to moderate 
staining was observed within the pre-retinal vessels of the membranes with 4/6 showing 
positive immunoreactivity for Tie-2 (Fig. 4.47). Weak to moderate staining was also 
associated with the non-vascular components of the membranes (3/6).
In those diabetic retinas which had undergone successful laser therapy the intensity of 
staining showed a similar pattern to that observed in the PDR retinas. However the level of 
staining was raised to moderate levels within the retinal vessels (11/14) [Fig. 4.48].
Staining for Tie-2 was minimal within the pre-retinal vessels of the excised 
fibrovascular membranes (2/11). Weak staining was demonstrated within the non-vascular 
component of the membranes (8/11) [Fig. 4.49].
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TABLE 4.8. MEAN INTENSITY OF TIE-2 IMMUNOSTAINING
Tissue Retina Layer Retinal Membrane
Category Photo­ Outer Inner GCL Vessels Vessels Matrix
receptors Retina Retina
Non­ 1.7 1.7 1.7 1.7 1.1
diabetic
(n=14)
(1.1) (1.1) (1.1) (1.1) (1.4)
No Overt 2.3 2.1 1.7 2.7 1.3
Retinopathy
(n=12)
(1.2) (0.1) (1.0) (0.9) (1.5)
Intraretinal 1.8 1.4 2.0 3.0 1.6
Changes
(n=10)
(1.6) (1.5) (1.0) (0.0) (1-3)
PDR 2.8 2.8 2.0 2.7 1.5 1.8 1.5
(n=9) (0.5) (0.5) (1.6) (0.5) (1.6) (1.5) (1.6)
Laser-No
Residual 2.5 2.5 2.3 2.7 2.1
PDR
(n=14)
(0.9) (0.8) (0.7) (0.6) (1.3)
Excised
membranes 0.6 1.1
(n=17) (1.2) (0.9)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.44 Transverse Sections Showing the Immunolocalisation of 
Tie-2 in Non-Diabetic Retinas.
Staining was observed in the retinal vessels and across all the retinal 
layers
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Figure 4.45 Transverse Tie-2 in Unlasered Diabetic Retinas with No obvious 
M icrovascular Abnormalities.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 4.46 Transverse Sections Showing the Immunolocalisation of Tie-2 in 
Unlasered Diabetic Retinas with NPDR.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 4.47 Transverse Sections Showing the Immunolocalisation of Tie-2 in 
Diabetic Retinas with PDR.
Sections are shown where few Tie-2 antibody precipitates are present. Staining 
was observed in the retinal vessels and across all the retinal layers.
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Figure 4.48 Transverse Sections Showing the Immunolocalisation of Tie-2 in
Lasered Diabetic Retinas.
Staining was observed in the retinal vessels and across all the retinal layers.
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Figure 4.49 Transverse Sections Showing the Immunolocalisation of Tie-2 (Arrows)
in Fibrovascular M embranes
4.3.5 TNF alpha immunostaining of retinal sections and fibrovascular membranes
When examined by light microscopy immunostaining for TNF-a was observed in 
both non-diabetic and diabetic vascular and extravascular tissue. Increased immunostaining 
was observed in preretinal and intraretinal blood vessels as compared to non-diabetic tissue. 
Variable staining of the vessels within each retina was observed with some staining positive 
and some staining negative. In some instances staining was associated with both ECs and the 
perivascular region of the vessel. Variability of staining was observed for each retina within 
each category, which is represented by the standard deviations in table 4.9, but this did not 
correlate with either donor age, or time post mortem.
The average scores and standard deviations for TNF-a immunostaining are 
represented in table 4.9. Statistical analysis demonstrated that significant differences were 
observed within the outer retina across the tissue categories (P = <0.05%) but not within the 
other retinal layers or the retinal vessels.
In the non-diabetic retinas staining intensity for TNF-a was generally minimal or 
absent within the photoreceptors, the cell bodies of the outer retina and the retinal vessels. 
Weak to moderate staining was observed within the cell bodies of the inner retina (9/11) and 
the GCL (9/11) [Fig. 4.50].
In the diabetic retinas with no overt retinopathy immunostaining was again generally 
minimal or absent within the photoreceptors and the cell bodies of the outer retina. Staining 
was reduced to minimal or absent in the cell bodies of the inner retina as compared to the 
non-diabetic retinas. Staining was again weak to moderate within the GCL (6/11). The most 
intense staining for TNF-a was observed within the retinal vessels with all retinas (11/11) 
showing positive staining [Fig. 4.51].
In the diabetic retinas showing vascular changes but no evidence of PDR staining for 
TNF-a was again minimal or absent within the photoreceptors and cell bodies of the outer 
retina. Staining also remained weak to moderate within the cell bodies of the inner retina 
(5/10) and the GCL (6/10). Staining was reduced to weak to moderate levels in the retinal 
vessels as compared with the diabetic retinas with no overt retinopathy (4/10) [Fig. 4.52].
In the diabetic retinas with active neovascular PDR membranes on their surfaces 
staining for TNF-a was absent within the photoreceptors and cell bodies of the outer retina. 
Staining was reduced within the cell bodies of the inner retina (3/5) and GCL (3/5) as 
compared to the retinas with vascular changes but no evidence of PDR. Staining was slightly 
raised in the retinal vessels (3/5) as compared to the retinas with vascular changes but no
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evidence of PDR. Staining was weak to moderate within the preretinal vessels of the 
membranes (2/5) [Fig. 4.53].
In those retinas which had undergone successful laser therapy staining for TNF-a was 
absent or minimal within the photoreceptors. Staining was raised within the cell bodies of the 
outer retina as compared to all the other categories of tissue (7/13). Staining was raised to 
weak to moderate levels in the GCL as compared to the PDR retinas (10/13). Staining was 
raised within the retinal vessels (9/13) as compared to the PDR retinas (Fig. 4.54].
Weak staining was observed within the preretinal vessels of the excised membranes 
(5/13). Staining was absent within the non vascular components of the membranes [Fig. 
4.55].
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TABLE 4.9 MEAN INTENSITY OF TNF- a IMMUNOSTAINING
Tissue Retina Layer | Retinal Membrane
Category Photo-
Receptors
Outer
Retina
Inner
Retina
GCL Vessels Vessels Matrix
Non-diabetic 0.1 0.5 1.1 1.5 0.8
(n-14) (0.3) (0.3) (0.8) (0.9) (0.6)
No Overt 0.6 0.6 0.6 1.3 2.6
Retinopathy
(n=12)
(0.4) (0.4) (0.4) (1.1) (0.3)
Intraretinal 0.4 0.6 1.2 1.5 1.2
Changes
(n=10)
(0.3) (0.5) (1.0) (1.0) (0.8)
PDR 0 0 0.8 0.8 1.6 1.2 0.2
(n=9) JO) (0) (0.4) (0.4) (1.2) (0.6) (0.1)
Laser-No 0.5 1.5 1.5 1.8 2.0
Residual
PDR
(n=14)
Excised 1.0 0
Membranes
(n=17)
(0.5) (0)
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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Figure 4.50 Transverse Sections Showing the Immunolocalisation of TN F-a
(Arrows) in Non-Diabetic Retinas.
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Figure 4.51 Transverse Sections Showing the Immunolocalisation of TN F-a 
(Arrows) in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities.
Figure 4.52 Transverse Sections Showing the Immunolocalisation of TNF
a  (Arrows) in Unlasered Diabetic Retinas with NPDR.
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Figure 4.53 Transverse Sections Showing the Immunolocalisation of TN F-a
in Diabetic Retinas with PDR.
Arrows showing the location of staining in most of the membranes.
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Figure 4.54 Transverse Sections Showing the Immunolocalisation of TN F-a
(Arrows) in Lasered Diabetic Retinas.
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Figure 4.55 Transverse Sections Showing the Immunolocalisation of TNF
a  (Arrows) in Fibrovascular M embranes
4.4 DISCUSSION
The data presented in this study demonstrate that VEGF, the angiopoietins and TNF-a 
are localised in diabetic tissue and that they are upregulated in diabetic retinopathy. These 
observations add support for a role of VEGF and its receptors in diabetic retinopathy and 
indicate the importance of the angiopoietins, its receptor Tie-2 and TNF-a in pathological 
angiogenesis.
The VEGF/Receptor Family
Immunostaining for VEGF-A, VEGF-C and the VEGF receptors was performed 
using a dilution series of the primary antibodies, against a set number of sections, as 
recommended by the manufacturer. Initially only weak staining was observed. Successful 
staining for VEGF-A was eventually achieved using a highly concentrated dilution of the 
primary antibody and by exposing the angiogenic bindings sites with proteolytic digestion 
using 0.1% chymotrypsin. VEGF-C and the receptor antibodies were used at lower dilutions 
than VEGF-A and in addition proteolytic digestion was also needed to produce satisfactory 
staining for VEGF-C. Also some non-specific background staining was observed with all 
antibodies which was removed by blocking with a solution of 10% milk protein/10% rabbit 
serum prior to adition of the primary antibody. Deposits were observed when examining the 
sections stained with VEGF-C. After consultation with the manufacturer the VEGF-C 
antibody was spun at 25000 rpm at 4°C for 10 mins but this did not remove the deposits. 
Staining for VEGF-C was retried using both a new primary antibody, a new secondary 
antibody and new fast red substrate but again the deposits were observed. Photographs were 
taken of areas showing minimal deposits.
VEGF-A was present, albeit at low levels, within the vessels of non-diabetic retinas 
and diabetic retinas with no overt retinopathy. Several adult organs and tissues in guinea pig 
and man have been found to constitutively express VEGF-A mRNA (Ladoux et al., 1993b). 
Various other workers have shown that VEGF-A is expressed weakly within the retinal 
vessels of human and animal non-diabetic retinas (Murata et al., 1995; Lutty et a l , 1996; 
Gerhardinger et al., 1998; Spirin et al., 1999; Kim et a l , 1999b; Witmer et al, 2002). VEGF- 
A may be secreted in these adult organs in small amounts that are insufficient to induce 
angiogenesis but may be necessary for regulating baseline microvascular permeability which 
is essential for tissue nutrition and waste removal and/or maintaining the differentiated state 
of blood vessels. (Kevil et al, 1998; Luo et al, 1998; Zebrowski et al, 1999; Bates and 
Harper., 2002; Fu and Shen, 2004; Shibuya, 2005). Kunz Mathews et al. (1997)
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demonstrated that increased VEGF-A immunoreactivity was correlated with increased 
vascular permeability before morphologic changes occurred in the vasculature. It has been 
shown that the activity of specific Src family kinases is essential for the VEGF-induced 
enhancement of vascular permeability through the disruption of the VEGFR- 
2/cadherin/catenin complex (Eliceiri et al., 1999; Weis et al., 2004). Alternatively VEGF-A 
may be stored within the cells that synthesise it, perhaps awaiting an emergency situation that 
requires angiogenesis.
In this study the level o f VEGF-A expression was raised considerably within the 
retinal vessels of the eyes with intraretinal vascular changes. This suggests that VEGF exerts 
its action(s) during the earlier stages of diabetic retinopathy before proliferation occurs. In 
animal models of background retinopathy and in studies of human diabetic retinas with pre- 
proliferative diabetic retinopathy VEGF-A expression within the retinal vessels was also 
shown to be significantly increased as compared to non-diabetic controls (Lutty et al., 1996; 
Shima et a l, 1996; Amin et al., 1997; Segawa et al., 1997; Hammes et al., 1998; Spirin et 
al., 1999; Ellis et al., 2000; van Eeden et al., 2006; Kaur et al, 2006) and VEGF was shown 
to induce diabetic induced early retinal abnormalities such as increased vascular permeability 
(El-Remessey et a l, 2003; Cukiemik et a l, 2004). VEGF-A was effective in inducing 
ICAM-1-mediated retinal leukostasis and BRB breakdown in vivo in diabetic rats, indicating 
that both are important in the pathogenesis of early diabetic retinopathy. (Joussen et al, 
2002b; Ishida et a l, 2003).
More direct evidence for VEGF-A as a primary candidate in pre-proliferative 
retinopathy (and PDR) comes from studies in which VEGF-A administration to animals was 
shown to be sufficient to produce many of the vascular abnormalities common to background 
diabetic retinopathy (Tolentino et al., 1996; Tolentino et a l, 2002; Witmer et a l, 2004; 
Kinnunen et a l, 2006). Studies with VEGF inhibitors have confirmed that VEGF plays a 
central role in ischaemia-induced vascular permeability and intraocular neovascularization 
(Campochiaro and Hackett., 2003; Patel et a l, 2003).
Factors such as oxidative stress, cyclooxygenase-2, prostaglandin E2, AGES, and 
IGF-1, which are correlated with diabetic retinopathy may also serve as the primary stimuli 
to increase retinal VEGF-A expression in background diabetic retinopathy (Segawa et al., 
1997; Ellis et al, 2000; Mamputu and Renier, 2002; El-Remessy et a l, 2003; 
Ayalasomayajula et al, 2004; Roybal et a l, 2005; Yokoi, 2005; Sreekumar et a l, 2006). 
AGES and Interleukin-6 have been shown to increase retinal VEGF-A expression from
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Muller cells, RPE cells, ECS, and SMCs and pericytes (Hirata et al., 1997; Lu et al., 1998; 
Endo et al., 2001; Yamagishi et al., 2002; Li et al., 2006; Yao et al., 2006).
The highest level of VEGF-A expression was observed in the intraretinal vessels and 
preretinal vessels of subjects with active PDR which further supports a role of VEGF-A in 
PDR. This is consistent with the findings of other studies where VEGF-A was demonstrated 
in neovascular membranes (Malecaze et al., 1994; Chen et al., 1997; Schneeberger et al., 
1997; Armstrong et al., 1998a; Funatsu et al., 2003; Tsanou et al., 2005). Levels of VEGF-A 
were also significantly higher in the vitreous and aqueous and plasma from PDR subjects 
than in non-diabetic subjects, subjects with non-proliferative retinopathy, quiescent 
retinopathy and those which had received laser therapy (Adamis et al., 1994; Aiello et al., 
1994; Hernandez et al., 1998; Lin Lip et al., 2000; Endo et al., 2001; Umeda et al., 2001; 
Hogeboom van Buggenum et al., 2002; Mitamura et al., 2002; Ogata et al., 2002abc; Simo et 
al., 2002; Funatsa et al., 2003; Funatsu et al., 2004; Lip et al., 2004; Yokoi et al., 2005; 
Ishizaki et al., 2006).
In situ hybridization and immunohistochemical studies on human retinas have 
demonstrated that proliferation of vascular elements in PDR and neovascularization of the 
retina and/or iris secondary to central retinal vein occlusion, retinal detachment, and 
intraocular tumours were always accompanied by upregulation of VEGF-A mRNA (Murata 
et al., 1995; Pe’er et al., 1995; Lutty et al., 1996; Pe’er et al., 1996; Sueshi et al., 1996; Amin 
et al., 1997; Kunz Mathews et al., 1997; Witmer et al., 2002). Similarly in animal models of 
proliferative retinopathy, including ROP, VEGF-A expression was increased in retinal 
vessels and pre-retinal growths during the period of retinal hypoxia and remained elevated 
during the development of neovascularization (Pierce et al., 1995; Dorey et al., 1996; Stone 
et al., 1996; Robbins et al., 1997; Ozaki et al., 1999; Witmer et al., 2002; Bullard et al.,
2003). Ozaki et al. (1999) also demonstrated that increased levels VEGF in ischaemic retina 
showed a temporal and spatial correlation with increased expression of H IF-la.
All these findings demonstrate that VEGF-A is expressed in the retina prior to the 
development of neovascularization, remains elevated until neovascularization develops and 
then declines as the neovascularization regresses. This demonstrates an especially strong 
correlation between VEGF-A expression and retinal neovascularization.
In this study the finding that immunostaining for VEGF-A is reduced in diabetic 
retinas that have no overt preretinal neovascularization following laser therapy is consistent 
with the findings that vitreous and plasma concentrations of VEGF-A decline after successful
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laser therapy (Aiello et al., 1994; Lin Lip et al, 2000). It is also consistent with the finding 
that the levels of VEGF, VEGFR-2 and VEGFR-1 are reduced in neovascular membranes 
receiving cryotherapy as compared to membranes containing active proliferating vessels 
(Armstrong et al., 1998a). Both therapies result in the destruction of a large area o f ischaemic 
retinal tissue presumably resulting in a reduction of VEGF-A, the suppression of 
neovascularization leading to vessel regression and quiescence.
VEGF-C has been shown to stimulate EC migration, proliferation and chemotaxis and 
has a strong chemotactic effect on VEGFR-3 producing cells in vitro (Joukov et al., 1996; 
Witzenbichler et al., 1998b; Kroon et al., 1999; Lohela et al, 2003; Saharinen et a l, 2004). 
VEGF-C also stimulated the release o f NO, a potential mediator of VEGF-induced 
angiogenesis, from ECs and increased vascular permeability in the Miles assay 
(Witzenbichler et al., 1998b). In a rabbit ischaemic hindlimb model VEGF-C promoted 
angiogenesis (Witzenbichler et al., 1998b). It was also detected in haematopoietic cells and 
platelets and in bone marrow samples of acute leukaemia patients (Wartivaara et al., 1998). 
The investigators suggested that VEGF-C release from activated platelets may have a role in 
angiogenesis during wound healing, and possibly other pathological conditions, such as 
atherosclerosis, tumour growth, and metastasis. VEGF-C has also been shown to be 
associated with the regulation of angiogenesis in the lymphatic vasculature (Kukk et al., 
1996; Jussila and Alitalo, 2002; Karkkainen et al, 2004). Although no other investigators 
have looked at VEGF-C expression in diabetic retinopathy, it may not be unreasonable to say 
that, from the findings of my study, VEGF-C does appear to play some part in the 
pathogenesis of diabetic retinopathy. It is expressed in the early stages of diabetic retinopathy 
which suggests its action could be to induce vascular permeability. It is strongly expressed in 
PDR retinas which suggests that it could be involved in proliferation and migration of 
endothelial cells. Its expression in the non-diabetics suggests it may also have a role in the 
quiescent vasculature.
The observation in this study that VEGFR-2 is greatly elevated in both intra- and 
preretinal vessels in PDR tissue and minimal in the retinal vessels of non-diabetic retina and 
the quiescent vessels of lasered diabetic retina with no evidence of PDR is in agreement with 
the view that VEGFR-2 is involved in PDR. VEGF-A and VEGF-C have both been shown to 
induce invasion, and tube formation when bound to VEGFR-2 (Tille et al, 2003). It is 
consistent with the finding that VEGFR-2 is present in neovascular membranes and diabetic 
retinas and in animal models of ischaemia-induced retinal neovascularization (Malecaze et 
al., 1994; Chen et al., 1997; Armstrong et al., 1998a; Suzuma et al., 1998; Ishida et al., 2000;
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Ishimama et al., 2001; Witmer et al, 2002; Gerber and Ferrara., 2003; Cerdan et al., 2004; 
Wilkinson-Berka et al., 2006). Blockade of VEGFR-2 receptor signalling was sufficient to 
completely prevent retinal neovascularization (Ozaki et al, 2000). VEGFR-2 may be 
associated with integrin-dependent migration of ECs, as it forms a complex with integrin 
aVp3 upon binding VEGF (Soldi et al., 1999; Hutchings et al, 2003). An interaction 
between VEGFR-2 and VE-cadherin, a cell-cell adhesion molecule has also been described.
These findings also correlate with studies where VEGFR-2 levels were elevated in 
non-ocular pathologies that are characterised by neovascularization (Shweiki et al., 1992; 
Brown et al., 1993a; Brown et al., 1993b; Fava et al., 1994; Abu-Jawdeh et al., 1996; Guidi 
et al., 1996; Leung et a l ,  1997; Samaniego et al., 1998; Hiratsuka et al, 2002; Inoue et al, 
2002; Stewart et a l ,  2003; Takekosh et al, 2004; Pallares et al, 2006), and in 
embryogenesis where VEGFR-2 expression has been shown to be imperative for EC 
mitogenesis, the formation of blood vessels and for haematopoiesis. (Ferrara et al., 1996).
Although VEGFR-2 gene expression appears to be upregulated in various pathologies 
characterised by hypoxia, in vitro studies have yielded conflicting results. The level of 
VEGFR-2 expression appears either to decline or not change by exposure to acute hypoxia 
(Brogi et al., 1996; Takagi et al., 1996a) whereas exposure to prolonged periods of hypoxia 
results in an increase in VEGF binding sites (Thieme et a l ,  1995). Although the in vivo 
significance of increased VEGF-A expression, combined with initial decreased VEGFR-2 
expression observed in vitro, is not certain, Takagi et a l  (1996a) suggested that the 
physiological significance of the biphasic VEGF receptor response may be to regulate 
hypoxia induced neovascularization more tightly. Initial, possibly transient, decreases in 
oxygen concentrations, where VEGF-A levels can be dramatically elevated but where 
angiogenesis may not be urgently required, lead to a reduction of VEGFR-2 and thus an 
amelioration of VEGF-A's angiogenic stimuli. However, under conditions of chronic oxygen 
deficits, in which angiogenesis is a more appropriate response, VEGF receptors are increased 
and so potentially facilitate VEGF action. This is supported by the finding that hypoxia 
increases VEGF receptor number by 50% in cultured BRECs (Thieme et al., 1995). In vitro 
studies have demonstrated that adenosine is a mediator of the angiogenic effects of VEGF-A 
through the regulation of VEGFR-2 expression during acute hypoxia (Takagi et al., 1996a). 
Adenosine plays a major role in neuronal and vascular responses of the retina to alterations in 
oxygen delivery (Ghiardi et al., 1999; Adair 2005).
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The presence of VEGFR-1 in non-diabetic tissue adds support to the suggestion that 
VEGF-A has a function in endothelial maintenance and vascular permeability, for example, 
and that these effects are mediated through VEGF-A binding to the VEGFR-1 receptor.
The presence of VEGFR-1 in diabetic vessels, particularly in those undergoing active 
neovascularization, indicates that VEGFR-1 plays a role in both pre-proliferative retinopathy 
and PDR. As VEGFR-1 has previously been shown to promote vascular permeability (Kolch 
et al.y 1995), in diabetic retinopathy it may be involved in transducing signals within ECs 
which induce vascular leakage. It is upregulated during hypoxia (Gerber et al., 1997; 
Partanen et al., 1999. It may also be co-expressed with VEGFR-2 and it has been suggested 
that it may participate in VEGF-A induced mitogenesis by forming a heterodimer with 
VEGFR-2 (Waltenberger et al., 1994). VEGFR-1-mediated signalling appears to modulate 
the reorganization of actin via p38 MAPK, whereas VEGFR-2 contributes to the 
reorganization of the cytoskeleton by phosphorylating FAK (focal adhesion kinase) and 
paxillin, suggesting a different contribution of the two receptors to the chemotactic response 
(Kanno et a l, 2000). VEGFR-1 has also been shown to act as a negative regulator of VEGF- 
A induced angiogenesis; a soluble form of VEGFR-1 can form a VEGF-A-stabilised ternary 
complex with the extracellular region of VEGFR-2 in vitro (Kendall et al., 1996). In support 
of this, endogenous trophoblast DNA synthesis was shown to be increased 3-fold in the 
presence o f anti-VEGFR-1 antibody but not in the presence of anti-VEGFR-2 antibody 
(Ahmed et al., 1997).
VEGFR-1 has previously been detected in samples of neovascular membranes and 
diabetic retinas (Malecaze et al., 1994; Chen et al., 1997; Armstrong et al., 1998a; Witmer et 
al, 2002). In addition, these findings also correlate with studies where VEGFR-1 levels were 
elevated in other pathologies that are characterised by neovascularization (Peters et al., 1993; 
Fava et al., 1994; Leung et al., 1997; Pallares et al., 2006) and in developing embryos (Fong 
et al., 1995; Ferrara et al.y 1996) indicating that VEGFR-1 is essential for endothelial 
differentiation, EC and vessel organisation, blood vessel growth, and vascular repair.
The findings from this study that VEGFR-3 is elevated in diabetic vessels, 
particularly in the intra- and preretinal vessels of the PDR retinas suggest that VEGFR-3 may 
a have a role in the pathogenesis of diabetic retinopathy. As mentioned previously, VEGF-C 
is a ligand for this receptor which is known to have angiogenic effects on endothelial cells 
(Joukov et al.y 1996; Witzenbichler et a l ., 1998b). In developing mouse embryos, VEGFR-3 
is specifically expressed in endothelial precursors although its expression does become 
confined to higher venules and the lymphatic system in adults (Kaipainen et al., 1993;
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Kaipainen et al., 1994a; Lymboussaki et al., 1998; Partanen et al., 2000; Makinen et al., 
2001; Veikkola et al., 2001). Targeted inactivation of the gene encoding VEGFR-3 resulted 
in defective blood vessel development in early mouse embryos indicating that VEGFR-3 is 
important for the remodelling and maturation of primary vascular networks into larger blood 
vessels (Dumont et al., 1998). VEGFR-3 has also been detected in samples from patients 
with myeloid leukaemia, and in various tumour cell lines including a retinoblastoma cell line, 
indicating it plays a role in pathological neovascularization (Pajusola et al., 1992; Fielder et 
al., 1997; Partanen et al., 1999; Valtola et al., 1999; Skobe et al., 2001 ab; Witmer et al., 
2001; Clarijs et al., 2002). A role for VEGFR-3 in adult angiogenesis was shown by Witmer 
et al., 2004 who demonstrated that VEGFR-3 was expressed in pre-existing blood vessels in 
human tissues undergoing angiogenesis and in a VEGF-A induced model of iris 
neovascularization. VEGFR-3 has also been demonstrated in retinal vessels during early 
diabetic retinopathy (Witmer et al., 2002). VEGFR-3 has recently been shown to 
heterodimerize with VEGFR-2 in ECs and stimulates VEGFR-2 signalling in response to 
VEGF-C (Alam et al., 2004; Suzuki et al., 2005). Together VEGFR-3 and VEGFR-2 induced 
the formation o f capillary-like structures and the proliferation of human ECs. Use of an anti­
human VEGFR-3 monoclonal antibody that antagonized the receptor activation by VEGF-C 
resulted in the reduction of tubule formation (Persaud et al., 2004).
Various workers have demonstrated that production of VEGF and its receptors is not 
specifically confined to retinal vascular ECs in the diabetic retina. VEGF has been shown to 
be highly expressed in ganglion cells and glial cells (Muller cells and astrocytes) in non­
diabetic retina (Famigietti et al., 2003) and diabetic retina ( Pe'er et al., 1996; Sueshi et al., 
1996; Amin et al., 1997; Hammes et al., 1998). In addition VEGF expression is also 
significantly raised in these cells in animal models of ischaemic retinopathy (Shima et al., 
1996; Stone et al., 1996; Robbins et al., 1997; Kaur et al., 2006) and during the development 
of the retinal vasculature (Stone et al., 1995). RGCs have been shown to synthesise and 
release VEGF which is enhanced by hypoxia (Sueshi et al., 1996; Jingjing et al., 1999) and 
conditioned media from hypoxic RGCs stimulates in vitro angiogenesis in collagen gels 
(Jingjing et al., 1999). Therefore VEGF appears to be released by Muller cells and astrocytes 
under hypoxic conditions. Increased VEGFR-2 and VEGFR-1 expression have also been 
demonstrated in the GCL, INL, and ONL in animal models of background retinopathy and 
ischaemia-induced retinal neovascularization (Hammes et al., 1998; Suzuma et al., 1998; van 
Eeden et al., 2006) with VEGFR-1 mRNA also being present in cultured retinal glial cells 
(RGCs), and glial cells of epiretinal membranes. (Chen et al., 1997).
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Retinal capillaries are largely ensheathed by perivascular glial cells, which participate 
in the formation of barrier properties in capillaries (Janzer et al., 1987; Tout et al., 1993). In 
my study VEGF-A levels were raised in the GCL of the unlasered diabetic retinas with 
microvascular abnormalities. Therefore it may be reasonable to say that VEGF localised in 
glial cells plays some role as a vascular permeability factor both in normal retinal vessels and 
in the early stages of diabetic retinopathy. This VEGF expression may make the retinal 
vessels permeable so that the retinal cells can get a supply of oxygen and nutrition. This is 
supported by the finding of Sueshi et al. (1996) who demonstrated that VEGF expression in 
diabetic retina was associated with vascular hyperpermeability and that astrocytes intimately 
surrounded these blood vessels.
As glial cells and ganglion cells appear to be a major source of VEGF in ischaemic 
retina, the above studies suggest that glial cells and possibly ganglion cells are able to detect 
hypoxia and in response they secrete VEGF and increase their expression of the VEGF 
receptors. During retinal development and the associated network of blood vessels, astrocytes 
were shown to be sensitive to hypoxia and astrocytes only enter retinas in which the retinal 
vasculature will form (Stone et al., 1987; Schnitzer, 1988ab In response to hypoxia the 
astrocytes are able to migrate ahead of the developing vessels and secret VEGF, inducing the 
formation o f developing vessels toward the VEGF-producing astrocytes (Stone et al., 1995). 
In support o f this rat astrocytes in avascular retina promote fibronectin production, and 
fibronectin can provide guidance for migrating spindle cells (EC precursors and glial cells) 
and extending vessels (Jiang et al., 1994). Astrocytes can also induce ECs to form capillary- 
like structures in culture (Laterra et al., 1990). As the hypoxic pressures ease after the arrival 
o f the blood vessels, the production of VEGF by astrocytes decreases. In the INL of the 
developing retina VEGF is also expressed transiently by cells which are presumed to be 
Muller cells. As Muller cells extend from the ILM to the OLM of the retina, they are thought 
to be affected by abnormal biologic activities in the vitreous. Penn et al. (1988) showed that 
the b-wave of electroretinograms, which is produced by Muller cell activity alone, is 
specifically affected in oxygen-induced rats. This finding points to a significant effect of 
variable oxygen levels on Mtiller cell function and suggest that Muller cells are important in 
building the vasculature, maintaining vascular homeostasis, and promoting 
neovascularization.
However, VEGF is present in glial cells of retinas from patients without proliferative 
retinopathy, indicating that hypoxia may not be the sole stimulus for VEGF expression from 
these cells (Sueshi et al., 1996; Amin et al., 1997; Hammes et al., 1998). The production of
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VEGF protein by hypoxic retinal glial cells in vivo may be influenced by glucose 
concentrations (Brooks et al., 1998) and elevation of AGEs in the vitreous may also increase 
the expression and release of VEGF from Muller cells. Adenosine is also present in the GCL, 
INL, and the plexiform layers of the retina (Ghiardi et a l , 1999), and as it has been shown to 
regulate VEGFR-2 expression (Takagi et al., 1996a), its release from glial cells and possibly 
other cell types under hypoxic conditions may be of relevance in the pathogenesis of diabetic 
retinopathy. Adenosine was also shown to increase VEGF-induced proliferation of canine 
retinal microvascular cells (Lutty et al., 1998).
Mtiller cells and astrocytes also share the ability to form the glia limitans of the retina 
and o f vessels (Hollander et al., 1991). In ROP, preretinal vessels form when intensive 
hypoxia causes the degeneration of astrocytes and the strong expression of VEGF by other 
cells, particularly neurones (Chan-Ling et al., 1992; Chan-Ling et al., 1995ab; Stone et al., 
1996). Therefore the glia limitans becomes damaged, and with high expression of VEGF and 
the glia limitans breached, VEGF may diffuse in to the vitreous and induce vessel growth 
away from the retina. PDR may therefore be caused by exaggeration of the mechanisms that 
cause normal vascularization of the retina; preretinal vessels may from, as do normal vessels, 
by the hypoxia-induced secretion of VEGF and may be proliferative because of the high level 
of VEGF expression.
Takagi et al. (1996b) demonstrated that bovine retinal PCs (BRPCs) predominantly 
express VEGFR-1 in contrast to retinal ECs which predominantly express VEGFR-2. Witmer 
et al., 2004 also demonstrated that activated pericytes express VEGFR-1 in a monkey model 
of iris neovascularization. Retinal PCs possess large numbers of high affinity VEGF binding 
sites, which result in tyrosine phosphorylation of intracellular substrates and weak growth 
promoting effects after long-term VEGF stimulation. This suggests that VEGF may mediate 
the response of retinal PCs as well as retinal ECs during the pathological angiogenesis 
characteristic of PDR and other ischaemic retinal disorders.
Hypoxia also increased VEGF expression in BRPCs. Although the role of PCs during 
angiogenesis is poorly understood, it is likely that hypoxia would turn them predominantly 
mitogenic, resulting in their loss of contact with endothelial cells, thereby promoting 
endothelial cell growth. AGES have been shown to upregulate the secretory forms of VEGF 
mRNA in retinal pericytes (Yamagishi et al., 2002). This suggests that AGEs disturb retinal 
microvascular homeostasis by inducing pericyte apoptosis and VEGF overproduction, 
therefore playing a role in the pathogenesis of early diabetic retinopathy.
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The Angiopoietin/Tie-2 Family
Immunostaining for Ang-1, Ang-2, and Tie-2 was performed using a dilution series of 
the primary antibodies, against a set number of sections, as recommended by the 
manufacturer. Initially only weak staining was observed for all antibodies. Successful 
staining was eventually achieved using a highly concentrated dilution of each primary 
antibody and by exposing the angiogenic binding sites with proteolytic digestion using 0.1% 
chymotrypsin. Deposits were observed when examining the sections stained with all three 
antibodies. After consultation with the manufacturer the antibodies were spun at 25000 rpm 
at 4°C for 10 mins but this did not remove the deposits. Staining was retried using new 
primary antibodies, a new secondary antibody and new fast red substrate but again the 
deposits were observed. Photographs were taken of areas showing minimal deposits. The 
sections were imaged several months after staining and some drying out of the mountant was 
observed which is evident from the photomicrographs.
In this study Ang-1 and Tie-2 were localised to the endothelial and perivascular cells 
of both the non-diabetic and diabetic retinas. In the vessels of the non-diabetic retinas and the 
diabetic retinas with no overt retinopathy this is consistent with the observation that Ang-1 is 
expressed in normal arterial and venous specimens (Witzenbichler et al., 1998a) and in 
BRECs and BAECs (Oh et al., 1999). Tie-2 is also expressed and phosphorylated in the 
entire spectrum of the quiescent vasculature (arteries, veins and capillaries) which also 
suggests a role for Tie-2 signalling in the maintenance o f the quiescent adult vasculature 
(Wong et a l ,  1997). Maisonpierre et al., 1997 also demonstrated that during ovulation Ang-1 
is expressed in early follicles where the vasculature is in a quiescent state.
The initiation of blood vessel growth involves focal reduction of intercellular 
interactions and interactions between the cells of the blood vessel and the surrounding ECM 
(Lauren et al., 1998). This is associated with a loss of PCs and possibly of SMCs from the 
existing vessels (Risau, 1997). The maturation of newly formed vessels involves the 
accumulation of a basal lamina and tightly associated PCs or SMCs on the abluminal side.
In normal adult quiescent vessels, perivascular cells have previously been shown to 
constitutively secrete Ang-1, enhancing contact between neighbouring ECs and between 
ECs/perivascular cells, therefore maintaining endothelial integrity and orientation of ECs on 
the basal lamina leading to vessel stabilisation and maturation of the vasculature (Mandriota 
et al., 1998; Gamble et al, 2000; Hori et al., 2004).
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The presence of Ang-1 and Tie-2 in the diabetic vessels is also consistent with a 
proposed role for the Ang-1/Tie-2 system at all stages of diabetic retinopathy. Ang-1 is 
chemotactic for ECs and induces migration, tube formation, sprouting and survival, but not 
proliferation of ECs in vitro (Davis et al., 1996; Witzenbichler et al., 1998a; Koblizek et al., 
1998; Hayes et a l, 1999; Kwak et a l, 1999; Papapetropoulos et al, 1999; Kim et al, 
2000a,b; Kwak et al, 2000). Under conditions of postnatal angiogenesis, Ang-1 expression 
may be important for initiation of new capillary sprouting, the movement of ECs toward each 
other and the recruitment of perivascular cells required for fusion into capillary structures 
(Koblizek et al., 1998; Fujikawa et a l, 1999; Kim et al, 2000a, b; Papapetropoulos et al, 
2000; Harfouche et al, 2002; Babaei et a l, 2003; Harfouche et al., 2003; DeBusk et al, 
2004; Metheny-Barlow et a l, 2004; Saito et a l, 2004). In addition, Ang-1 also has anti­
permeability and anti-inflammatory functions (Thurston et a l , 1999; Gamble et a l, 2000; 
Thurston et a l, 2000; Wang et al., 2000; Kim et a l, 2001; Joussen et al., 2002a; Pizurki et 
al, 2003; Hori et a l, 2004; Li et a l, 2004; Wang et al., 2004; Jho et al., 2005; Baffert et al., 
2006). The observations that Ang-1 and Tie-2 are expressed in endothelial cells of 
glioblastomas, in leukaemia cell lines, metastatic melanomas and gastric carcinoma 
(Kaipainen et al., 1994b; Stratmann et a l , 1998; Witzenbichler et a l , 1998a; Yoshizaki et al,
2004) further supports their role in angiogenesis. Ang-1 has also been shown to promote 
wound healing through enhanced angiogenesis in a diabetic mouse model (Cho et al., 2006). 
Tie-2 is also expressed during active vasculogenesis in mice embryos and during 
vasculogenesis in the developing human placenta (Sato et a l , 1993; Schnurch and Risau, 
1993; Kayisli et al., 2006). Also, following on from the findings that Ang-1 is expressed in 
quiescent vasculature during ovulation, Maisonpierre et al. (1997) demonstrated that Ang-1 
is also present, alongside that of Ang-2, in late pre-ovulatory follicles and the corpus luteum 
where angiogenesis is ongoing. Ang-1 when given intravitreally to newly diabetic rats, 
normalized retinal VEGF and intercellular adhesion molecule-1 mRNA and protein levels, 
leading to reductions in leukocyte adhesion, endothelial cell injury, and blood-retina barrier 
breakdown, early pathological changes observed in diabetic retinopathy showing that Ang-1 
directly protects the retinal vasculature in diabetes.
Wong et al. (1997) also demonstrated that Tie-2 expression was upregulated in the 
endothelium of neovessels in rat tissues undergoing angiogenesis during hormonally 
stimulated follicular maturation and uterine development and in healing skin wounds. 
However, downregulation of Tie-2 was demonstrated during the later stages coinciding with 
regression of vessels. This appeared to be apparent in my study where Tie-2 was high in the
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preretinal vessels undergoing active angiogenesis but downregulated in the preretinal vessels 
undergoing regression in the excised membranes. It was also consistent with my finding that 
Ang-1 was downregulated in the pre-retinal vessels of the excised membranes which supports 
the observation that the Ang-1 signal is blocked by Ang-2 during vascular regression in 
ovarian follicles (Maisonpierre et al., 1997).
Ang-2 appears to initiate angiogenesis by binding to the Tie-2 receptor on ECs which 
results in weakening of the phosphorylation of, and blocking of, the chemotactic effects of 
Ang-1 (Maisonpierre et al., 1997; Sato et al., 1998; Witzenbichler et al., 1998a). Because 
Ang-1 is thought to be important for stabilising the vessel wall, local Ang-2 expression might 
promote SMC/PC drop-off, which is thought to be a requirement for rendering and 
maintaining ECs accessible to angiogenic inducers. This is supported by the finding that 
Ang-2 destabilizes quiescent endothelial cells (Scharpfenecker et al., 2004). This loss of PCs 
was associated with the upregulation of Ang-2 in the ECs of glioblastomas (Stratmann et al., 
1998). This role of Ang-2 is also supported by the demonstration that the addition of Ang-2 
to VEGF induced neovascularization by promoting vascular destabilisation and sprouting in 
the comeal micropocket assay (Asahara et al., 1998). Few perivascular cells were present in 
the vessels supporting the concept that loosening of contacts between ECs and perivascular 
cells initiates angiogenesis by recruiting VEGF (and possibly other growth factors). Similar 
findings were observed in the corpus luteum where in the presence of abundant VEGF, Ang- 
2 may promote vessel sprouting by blocking a constitutive (stabilising) Ang-1 signal, 
whereas in the absence of VEGF, Ang-2 inhibition of a constitutive Ang-1 signal can 
contribute to vessel regression (Maisonpierre et al., 1997). Furthermore, Oh et al., 1999 
demonstrated that in BRECs VEGF and hypoxia induced an increase in Ang-2. They 
suggested that the angiogenic stimuli of hypoxia might deteriorate the integrity of the 
vasculature by suppressing Ang-1 activation of Tie-2. Ang-2 expression has been 
demonstrated in SMCs, PCs, and microvascular ECs (Mandriota et al., 1998). BMEC Ang-2 
mRNA levels were increased by VEGF, VEGF and bFGF in combination, by hypoxia and 
were decreased by Ang-1 and Ang-2 itself (Maisonpierre et al., 1997; Mandriota et al., 1998; 
Yamakawa et al., 2003; Pichiule et al., 2004). This suggests that the angiogenic effect of a 
number of regulators may be achieved in part through the regulation of an autocrine loop of 
Ang-2 activity in microvascular ECs. That Ang-2 was stimulated by hypoxia further supports 
it role in pathological diseases characterised by hypoxia. This points to Ang-2 as a potential 
important component of the angiogenic switch that characterises the passage of diabetic 
retinopathy from the avascular to the vascular phase, and provides strong evidence for a
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collaboration between VEGF and Ang-2 in the regulation of neovascularization in ischaemic 
tissues. Ang-2 mRNA is also strongly expressed in highly vascularized tumours (Bunone et 
al, Stratmann et a l, 1999; 1999; Brown et a l, 2000; Etoh et al, 2001).
My finding that the level of Ang-2 staining was raised in the non-diabetic retinas and 
the diabetic retinas with no overt retinopathy as compared to the diabetic retinas with 
vascular changes was unexpected. Ang-2 would be expected to be downregulated in 
quiescent retina in order to allow Ang-1 to exert its stabilising effects on the vasculature. 
However, Maisonpierre et a l  (1997) also reported the expression of Ang-2 in the normal 
quiescent wall which suggests a balance of vessel maintenance by positive and negative 
regulators and the distinct but overlapping expression pattern of Ang-1 and Ang-2 is 
consistent with the possibility that Ang-2 may regulate Ang-1 function at particular sites and 
stages of vascular development. Patel et a l, 2005 showed that Ang-2 concentrations were 
higher in the vitreous of patients with NPDR compared to Ang-1 but was found at low 
concentrations in patients with PDR. The suggested that the levels were lower in the PDR 
patients due to the established nature o f the vitrectomy. That is in long standing and treated 
PDR, there is little active vessel replication. In established PDR, new vessels are mature and 
limited active angiogenesis is taking place. They showed that in patients with NPDR the 
Ang-1 concentrations were half that of Ang-2. Early neovascularization is initiated at this 
stage o f retinopathy as intravascular changes are taking place where changes in Ang-2 levels 
relative to Ang-1 occur and this allows Ang-2 to predominate at the Tie-2 receptor. Ang-2 is 
able to competitively inhibit Ang-1 binding to Tie-2. The predominance of the Ang-2 at the 
Tie-2 receptor would promote increased vascular permeability leading to breakdown of the 
blood-retinal barrier and neovascularization.
I also demonstrated low levels of Ang-2 in the intra-retinal vessels of the diabetic 
retinas with vascular changes and in PDR retinas. This finding also contradicts the 
hypothesised role of Ang-2 as this factor may be expected to be upregulated during these 
stages o f angiogenesis in order to antagonise the vessel stabilising effects of Ang-1. Also 
Ang-2 is known to promote inflammation and vascular leakage, both features of diabetic 
retinopathy (Roviezzo et al, 2005). However, it has been shown that Ang-2 may lead to 
angiogenesis or vessel regression and apoptosis depending on the presence of VEGF 
(Hanahan, 1997; Lobov et al, 2002). I also encountered some problems with staining using 
the Ang-1 and Ang-2 antibodies. Stain deposits were apparent on some of the retinal sections 
which were not removed by centrifuging the antibodies. These observations were less 
obvious with the Tie-2 antibody. Therefore it must be taken into account that in this study
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some non-specific staining may possibly have been observed. Any future studies on 
immunohistochemistry using the angiopoietin and Tie-2 antibodies should involve some prior 
treatment of the antibodies (e.g. immunoprecipitation) in order to remove these deposits. 
Other types of studies such as in situ hybridisation may also produce more reliable results.
In this study Ang-2 was present in the pre-retinal vessels of diabetic retinas 
undergoing active proliferation which is consistent with its role in angiogenesis. Lower levels 
in the preretinal vessels of the excised membranes may reflect the fact that they are no 
longer undergoing active proliferation. This is consistent with the finding that Ang-2 is 
upregulated during angiogenesis and the progression of hepatocellular carcinoma (Zhang et 
al., 2006). Also Ang-2 has been shown to stimulate endothelial progenitor cell (EPC) 
migration to areas of neovascularization (Gill and Brindle, 2005). EPCs have been shown to 
localize at sites of active angiogenesis and vessel remodelling such as healing wounds, 
tumours, and ischaemic retina, where they contribute to neovasculization (Asahara et al, 
1997; Lyden et al., 2001; Grant et al., 2002).
Ang-2 mRNA was shown to be upregulated in mice models of ischaemia-induced 
retinal neovascularization, in the INL, GCL, and in the neovascular vessels (Oh et al., 1999; 
Hackett et a l, 2000). When retinal neovascularization started to regress, strong staining was 
still observed in the GCL and the INL of the hypoxic retinas. Also Ang-2 deficient mice were 
shown to lack ischaemia-induced retinal neovascularization (Hackett et al., 2002). These data 
suggest that both hypoxia- and VEGF-induced neovascularization might be facilitated by 
selective induction of Ang-2 which deteriorates the integrity of the pre-existing vasculature. 
In my study I also found Ang-2 protein in the GCL and the INL which suggests that the 
upregulation of Ang-2 precedes the development of neovascularization and parallels the 
temporal and spatial changes of neovascularization development, which suggests that Ang-2 
plays a critical role in retinal neovascularization. Tie-2 was also located in glial cells and 
ganglion cells. Therefore the angiopoietins appear to have both paracrine and autocrine 
actions on ECs. Takagi et al., 2002 demonstrated upregulation of Ang-2 and Tie-2 in highly 
vascularized regions of human epiretinal membranes. Ang-2 were shown to promote tube- 
forming activity and enhanced the effects of VEGF in cultured BRECs suggesting that in 
microvascular ECs, Ang-2 can probably induce at least some level of Tie-2 signalling, which 
contributes to endothelial angiogenic functions.
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TNF-a
Immunostaining for TNF-a was performed using a dilution series of a primary 
antibody from Abeam, against a set number of sections, as recommended by the 
manufacturer. Initially I found that staining was inconsistent and weak, staining very few 
sections. I tried changing the dilutions of the antibody, followed by chymotrypsin pre­
digestion but again minimal staining was observed. I repeated the same procedure with a 
different antibody from Autogen Bioclear but again had the same problems. I then purchased 
a different antibody from Abeam. This time I tried a dilution series followed by proteolytic 
predigestion with chymotrypsin but again successful staining wasn’t achieved. Following 
consultation with the manufacturer I tried 2 different methods of proteolytic predigestion. 
The first method involved placing the sections in a solution of sodium citrate in a pressure 
cooker for either 1, 2, or 3 minutes. The second method involved placing the sections in a 
pressure cooker for 1, 2, or 3 minutes followed by chymotrypsin pre-treatment. I found that 
placing the sections in the pressure cooker for 3 minutes produced satisfactory results. 
However following this with chymotrypsin solution damaged the retinas. Therefore for the 
purposes of this study sections were placed in a pressure cooker for 3 minutes followed by 
incubation with the primary antibody.
Initially only weak staining was observed for all antibodies. Successful staining was 
eventually achieved using a highly concentrated dilution o f each primary antibody and by 
exposing the angiogenic binding sites with proteolytic digestion using 0.1% chymotrypsin. In 
this study low levels of TNF-a were localised to the endothelial and perivascular regions of 
the non-diabetic retinas and higher levels were demonstrated in diabetic retinas indicating 
that it may play a role in the pathogenesis of both diabetes and diabetic retinopathy. This is in 
agreement with Tezel et al, 2001 who demonstrated that TNF-a is constitutively and weakly 
expressed in normal human retinas.
The highest level of TNF-a immunostaining was observed in the vessels of the 
diabetic eyes without obvious microvascular changes and was then reduced in retinas with 
PDR. This supports the finding that high doses of TNF-a have been shown to inhibit 
angiogenesis whereas low doses were shown to induce angiogenesis (Fajardo et al, 1992). 
TNF-a is increased during periods of hypoxia (Lahat et al, 2003; Ben-Yosuf et a l, 2005) 
and was more specifically shown to be increased during hypoxia in mouse models of oxygen- 
induced retinopathy in mice, perhaps before microvascular changes become obvious 
(Yossuck et al, 2001; Majka et a l, 2002). Kerkar et al, 2006 also showed that TNF-a was
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able to relax pericyte contractility, which may lead to pericyte dropout, an event which 
occurs early in diabetes before retinal microvascular changes become obvious.
TNF-a has been shown to play a role in diabetic retinopathy, because it alters the 
cytoskeleton of ECs, resulting in leaky barrier function and EC activation and an 
inflammatory response. Studies using diabetic animals have shown that increased leukocyte 
adhesion to retinal capillaries is an early event in diabetic retinopathy associated with areas of 
capillary nonperfusion and capillary obstruction and the development of EC damage 
(Camussi et a l, 1991; Kim et a l, 1992; Claudia et a l, 1994; Deli et al, 1995; Bamforth et 
a l, 1996; de-Vries et al, 1996; Luna et a l, 1997; Lutty et al, 1997; Mark et a l, 1999; 
Miyamoto et a l, 1999; Joussen et a l, 2001; Mark et a l, 2001; Mayhan et al, 2002; Trickier 
et al., 2005; Kerkar et a l, 2006; Koss et a l, 2006). Joussen et al, 2001 showed that TNF-a 
in diabetic plasma increases adherence of human leukocytes to retinal ECs, which was 
increased with the severity of diabetic retinopathy. Menon et al, 2006 showed that TNF-a 
was able to disrupt VE-cadherin complexes at vascular EC junctions leading to gapping 
between ECs, causing increased vascular leakage in tumours.
These changes in retinal ECs are central in the progression of diabetic retinopathy. 
This may explain why it was slightly raised in the diabetic retinas with microvascular 
abnormalities in my study. The production of TNF-a has been shown to be significantly 
increased during long-term hyperglycaemia in spontaneously diabetic rats and mice, as well 
as in streptozotocin-induced diabetic rats. Ages, produced as a result of hyperglycaemia have 
been shown to promote mRNA expression and secretion of TNF-a in HUVEC (Rashid et al,
2004).
In this study the level of TNF-a expression in the retinal vessels of the PDR retinas 
was below that observed in the diabetic retinas without microvascular abnormalities but was 
raised above that seen in the non-diabetic retinas. The level of TNF-a expression was also 
raised in the neovessels of the PDR retinas and the fibrovascular membranes. This suggests 
that TNF-a production plays some role in PDR. This is consistent with the findings of 
Spranger et al, 1995 who demonstrated that there was an increase in TNF-a production in 
neovascular eye disease and PDR. Levels of TNF-a were shown to be elevated in animal 
models of ischaemia-induced retinal neovascularization compared with the retinas of non 
diabetic animals (Yossuck et a l, 2001; Joussen et al, 2002c; Majka et al, 2002). TNF-a has 
previously been detected in the neovessels and extracellular matrix of PDR membranes 
(Limb et a l, 1994; Limb et a l 1996; Armstrong et al, 1998a). Armstrong et a l, 1998b 
showed that oxidative damage associated with tissue hypoxia stimulated retinal
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neovascularization in rabbit retina through expression of TNF-a along with VEGF and 
PDGF. Inhibition of TNF-a or TNF-a knockout was shown to reduce pathological 
neovascularization in mouse models of oxygen-induced retinopathy by increasing 
physiological angiogenesis (Gardiner et a l, 2005; Kociok et al, 2006). TNF-a has also been 
found in the vitreous of eyes with PDR (Limb et a l, 1991; Franks et al, 1992; Limb et al,
2001) and an association between the serum level of TNF-a and the development o f PDR has 
also been demonstrated (Limb et al., 1996).
TNF-a is a potent inducer of angiogenesis in vivo (Frater-Shroder et a l, 1987; 
Leibovich et a l, 1987; Montrucchio et a l, 1994). However, in vitro, TNF-a seems to inhibit 
in vitro angiogenic activities such as endothelial proliferation and tube formation (Frater- 
Shroder et a l, 1987; Sato et a l, 1987), suggesting that TNF-a may induce angiogenesis 
indirectly by activating other regulators of angiogenesis, e.g. inflammatory cell secretion of 
VEGF, IL-8 etc. TNF-a can induce Tie-2 expression (Wiliam et al, 2000). Ang-1 is up­
regulated by TNF-a (Scott et al 2002; Scott et a l, 2005). TNF-a upregulated Ang-2 in 
HUVECs (Kim et a l, 2000d). Therefore TNF-a-induced inflammation angiogenesis might be 
facilitated by the induction o f Ang-2. TNF-a was found in human choroidal neovascular 
membranes and it colocalized with VEGF, Ang-1, and Ang-2 in cultured choroidal ECs 
(Hangai et a l, 2006). It increased Ang-2 mRNA and protein levels prior to those of Ang-1 
and VEGF. These results raise the possibility that during neovascularization, TNF-a may 
modulate endothelial plasticity and survival by sequential inactivation of Tie-2 followed by 
activation of Tie-2 and VEGF receptors. Chen et al, 2004 also showed that TNF-a induced a 
weak angiogenic response in a mouse cornea assay and systemic overexpression of Ang-1 or 
Ang-2 dramatically increased corneal angiogenesis induced by TNF-a.
In this study the level o f TNF-a was raised in the lasered retinas compared to the PDR 
retinas and was raised significantly compared to the non-diabetic retinas. This is in contrast 
to other studies in diabetic eyes with intensive coagulation, TNF-a could not be detected 
(Kutty et al., 1995; Platts et al, 1995).
In this study production of TNF-a was not specifically confined to the retinal vessels. 
Staining was also observed within the inner retinal layer and the GCL. Staining was also 
observed within the outer retina in the lasered retinas. This is consistent with the findings of 
other workers (Fontane et al, 2002; Majka et al, 2002) who showed that in mouse models of 
retinal ischaemia, TNF-a was found mainly in the inner retina with a stronger expression in 
the GCL compared with cells of the INL particularly in neurons such as amacrine cells. TNF- 
a  was also detected within structures of the ONL resembling Muller cell processes.
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Significant increase of TNF-a expression was observed after reperfusion, in particular the 
GCL, and to a lesser extent, in INL cells (Fontane et a l, 2002) which is consistent with the 
observation that TNF-a was raised in the lasered retinas in my study. Other workers have 
shown that retinal Miiller cells express TNF-a under hypoxic conditions (Fuchs et a l, 2005). 
TNF-a has been shown to increase the expression of MT1-MMP, MMP-3 and MMP-9 in 
cultured retinal Miiller cells (Migita et a l, 1996; Zhang et al., 1998; Majika et a l, 2002). 
MMP-9 has been implicated in cell migration and matrix degradation. The investigators 
suggested that TNF-a plays a role in the regulation of extracellular proteinase expression 
during retinal neovascularization. TNF-a binds to ECM proteins, including collagen, 
fibronectin, and laminin which constitute the main matrix components of epiretinal 
membranes (Scheiffarth et al., 1988; Alon et al, 1994; Hershkoviz et al, 1995; Franitza et 
al, 2000). Fontaine et a l, 2002 suggested that TNF-a could have neuroprotective or 
neurotoxic effects in ischaemic retina dependent upon whether it bound to TNF-R1 or TNF- 
R2.
TNF-a is secreted by glial cells in the CNS and has been shown to be released in 
activated cultured rat retinal microglia (Morigiwa et al, 2000). Yoshida et a l, 2004 showed 
that TNF-a is produce by activated macrophages/microglia during post-ischaemic 
inflammation in a mouse model of ischemic retinal neovascularization. Tezel et a l, 2001 
showed that retinal glial cells weakly stained for TNF-a in normal human retinas. In vitro 
studies using cocultures of retinal ganglion cells and glial cells showed that TNF-a is 
upregulated in retinal glial cells after exposure to simulated hypoxia (Tezel et al., 2000).
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CHAPTER 5 EXPRESSION OF THE ANTI-ANGIOGENIC GROWTH FACTOR 
PEDF IN NORMAL AND DIABETIC HUMAN RETINAS.
5.1 INTRODUCTION
To investigate spatial and temporal changes of PEDF expression in the progression of 
diabetic retinopathy, 25 human retinas were stained with anti-PEDF antibody. 5 non-diabetic 
retinas and 5 retinas from each o f the diabetic groups, summarized in chapter 3 were stained. 
The intensity of staining was recorded for each retina and an average score calculated for 
each category of tissue.
5.2 Control Staining
To confirm specificity negative controls were incubated without primary antibody or 
with primary antibody after pre-absorption with recombinant PEDF. Staining was negative 
on all the control sections (see figure 5.1).
5.3 PEDF Immunostaining of Retinal Sections
When examined by light microscopy PEDF staining was observed in the non-diabetic 
retinas (mean 2.2), in retinas without ocular abnormalities (1.6), and in retinas with non­
proliferative diabetic retinopathy (1.2) [see figure 5.1). Intraretinal staining was nearly 
abolished in patients with PDR (mean 0.4) compared with non-diabetic retinas, retinas with 
diabetes but without ocular disease and patients with NPDR. Retinas with previous scatter 
photocoagulation resulting in quiescent PDR had weak intraretinal immunochemical staining 
that was, on average, slightly more intense than that of the patients with active PDR (mean 
1.0).
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Figure 5.1 Transverse Sections Showing the Immunolocalisation of 
PEDF
PEDF immunostaining was localised to non-diabetic retina (A), unlasered 
diabetic retina with no obvious intraretinal vascular changes (B), 
unlasered retina with intraretinal vascular changes (C), diabetic retina with 
PDR (D), and lasered diabetic retina (E). Immunoreactivity was abolished 
in control retinas processed with normal pig serum (F).
5.4 Discussion
The data presented in this study demonstrate that PEDF was strongly expressed in 
non-diabetic retinas but that there was almost no staining in retinas with active proliferation. 
These observations support the view that induction of angiogenesis in diabetic human retinas 
requires not only elevation of growth factors such as VEGF (Aiello et al., 1994) but also a 
decrease in angiogenesis inhibitors such as PEDF (Dawson et al., 1999; King et al., 2000).
Several other workers have shown that in normal foetal and adult human and animal 
retinas, PEDF is expressed in the RPE, photoreceptors, interphotoreceptor matrix (IPM) , 
retinal ganglion cells, cells o f the inner retinal layer, nerve fibre layer, inner and outer 
plexiform layers. (Tombran-Tink et al., 1995; Wu et al., 1995; Ortego, 1996; Wu et al., 
1996; Alberdi et al., 1998; Karakousis, 2001; Behling and Bennett, 2002; Ogata et al., 
2002bc Eichler et al., 2004; Hattenbach et al., 2005; Becerra, 2006). It has been suggested 
that secretion of PEDF in the retina, both during vascular development and in adults, 
accumulates in avascular spaces o f the eye such as the aqueous and vitreous humor, and the 
interphotoreceptor matrix where it is responsible for excluding vessels from invading the 
retina, vitreous, and cornea (Dawson et al., 1999; Karakousis, 2001; Behling and Bennett,
2002). PEDF has been shown to inhibit VEGF-induced proliferation and migration of 
microvessel ECs (Duh et al., 2002) and has been shown to inhibit VEGF-induced retinal 
endothelial cell growth and migration in several animal models of ischaemia induced retinal 
neovascularization (Mori 2001; Stellmach et al., 2001; Auricchio et al., 2002; Duh et al., 
2002; Mori et al., 2002c; Raisler et al., 2002). The mechanism by which PEDF exerts its 
antiangiogenic action is not fully understood. However, several reports showed that it causes 
apoptosis of stimulated or proliferating ECs (Stellmach et al., 2001; Guo, 2002; Volpert et 
al., 2002; Chen et al., 2006 ) and this may be the mechanism of inhibition of angiogenesis. 
Cai et al., 2006 demonstrated that PEDF was able to inhibit VEGF-induced angiogenesis via 
y-secretase cleavage of VEGFR-1. They also showed that PEDF was also able to inhibit 
VEGF-induced phosphorylation of VEGFR-1. Phosphorylation of VEGFR-1 was also shown 
to regulate VEGFR-2 signalling.
The presence of PEDF in the neuronal layers of the retina is also consistent with a 
role for PEDF as a neuronal survival and neuronal differentiating factor in the retina 
(Becerra, 1997; Cayouette et al., 1999; Houenou et al., 1999; Jablonski et al., 2000; Cao et 
al., 2001; Crawford et al., 2001; Ogata et al., 2001c; Becerra et al., 2006; Li et al., 2006). 
PEDF has been shown to promote photoreceptor outer segment formation and maturation,
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and maintains steady state levels of opsin and glutamine synthetase expression in 
photoreceptor and Muller glial cells (Jablonski et al., 2000; Jablonski et al., 2001).
In this study there was a small reduction in staining intensity in diabetic retinas 
without microvascular abnormalities and in diabetic patients with NPDR compared with non­
diabetic retinas. The finding that PEDF is reduced in patients with NPDR is consistent with 
the finding that under hypoxic conditions in culture, secretion of PEDF is decreased 
(Dawson, 1999). It has been shown that PEDF acts as an anti-inflammatory and anti­
permeability in the eye (Mori et al., 2001; Stellmach et al., 2001; Liu et al., 2004; Zhang et 
al., 2005). Yamagishi et al., 2006 showed that PEDF could inhibit AGE-induced retinal 
vascular hyperpermeability. Down-regulation of PEDF expression has been shown to 
increase the secretion of VEGF and TNF-a in retinal Mtiller cells suggesting that a decrease 
in ocular PEDF levels may play contribute to inflammation and vascular leakage in the eye 
(Zhang et al., 2005). PEDF has also been shown to protect cultured retinal pericytes from 
advanced glycation endproduct-induced injury. As pericyte loss from retinal blood vessels is 
an early feature NPDR a reduction in PEDF, as observed in this study, could lead to pericyte 
dropout (Yamagishi et al., 1995; Yamagishi et al., 2002).
The finding that there was almost no staining for PEDF in the retinas undergoing 
active proliferation is consistent with the view that PEDF loss creates a permissive 
environment for angiogenesis that my contribute to the progression of ocular neovascular 
disease. Ischaemia- induced retinal neovascularization has been shown to cause a significant 
reduction in retinal PEDF and a substantial increase in VEGF mRNA and protein in rat 
models (Gao et al., 2001; Crossen, 2002). A decrease in levels of PEDF has also been 
described in the vitreous of patients with PDR (Holekamp et al., 2002; Ogata et al., 2001a; 
2002a). Vitreous levels of PEDF were shown to be low in eyes with proliferative 
vitreoretinopathy whereas VEGF levels were raised supporting the view that lower levels of 
PEDF and higher levels of VEGF may be related to ocular proliferation. However, recently 
Apte et al., 2004 showed that PEDF stimulated choroidal neovasculariation at high 
concentrations but at low concentrations it decreased neovascularization. Therefore the 
concentration of PEDF appears to be important, whether this applies to diabetic retinopathy 
remains to be determined.
It therefore appears that there is a direct correlation between PEDF and the extent of 
neovascularization and that there is an equilibrium shift between PEDF and VEGF in the 
uncontrolled growth of blood vessels in the eye (Gao et al., 2001; Ohno-Matsui et al., 2001; 
Gao and Ma, 2002; Ogata et al., 2001a; 2002a, b, c). Eichler et al., 2004 showed that
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exposure of Muller cells to VEGF suppressed PEDF release in a dose-dependent manner. 
These findings suggest that in ischaemic retina Muller cells generate a permissive condition 
for angiogenesis by secreting more VEGF and less PEDF.
More direct evidence for PEDF as an anti-angiogenic factor in PDR comes from 
studies in which delivery of PEDF protein through virus-mediated gene transfer and direct 
protein introduction was used successfully to inhibit angiogenesis in a number of animal 
models of ischaemia-induced retinopathy and choroidal neovascularization (Mori, 2001; 
Rasmussen, 2001; Stellmach, 2001; Auricchio, 2002; Duh, 2002; Mori et al., 2002ab; 
Raisler, 2002).
Retinas with quiescent retinal neovascularization who had had retinal 
photocoagulation had higher levels of PEDF compared with retinas with active PDR. 
Photocoagulation induces regression of retinal neovascularization and has been shown to be 
associated with a reduction in the incidence of severe visual loss and retinal 
neovascularization (Early Treatment Diabetic Retinopathy Study Research Group, 1991). 
The findings suggests therefore that the positive effects of retinal photocoagulation are 
mediated at least in part by the re-establishment o f near-normal PEDF levels. Hattenbach et 
al., 2005 observed a considerable upregulation of PEDF mRNA and protein and an increased 
secretion into the culture medium of RPE cells. PEDF has also been shown to be secreted by 
RPE cells into the interphotoreceptor matrix of the retina (Siegel et al., 1994; Wu et al., 
1995; Wu et al., 1996). Ogata et al., 2001b demonstrated an increased expression of various 
angiogenic and antiangiogenic cytokines including PEDF mRNA in photocoagulated human 
RPE cells. The findings from these studies and my study supports the hypothesis that 
antiangiogenic factors play a critical role in the regression of intraocular neovascularization 
observed after photocoagulation (Diabetic Retinopathy Study Research Group, 1978; Doft et 
al., 1984).
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CHAPTER 6 EXPRESSION OF CAVEOLIN-1, -2, AND -3 IN THE NORMAL AND 
DIABETIC RETINA
6.1 INTRODUCTION
Sections were stained to localise and assess the extent of caveolin-1 presence in the 
retina and preretinal membranes. Sections were also stained to localise and assess the extent 
of caveolin-2 and -3 in normal retinas. Immunostained sections of retina were examined by 
light microscopy to determine if there was a temporal and spatial relationship between 
staining intensity and the various pathological changes associated with diabetic retinopathy.
6.2 CONTROL STAINING
To confirm specificity of the immunostaining control sections were processed with 
omission of the primary antibodies. Staining was negative on all the control sections (see 
figure 6.1).
6.3 Immunolocalisation of Caveolin-1, -2, and -3
Sections were stained to localise and assess the extent of Caveolin-1, -2, and -3 
presence in the retina and preretinal membranes. Immunostained sections of retina were 
examined by light microscopy to determine if there was a temporal and spatial relationship 
between staining intensity and the various pathological changes associated with diabetic 
retinopathy.
6.3.1 Caveolin-1 immunostaining of retinal sections and flbrovascular membranes
When examined by light microscopy staining for caveolin-1 was observed in both 
non-diabetic and diabetic extravascular tissue. However, caveolin-1 immunoreactivity was 
generally absent or weak around the intraretinal vessels. Where staining was observed within 
the vessels, in some instances staining was associated with both endothelial cells and the 
perivascular region of the vessels. The staining pattern depended upon the category of tissue. 
Variability of staining within retinal layers and intra-retinal vessels across all categories was 
observed, with some cells staining negative and some staining positive. Variability of 
staining was observed for each retina within each category, which is represented by the 
standard deviations in table 6.1 to 6.6 but this did not show a correlation with either donor 
age, the type of glycaemic control in the case of diabetic groups or time post-mortem.
In the non-diabetic retinas staining intensity for caveolin-1 was generally minimal or 
weak within the photoreceptors and the retinal vessels. Only 4/12 retinas demonstrated
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staining within the vessels. Weak to moderate staining was observed within the cell bodies of 
the outer retina (12/12), and the cell bodies of the inner retina (12/12). Moderate staining was 
observed within the GCL (12/12) [figure 6.1].
In the diabetic retinas with no overt retinopathy minimal to weak staining was again 
observed within the photoreceptors and the retinal vessels. In comparison to the non-diabetic 
retinas the number of retinas showing staining for caveolin-1 within the retinas was raised 
(9/11). As in the non-diabetic retinas, weak to moderate immunoreactivity was associated 
with the cell bodies of the outer retina (10/11), and the cell bodies of the inner retina (11/11). 
Staining in the GCL was slightly raised to moderate to intense levels as compared to the non­
diabetic retinas (11/11) [figure 6.2].
In the diabetic retinas showing vascular changes but no evidence of PDR staining was 
raised in the photoreceptors (8/9) and the cell bodies of the inner retina (9/9), as compared 
with the non-diabetic and diabetic retinas with no overt retinopathy. Staining within the cell 
bodies of the outer retina was slightly reduced, as compared with the non-diabetic and 
diabetic retinas with no overt retinopathy (9/9). Staining was again moderate to intense 
within the GCL (9/9). Staining was still weak within the retinal vessels (5/9) [figure 6.3].
In the diabetic retinas with active neovascular PDR membranes on their surfaces 
intensity of staining for caveolin-1 was raised in all the retinal layers as compared to all the 
other previous categories of tissue. Staining was moderate to intense within the 
photoreceptors (5/5), the cell bodies of the outer retina (5/5), the cell bodies of the inner 
retina (5/5) and the GCL (5/5). Staining was reduced slightly within the retinal vessels as 
compared to the other categories of tissue (3/5).Within the pre-retinal membranes staining 
was weak to moderate within the pre-retinal vessels (5/5) and weak within the non-vascular 
components of the membranes (4/5) [figure 6.4].
In those diabetic retinas which had undergone successful laser therapy staining was 
reduced within all the retinal layers as compared to the PDR retinas. Staining was minimal to 
weak within the photoreceptors (5/11) and the retinal vessels (6/11).Staining was weak to 
moderate within the cell bodies of the outer retina (10/11), the cell bodies of the inner retina 
(10/11) and the GCL (10/11) [ figure 6.5].
Caveolin-1 staining was weak to moderate within the pre-retinal vessels of 15/17 of 
the excised membranes. Weak to moderate staining was also associated with the non-vascular 
components of the membranes [figure 6.6].
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TABLE 6.1. MEAN INTENSITY OF CAVEOLIN-1 IMMUNOSTAINING
Tissue
Category
Retina Layer Retinal
Vessels
Membrane
Photo-
Receptors
Outer
Retina
Inner
Retina
GCL Vessels Matrix
Non-diabetic
(n=14)
0.9 1.6 1.9 2.0 0.9
No Overt
Retinopathy
(n=12)
0.7 1.4 1.8 2.3 0.9
Intraretinal
Changes
(n=10)
1.3 1.1 2.2 2.3 1.0
PDR
(n=9)
2.2 2.4 2.4 2.4 0.6 1.4 1.0
Laser-No
Residual
PDR
(n=14)
0.9 1.1 1.9 1.9 0.6
Excised 
Membranes 
1 (n=17)
1.4 1.3
GCL = ganglion cell layer 
ILM = internal limiting membrane
0 = background staining
1 = weak staining
2 = moderate staining
3 = intense staining
Values in parenthesis = +/- standard deviation
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6.3.2 Caveolin-2 Immunostaining of retinal sections
Of the 8 non-diabetic retinas tested, staining was absent in the RPE, however staining 
was observed in the outer segments of the photoreceptors in 7/8 of the retinas. Staining was 
also observed in the outer region of 2/8 of the retinas, in the inner region of 3/8 of the retinas 
and in the ganglion cell layer of 4/8 of the retinas. Perivascular staining was observed in 3/8 
of the retinas and in one of the retinas one vessel showed endothelial cell staining [figure 
6.7].
6.3.3 Caveolin-3 immunostaining of retinal sections
Of the 8 non-diabetic retinas tested only one stained positively for caveolin-3 where 
immunostaining was localised to the outer and inner regions of the retina and the ganglion 
cell layer [figure 6.7].
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Figure 6.1 Transverse Sections Showing the Immunolocalisation of Caveolin-1 
in Non-Diabetic Retinas (A-E) and Negative Control Section (F).
Staining was observed in the retinal vessels and across all the retinal layers.
*Figure 6.2 Transverse Sections Showing the Immunolocalisation of Caveolin-1 
in Unlasered Diabetic Retinas with No obvious M icrovascular Abnormalities.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 6.3 Transverse section showing the immunolocalisation of Caveolin-1 
in Unlasered Diabetic Retinas with No obvious M icrovascular 
Abnormalities.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 6.4 Transverse Sections Showing the Immunolocalisation of 
Caveolin-1 in Diabetic Retinas with PDR.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 6.5 Transverse Sections Showing the Immunolocalisation of Caveolin-1 
in Lasered Diabetic Retinas.
Staining was observed in the retinal vessels and across all the retinal layers.
Figure 6.6 Transverse Sections Showing the Immunolocalisation of Caveolin-1 
(Arrows) in Fibrovascular M embranes
Figure 6.7 Transverse Sections Showing the Immunolocalisation of 
Caveolin-2 and Caveolin-3
Caveolin-2 immunsotaining was localised to non-diabetic retina (A, B). 
Caveolin-3 immunostaining was localised to non-diabetic retina (C,D). 
Immunoreactivity was abolished in control retina processed with normal goat 
serum (E).
6.4 DISCUSSION
Immunostaining for caveolin-1, caveolin-2 and caveolin-3 was performed using a 
dilution series of the primary antibodies, against a set number of sections, as recommended 
by the manufacturer. Initially only weak staining was observed for all antibodies. Proteolytic 
digestion using 0.1% chymotrypsin or proteinase K also only produced weak staining. 
Successful staining was eventually achieved using a highly concentrated dilution of each 
primary antibody and by exposing the angiogenic binding sites with proteolytic digestion 
using 0.2% triton X-100. I also found that there was a lot of background staining for 
caveolin-1 using the alkaline phosphatase/fast red system. I therefore substituted that 
enzyme/substrate complex for horseradish peroxidase/diaminobenzidine which produced 
more specific staining.
The data presented in this study demonstrate that caveolin is present in human retina. 
In addition caveolin-1 was shown to be present in diabetic retinas and fibrovascular 
membranes. These observations support a role for caveolin in the normal functioning of the 
retina and in diabetic retinopathy.
Caveolin-1 was present at low levels in the retinal vessels of the non-diabetic retinas 
and at all stages of diabetic retinopathy. Staining was slightly raised in the neovessels of the 
microvascular membranes of the PDR retinas. Several workers have demonstrated caveolin-1 
expression in retinal endothelial cells (Gardiner and Archer, 1986a, b; Feng et al., 1999b; 
Bridges et al., 2001; Kim et al 2006) indicating that it is involved in the normal physiological 
functioning of the retina.
Cav-1 and caveolae have been shown to serve as flow-activated mechanosensors or 
transducers of physiological responses in intact blood cells (Yu et al., 2006). Caveolae are 
also believed to be responsible for transcytosis, the process by which plasma proteins (e.g. 
albumin) are transported across capillary endothelium (Palade et al., 1979; Vasile et al., 
1983; Ghitescu et al., 1986; Milici et al., 1987; Schnitzer et al., 1995; Predescu et al., 1998).
Cav-1 is the major protein coat of endothelial caveolae and is necessary for caveolae 
assembly. Several studies have shown a complete loss of caveolae organelles in blood 
vessels, adipocytes and fibroblasts obtained from cav-1-deficient mice confirming the 
necessity of this protein in caveolae biogenesis (Drab et al., 2001; Razani et al., 2001; Rizani 
and Lisanti, 2001; Zhao et al., 2002; Cao et al., 2003). Cav-1 appears to play an important 
role in cholesterol homeostasis and caveolae has been shown to play a role in cholesterol 
trafficking as has been observed within lens epithelial cells and fibre cells (Lo et al., 2001; 
Sexton et al., 2004; Cenedealla et al., 2006).
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Caveolae are able to form mobile signalling platforms which concentrate and 
organize signal transduction cascades that regulate tissue structure, vascular tone, and basal 
permeability (Anderson, 1993; Lisanti et al., 1994; Parton, 1996). In caveolae, cav-1 can 
interact with itself to form homo-oligomers as well as with several other signalling 
molecules.
Caveolae have been implicated in signalling through the p42/44 MAP kinase pathway 
which is involved in the proliferation, survival, and migration of ECs. Other components of 
the p42/MAP kinase cascade are localized within caveolae membranes. These include 
receptor tyrosine kinases (VEGFR-2, Tie-2, EGFR, PDGFR, InsR) (Smart et al, 1995; Liu et 
al., 1996; Mineo et al., 1996; Liu et al., 1997; Liu et al., 1999; Cho et al., 2004b; Sonveaux 
et al 2004), H-Ras (Mineo et al., 1996; Song et al., 1996; Yoon et al., 2003), Raf kinase 
(Mineo et al, 1996), ERK (Lisanti et al., 1994; Liu et al., 1996), She (Liu et al., 1996), Grb- 
2 (Liu et al., 1996) and Nek (Liu et al., 1996) as well as PI-3 kinase, PLCy and protein kinase 
C and phosphatidylinositol (Lisanti et al., 1994; Liu et al., 1995; Pike et al., 1996; Liu et al., 
1997; Gingras et al., 1998; Okamoto et al., 1998; Ahn et al., 1999; Murthy and Makhlouf, 
2000; Predescu et al., 2001; Kawamura et al., 2003; Labrecque et al., 2003;). Both in vitro 
and cell culture experiments indicate that cav-1 can directly interact with and maintain some 
of these signalling molecules in an inactive conformation (Anderson, 1998; Okamoto et al,
1998) acting as a scaffolding protein, able to negatively regulate the activity of other 
molecules by binding to and releasing them in a timely fashion holding them in a quiescent or 
inhibited state. Down regulation of cav-1 expression and caveolae organelles may be a 
prerequisite for EC proliferation and subsequent angiogenesis. This is supported by the 
finding that exposure of Ecs to VEGF, has been shown to result in a reduced EC expression 
of cav-1 and caveolae which was mediated by a negative feedback mechanism through the 
VEGFR-2 and subsequent downstream p42/44 MAP kinase pathway (Liu et al, 1999; 
Labrecque et al, 2003). Cav-1 overexpression has been shown to reduce VEGF-mediated 
angiogenesis with defects in vasodilatation, permeability, and angiogenesis (Brouet et al., 
2004; Bauer et al, 2005). Sonveaux et al., 2004 showed that cav-/- Ecs formed tubes on 
Matrigel on VEGF stimulation which was dramatically repressed when compared with 
cav+/+ Ecs. With the exception of insulin receptor which appears to be stimulated by cav-1 
(Yamamoto et al., 1998), studies have demonstrated that cav-1 bound to and inhibited growth 
factor receptor kinase activity (Couet et al., 1997; Bilderback et al., 1999; Yamamoto et al.,
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1999) as well as other important secondary messengers and substrates (Shaul and Anderson,
1998).
Liu et al, 2002 showed that cav-1 is down-regulated by endothelial growth factors 
that stimulate the initial proliferative phase but upregulated during the differentiation phase 
into tubular networks. Under conditions of cell confluence, they showed that cav-1 
expression stimulates EC differentiation and tubule formation. They hypothesize that 
caveolin acts a both a pro- and anti-angiogenic factor by serving as a “differentiation sensor” 
that monitors and responds to changes in the relative balance of positive and negative factors 
to “tell” a target cell whether to remain quiescent or to become proliferative. This may 
explain why I observed the same levels of cav-1 staining across all tissue categories. In the 
PDR membranes the neovessels may have already undergone proliferation and so cav-1 may 
now be acting as an anti-angiogenic factor.
I also observed cav-1 staining in the photoreceptors, the ganglion cell layer and the 
inner and outer regions of both non-diabetic and diabetic retinas. Interestingly levels were 
raised in the diabetic retinas as compared to the non-diabetic retinas. Kim et al, 2006 also 
observed cav-1 immunostaining in the photoreceptors, ganglion cell layer, the inner 
plexiform layer and outer plexiform layer of normal rat retinas which is in agreement with 
my findings. This may indicate that cav-1 plays a role in signal transduction in glial and 
neuronal cells. As far as I am aware, no other studies have looked at the expression of cav-1 
in the diabetic retina and so its role in diabetic retinopathy is still to be determined. 
Photoreceptor detergent resistant membranes (DRMs) are enriched in cav-1 (Elliott et al.,
2003) and cav-1 has been shown to be localized to photoreceptor synaptic ribbons. DRMs 
from rod outer segments contain several proteins involved in phototransduction (Seno et al, 
2001). It was suggested that cav-1 may therefore be involved with regulating transmitter 
release and visual transduction and the formation of synaptic ribbons (Kachi et al., 2001).
In my study I observed cav-2 staining in the photoreceptors, the neuronal layers of the 
retinas and the ganglion cell layer of non-diabetic retinas, some staining was also observed 
around the vessels. As well as cav-1 expression endothelial cells also express cav-2 but not 
cav-3 (Garcia-Cardena et al, 1997). Cav-2 has to heteroligomerize with cav-1 to form the 
caveolar coat but cannot form the caveolar coat by itself (Monier et al, 1995; Sargiacomo et 
al, 1995; Scherer et al, 1997; Scheiffele et al, 1998; Mora et al, 1999; Parolini et al,
1999). Cav-2 has been shown to be expressed in adult rat retina where it showed similar but 
weaker staining than cav-1 (Kim et al, 2006) but staining was more intensely detected in 
vessels as compared to cav-1. As in my study cav-2 was present in the inner plexiform layer,
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inner nuclear layer, outer plexiform layer in the processes of glial cells and Muller cells. Also 
in the retinal neuronal cells including the ganglion cells, amacrine cells, bipolar cells, 
horizontal cells, and photoreceptor cells. Based on the functional role of caveolins, these 
molecules may be assumed to play an important role in the cholesterol homeostasis of the 
retina. Cav-2 may also be involved in synaptic signal transduction in the retina and cav-2 has 
also been shown to be expressed in brain astrocytes (Cameron et al., 1997; Ikezu et al.,
1998). Cav-2 has also been shown to be present in the RPE collected from rat eyes and in 
human RPE cell lines (Mora et al, 2006) which was in contrast to my study where 
immunostaining was not observed. Cav-2 has a non-polar distribution in RPE cells, 
consistent with the observation that cav-2 expression may be necessary in certain cells for the 
efficient assembly of plasmalemmal caveolae (Lahtinen et al., 2003; Sowa et al., 2003). The 
determination of the precise role of cav-2 in the retina will require further study.
Cav-3 is primarily expressed on skeletal muscle and smooth muscle cells (Song et al., 
1996; Tang et al, 1996; Kogo et al., 2006). In my study I showed that in one retina, cav-3 
was detected in the outer and inner regions of the retina and the ganglion cell layer indicating 
that it is expressed by cells other than muscle cells. Cav-3 was also shown to be expressed in 
brain astroglial cells (Ikezu et al., 1998) and has been shown to be upregulated in reactive 
astrocytes surrounding senile plaques in the brains of Alzheimer’s patients (Nishiyama et al.,
1999). Cav-3 shows high homology with cav-1 (85% similarity) (Tang et al., 1996) and 
either is sufficient for the formation of caveolae invaginations (Li et al, 1998; Hagiwara et 
al., 2000; Galbiati et al., 2001; Park et al., 2002). Cav-3 can interact with adenyl cyclase, 
eNOS and insulin receptor signalling (Yamamoto et al., 1998).
There is therefore some indication that cav-2 and cav-3 are involved both in the 
normal physiological functioning of the retina, as shown by my study, and in various disease 
processes but further studies need to be carried out to determine their precise roles.
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7. GENERAL DISCUSSION
7.1 MICROVASCULAR COMPLICATIONS AND DIABETIC RETINOPATHY
Retinopathy is a frequent microvascular complication of diabetes mellitus (DM) that remains 
a major therapeutic challenge (Lobo et al, 2004). To prevent and improve the treatment of 
DR, it is fundamental that we know the evolution of the earliest changes that occur in the 
retina affected by DM and how these changes relate to the progression of retinopathy. In this 
study retinas were selected for immunostaining based on clinical assessment and by 
microscopical examination of sections for microvascular abnormalities associated with 
diabetic retinopathy.
The overall purpose of this project was to try to demonstrate that the spatial and temporal 
expression of angiogenic growth factors was altered during the progression of diabetic 
retinopathy. In recent years it has become increasingly obvious that inhibitors of 
angiogenesis are just as important as pro-angiogenic factors in the pathogenesis of diabetic 
retinopathy. I therefore also examined the expression of the well known anti-angiogenic 
factor PEDF during different stages of diabetic retinopathy. Finally, this study was also 
undertaken to determine if the levels of caveolin changed during the progression of diabetic 
retinopathy as caveolae have been shown to play an important role in the 
compartmentalization of second messengers involved in growth factor receptor signal 
transduction pathways.
7.2 GROWTH FACTOR EXPRESSION DURING DIABETIC RETINOPATHY
The findings from my study clearly show that VEGF, the angiopoietins and TNF-a 
play different roles in the pathogenesis of diabetic retinopathy. It therefore appears that 
growth factors may act alone or in concert to bring about the microvascular abnormalities 
observed in diabetic retinopathy.
The specific localization of VEGFR-2 in PDR retina supports the previous suggestion that 
VEGF binding to the VEGFR-2 receptor sends a classic proliferative signal (Malecaze et al., 
1994; Chen et al., 1997; Armstrong et al., 1998a; Suzuma et al., 1998; Ishida et al., 2000; 
Ozaki et al, 2000; Ishimama et al., 2001; Witmer et al, 2002; Gerber and Ferrara., 2003; 
Cerdan et al, 2004; Wilkinson-Berka et al, 2006). The demonstration that VEGFR-1 is 
expressed in both non-diabetic retina and diabetic retina supports the concept that VEGF is 
involved in vascular maintenance as well as in other endothelial cell functions such as 
maintenance of vascular permeability and endothelial cell proliferation (Kolch et al., 1995).
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This study adds to the limited knowledge about the role of VEGFR-3 in pathological 
angiogenesis (Pajusola et al., 1992; Fielder et al., 1997; Partanen et al., 1999; Valtola et al., 
1999; Skobe et al., 200lab; Witmer et al., 2001; Clarijs et al, 2002). VEGF-C can induce 
angiogenesis under certain circumstances which could be due in part to its capacity to bind to 
an activate VEGFR-2, in addition to VEGFR-3 (Tille et al., 2003). Clearly VEGF-C binding 
to VEGFR-3 does play a role in diabetic retinopathy.
VEGF increases permeability and is mitogenic for ECs, acting early and at most 
points of the angiogenic cascade (Lim et al, 2003). In contrast, Ang-1 has vessel-maturing 
activates and acts at a later stage which involves recruitment of vessel-supporting cells, 
strengthening of intercellular junctions, and establishment of leakage-resistant vessels (Suri 
et al, 1996; Davis and Yancopoulos, 1999; Fujikawa et al, 1996b; Hanahan, 1997; 
Papapetropoulas et a l, 1999; Thurston et al, 1999; Gamble et al, 2000). It has been shown 
that a combination of Ang-1 and VEGF recruits smooth muscle actin-a-positive cells to 
vascular walls (Asahara et a l, 1998). Co-induction of endothelial Ang-1 and VEGF may 
exert such vessel-maturing effects on the sprouting vessels in an autocrine manner in the 
microenvironment of active sprouting. Ang-1 exerts a vascular endothelial barrier protective 
effect by blocking the action of VEGF (Gamble et al, 2000; Jho et al, 2005). I did find low 
levels of Ang-1 in PDR membranes which supports this role of Ang-1 however, a high level 
of Ang-1 immmunostaining was observed in the PDR retinal vessels. Perhaps it was localized 
to a subset of retinal vessels that were no longer undergoing active angiogenesis. However in 
the presence of VEGF, Ang-1 has been shown to significantly potentiate VEGF-induced 
neovessel sprouting (Zhu et a l, 2002).
Ang-2 signals cause vessel structures to become loosened, reducing endothelial cell 
contacts with the matrix and disassociation of perivascular support cells. This loosening 
appears to render the endothelial cells more accessible and responsive toward angiogenic 
inducers such as VEGF (and likely other angiogenic inducers) leading to capillary sprouting 
and the formation of new vessels. I only showed low levels of Ang-2 expression in the retinal 
vessels which was an unexpected finding. Again, perhaps it was localized to a subset of 
vessels that were not undergoing active angiogenesis. The action of Ang-2 has become 
controversial as in some instances Ang-2 can either promote angiogenesis or induce 
regression of vessels (Maisonpierre et a l, 1997; Holash et al, 1999; Yu and Stamenkoviv, 
2001). This appears to be dependent upon the presence of VEGF. When VEGF is present, 
Ang-2 appears to induce angiogenesis, but in the absence of VEGF it promotes vessel 
regression (Asahara et al., 1998; Lobov et al, 2002; Oshima et al, 2004). Hangai et al, 2006
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speculate that sequential induction of Ang-2 and then Ang-1 and VEGF in ECs may provide 
precise and stage-appropriate autocrine and/or paracrine angiogenic signals to ECs.
The findings from this study that TNF-a was upregulated in the vessels of PDR 
membranes and diabetic retinas supports the suggestion that it may also play some role in 
diabetic retinopathy (Spranger et al., 1995; Limb et al., 1996; Armstrong et al., 1998a; Limb 
et al., 2001; Yossuck et al., 2001; Majka et al., 2002). Studies of the angiogenic properties of 
TNF-a yield conflicting results. In vivo it appears to be a potent inducer of angiogenesis 
(Frater-Shroder et al., 1987; Leibovich et al., 1987; Montrucchio et al., 1994). However, in 
vitro, TNF-a seems to inhibit angiogenic activities such a endothelial proliferation and tube 
formation (Frater-Shroder et al., 1987; Sato et al., 1987; Yang et al., 2004), apart from in one 
study in HUVECs where TNF-a was shown to upregulate Ang-2 expression (Kim et al., 
2000d) . It has been suggested that TNF-a may induce angiogenesis indirectly by activating 
other regulators of angiogenesis. TNF-a has been shown to induce Ang-1, Ang-2, Tie-2 
VEGF, and VEGF-C expression (Kim et al., 2000d; Wiliam et al., 2000; Scott et al., 2002; 
Chen et al., 2004; Scott et al., 2005; Hangai et al., 2006; Zhao et al; 2006; Zhu et al., 2006). 
Results from our laboratory also showed that TNF-a was also able to upregulate KDR (Zhao 
et al., 2006). TNF-a was also shown to co-localize with VEGF and the angiopoietins in 
choroidal neovascular membranes and it increased Ang-2 levels prior to those of Ang-1 and 
VEGF. This suggests that during neovascularization TNF-a may modulate endothelial 
plasticity and survival by sequential inactivation of Ang-2 followed by activation of Tie-2 
and the VEGF receptors.
VEGF, Ang-2 and TNF-a have been shown to be hypoxia inducible (Oh et al., 1999). 
As VEGF, the angiopoietins and TNF-a were localized to vascular endothelial cells and non- 
vascular cells this supports the hypothesis that the retinal response to the hypoxic 
environment would be to upregulate the receptors and to stimulate the synthesis and secretion 
of VEGF, Ang-2 and TNF-a in retinal PCs, ECs, glial cells, ganglion cells, and possibly 
other cell types. The sustained production of VEGF, Ang-1, Ang-2 and TNF-a would 
eventually lead to an angiogenic response. Sustained production of these growth factors may 
be maintained by a positive feedback mechanism to the receptors on the retinal cells. The 
presence of Ang-1 in retinal vessels not involved in retinal angiogenesis may allow a shift in 
the local balance of Ang-1/Ang-2 back in favour of Ang-1, to effect maturation and 
stabilization of the newly formed vessels. Therefore there appears to be a collaboration 
between VEGF, Ang-1, Ang-2, and TNF-a to elicit angiogenesis, all of which appear to exert 
their effects on retinal cells via both autocrine and paracrine mechanisms.
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7.3 THE EXPRESSION OF PEDF IN DIABETIC RETINOPATHY
The findings from this study support the findings of other workers that PEDF is 
highly expressed in non-diabetic retinas and diabetic retinas with NPDR. (Tombran-Tink et 
al., 1995; Wu et al., 1995; Ortego, 1996; Wu et al., 1996; Alberdi et al., 1998; Karakousis, 
2001; Behling and Bennett, 2002; Ogata et al., 2002bc; Eichler et al., 2004; Hattenbach et 
al, 2005; Becerra, 2006). This study also showed that PEDF is downregulated in PDR which 
confirms findings obtained from previous studies (Holekamp et al., 2002; Ogata et al., 
2001a; 2002b, c).
It appears therefore that under normal physiological conditions, secretion of PEDF 
into avascular spaces in the eye such as the aqueous and vitreous, excludes vessels from 
invading the retina, vitreous and cornea (Dawson et al., 1999; Karakousis, 2001; Behling and 
Bennett, 2002). It may do this by inhibiting VEGF-induced proliferation and migration of 
ECS (Mori 2001; Stellmach et al., 2001; Auricchio et al., 2002; Duh et al., 2002; Mori et al., 
2002c; Raisler et al., 2002; Cai et al, 2006).
The general consensus is that loss of PEDF creates a permissive environment for 
angiogenesis that may contribute the progression of ocular neovascular disease. This is 
supported by the findings that ischaemia- induced retinal neovascularization caused a 
significant reduction in retinal PEDF and a substantial increase in VEGF mRNA and protein 
in rat models (Gao et al., 2001; Crossen, 2002). Down-regulation of PEDF expression has 
also been shown to increase the secretion of both VEGF and TNF-a from retinal Muller cells 
(Zhang et al, 2005). It therefore appears that there is a direct correlation between PEDF and 
the extent of neovascularization and that there is an equilibrium shift between PEDF and 
VEGF in the uncontrolled growth of blood vessels in the eye (Gao et al., 2001; Ohno-Matsui 
et al., 2001; Gao and Ma, 2002; Ogata et al., 2002a, b, c; Eichler et al., 2004). However, 
recently Apte et al, 2004 showed that PEDF stimulated choroidal neovasculariation at high 
concentrtations but at low concentrations it decreased neovascularization. Therefore the 
concentration of PEDF appears to be important, whether this applies to diabetic retinopathy 
remains to be determined and therefore caution should be taken when considering using 
PEDF for the treatment of PDR.
7.4 THE EXPRESSION OF CAVEOLINS IN DIABETIC RETINOPATHY
The observation that only cav-1 and cav-2 were observed in the retinal vessels is 
consistent with the findings from other studies where cav-1 and cav-2 have both been shown 
to be expressed by retinal endothelial cells but not cav-3 (Garcia-Cardena et al, 1997; Feng
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et al, 1999b; Bridges et al, 2001; Kim et al, 2006). The presence of cav-1 and cav-2 in 
non-diabetic retina supports previous observations that under normal physiological 
conditions caveolae act as flow-activated sensors in ECs (Yu et al, 2006). Shear stress is 
recognized by the endothelial cells and regulates vascular tone, vessel wall remodelling, cell 
adhesion, coagulation, and fibronolysis (Dewey et al, 1981; Davies et al, 1995). Caveolae 
are also believed to be involved in transcytosis, the process by which proteins (e.g. albumin) 
are transported across capillary endothelium (Palade et al, 1979; Vasile et al, 1983;1989; 
Predescu et al, 1998). In addition cav-1 and cav-2 hetrodimerize to form the protein coat of 
caveolae and both are necessary for caveolae assembly (Drab et al., 2001; Razani et al, 
2002).
As well as their physiological roles in vascular endothelium, caveolae are able to form 
mobile signalling platforms which concentrate and organize signal transduction cascades. 
(Anderson, 1993; Lisanti et a l, 1994; Parton, 1996). Several receptor tyrosine kinases are 
located in caveolae including VEGFR-2 and Tie-2 as well as the TNF receptors I and II 
(Feng et al, 1999a; Liu et a l, 1999; Yoon et al, 2003; Cho et al, 2004b; D’Allessio et al.,
2005). Cav-1 has been shown to interact with and maintain some of these signalling 
molecules in an inactive conformation acting as a scaffolding protein, able to negatively 
regulate the activity of these molecules by binding to and releasing them in a timely fashion 
holding them in a quiescent or inhibited state. Down regulation of cav-1 may be a 
prerequisite for EC proliferation and subsequent angiogenesis. Down-regulation of cav-1 was 
demonstrated in the retinal vessels of the PDR retinas in this study and exposure of ECs to 
VEGF has been shown to result in a reduced EC expression of cav-1 which was mediated by 
a negative feedback mechanism through the VEGFR-2 receptor and subsequent downstream 
p42/44MAP kinase pathway (Liu et al, 1999; Labrecque et al, 2003;). This does not 
support the findings that cav-1 expression was increased in the neovessels of the PDR retinas. 
These conflicting findings for cav-1 expression may be explained by the fact that cav-1 
expression appears to be down-regulated during the proliferative phase of angiogenesis, and 
then markedly upregulated during the differentiation phase (Liu et al, 2002). Liu et al, 2002 
showed that cav-1 is downregulated by endothelial growth factors that stimulate the initial 
proliferative phase but upregulated during the differentiation stage into tubular networks. 
They hypothesized that caveolin acts a both a pro- and anti-angiogenic factor by serving as a 
“differentiation sensor” that monitors and responds to changes in the relative balance of 
positive and negative factors to “tell” a target cell whether to remain quiescent or to become
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proliferative. In my study in the PDR membranes the neovessels may have already undergone 
proliferation and so cav-1 may now be acting as an anti-angiogenic factor.
The presence of the caveolins in the ganglion cells and glial cells agrees with the 
findings of other workers and may indicate that the caveolins play some role in signal 
transduction in these cells.(Kachi et al, 2001).
7.5 FUTURE WORK
Examination of immmunostained retinal sections by light microscopy provided only 
limited information on the exact cellular localization of these growth factors and their 
receptors in diabetic retinopathy. Further studies at the ultrastructural level using either 
electron microscopy or confocal microscopy should help. It would also have been helpful to 
undertake staining of all the diabetic tissue with cav-2 and cav-3 antibodies as this will 
further clarify their roles in diabetic retinopathy and also with antibodies to TNF receptors I 
and II. This should be supplemented with in situ hybridization studies which would provide 
information on the exact cellular localization of cytokine production.
The current methods of treatment for PDR, including laser photocoagulation, 
vitrectomy and cryotherapy are expensive and cause destruction of viable retinal tissue. Non- 
invasive therapies are currently being sought to replace these surgical interventions. Over the 
last decade much research has concentrated on using inhibitors of the VEGF signalling 
pathway for the treatment of retinal neovascular diseases such as PDR and age related macula 
degeneration (AMD) and some success has been achieved using aptamers and antibodies 
which bind VEGF (Afzal et al, 2007). Magugen®, an oligonucleitide aptamer and 
Lucentis®, a humanized antibody fragment have both been approved by the FDA for use in 
reversing the neovascularization associated with AMD and have been used successfully to 
treat macula oedema in clinical trials (Brown et a l , 2006; Rosenfield et a l , 2006). However 
these molecules are large and complex, are difficult to administer intravitreally and the 
regression of neovascularization is rarely permanent, which requires multiple applications of 
drug which is expensive. Bevacizumab (Avastin®), a humanized full-length antibody against 
VEGF, is a less expensive alternative which has been used in clinical trials for diabetic 
retinopathy and diabetic macula oedema where it was shown to exert its effects by blocking 
increased vascular permeability and angiogenesis (Averbukh et al, 1998; Cunningham et al,
2005). Several reports describe the use of off-label Bevacizumab in various proliferative 
retinopathies with subsequent good visual and structural outcomes (Abraham-Marin et al., 
2006; Rich et al., 2006). Various molecules which are smaller, can be administered less
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invasively and are less expensive are currently under investigation. Theses include Vatalanib 
(VEGFR tyrosine kinase inhibitor) (Steeghs et al, 2007), Sima-027 (SiRNA which down 
regulates VEGFR-1), VEGFR-SiRNA (SiRNA which down-regulates VEGF) [Reich et al., 
2003] and T2-TrpRS (a proteolytic fragment of tryptophan tRNA synthetase) [Banin et al.,
2006].
Precise understanding of the biologic roles of the VEGF, the angiopoietin family 
members, TNF, PEDF and caveolins and of how they may collaborate with each other and 
other growth factors may lead to novel and therapeutically significant strategies for 
promoting or inhibiting neovascularization. However, development of long-term therapeutic 
interventions based on the blocking of Tie-2, VEGFR-1, and possibly VEGFR-3, signalling 
should proceed with caution due to the possible dismption of crucial roles of these receptors 
in vascular maintenance. Further investigation into the specific signalling pathways used for 
vascular growth and maintenance may also lead to more specific and effective strategies for 
therapy.
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ABBREVIATIONS
a  Alpha
Ab Antibody
ABComplex Avidin-Biotinylated Alkaline Phosphatase Complex
AGES Advanced Glycation End Products
Ang-1 Angiopoietin-1
Ang-2 Angiopoietin-2
Ang-II Angiotensin-II
APES 3-Aminopropyltriethoxysilane
p Beta
BAEC Bovine Aortic Endothelial Cell
bFGF Basic Fibroblast Growth Factor
BM Basement Membrane
BMEC Bovine Microvascular Endothelial Cell
BREC Bovine Retinal Endothelial Cell
BRPC Bovine Retinal Pericyte
BSMC Bovine Smooth Muscle Cell
Cav-1 Caveolin-1
Cav-2 Caveolin-2
Cav-3 Caveolin-3
°C Degrees Centrigrade
cDNA Complementary Deoxyribonucleic Acid
CNS Central Nervous System
DCCT Diabetes Control and Complications Trial
ddH20 Double Distilled Water
EC Endothelial Cell
ECGF Endothelial Cell Growth Factor
EGF Epidermal Growth factor
ELM External Limiting Membrane
EPO Erythropoietin
ERM Epiretinal Membrane
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Etc. Et cetera [and other things]
Etal. Et alia [and others]
FGF Fibroblast Growth Factor
Fig Figure
5' Five Prime
r Gamma
GABA Gabaaminobutyric acid
GCL Ganglion Cell Layer
GH Growth Hormone
HBGF Heparin Binding Growth Factor
HIF Hypoxia Inducible Factor
h 2o Water
H andE Haematoxylin and Eosin
Hr Hour
HSMC Human Smooth Muscle Cell
HSC Haematopoietic Stem Cells
hUVECs Human Umbilical Vein Endothelial Cells
Ig Immunoglobulin
IgL Immunoglobulin-like
IGF Insulin-Like Growth Factor
IL-1 Interleukin-1
IL-4 Interleukin-4
IL-6 Interleukin-6
ILM Internal Limiting Membrane
IMS Industrial Methylated Spirit
INL Inner Nuclear Layer
kb Kilobase
kDa Kilodalton
KDR Kinase Insert Domain Containing Receptor
MAPK Map Kinase
mg Milligram
ml Millilitre
mm Millimetre
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MMP Matrix Metalloproteinase
mRNA Messenger Ribonucleic Acid
min Minute
NBF Neutral Buffered Formalin
NDRI National Disease Research Interchange
NO Nitric Oxide
NPDR Non-proliferative Diabetic retinopathy
NOS Nitric Oxide Synthase
ONL Outer Nuclear layer
% Percentage
PA Plasminogen Activator
PAEC Porcine Aortic Endothelial Cell
PAM Plasminogen Activator Inhibitor-1
PC Pericyte
PCR Polymerase Chain Reaction
PDECGF Platelet Derived Endothelial Cell Growth Factor
PDGF Platelet Derived Growth Factor
PDR Proliferative Diabetic Retinopathy
P1GF Placental Growth Factor
pH -Log 1 0  Hydrogen Ion Concentration
PKC Protein Kinase C
PLC-y Phospholipase C-gamma
p02 Oxygen Tension
PSMC Porcine Smooth Muscle Cell
RGC Retinal Glial Cell
ROP Retinopathy of Prematurity
ROS Reactive Oxygen Species
RPE Retinal Pigmented Epithelium
RTK Receptor Tyrosine Kinase
sFlt-1 Soluble Fms-like Tyrosine Kinase-1
SMC Smooth Muscle Cell
TEK Tunica Interna Endothelial Cell Kinase
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Tie-2 Tyrosine Kinase With Ig-like loops and epidermal growth 
factor homology domains-2
TBS Tris Buffered Saline
TGF-a Transforming Growth Factor-Alpha
TGF-p Transforming Growth Factor-Beta
TNF-a Tumour Necrosis Factor-Alpha
pm Micrometre
uPA Urokinase-Type Plasminogen Activator
UV Ultraviolet
VAS Vasculotropin
VEGF Vascular Endothelial Growth Factor
VEGFR Vascular Endothelial Growth Factor Receptor
VPF Vascular Permeability Factor
v/v Volume by Volume
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APPENDIX I: MATERIALS AND SUPPLIERS
ABComplex/Alkaline Phosphatase 
Aminopropyltriethoxysilane 
Anti-Angiopoietin-1 Antibody 
Anti-Angiopoietin-2 Antibody 
Anti-Caveolin-1 Antibody
Anti-Caveolin-2 Antibody
Anti-Caveolin-3 Antibody
Anti-TNF-a Antibody 
Anti-VEGFR-1 Antibody 
Anti-VEGFR-2 Antibody 
Anti-VEGFR-3 
Anti-Tie-2 Antibody 
Anti-VEGF 165 Antibody 
Anti-VEGF-C Antibody
Biotinylated Goat Anti-Rabbit Immunoglobulin (IgG)
Biotinylated Rabbit Anti-Goat Immunoglobulin (IgG)
Chloroform
a-Chymotrypsin
Cover Slips
Disodium Hydrogen Orthophosphate 
Eosin
Fast Red/TR Naphol AS-MX Tablets 
Filters (0.2pm)
Formaldehyde
Glass Microscope Slides
Haematoxylin(Harris and Mayers)
Hydrochoric Acid 
Hydromount
DAKO
Sigma
Santa Cruz
Santa Cruz
BD Transduction
Laboratories
BD Transduction
Laboratories
BD Transduction
Laboratories
Abeam
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz
Sigma
Sigma
BDH
Sigma
Raymond Lamb
BDH
BDH
Sigma
BDH
BDH
Raymond Lamb
BDH
Sigma
National Diagnostics
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Industrial Methylated Spirit Genta Medical
Loctite Adhesive Till and Whitehead
Milk Protein Premier Beverages
Normal Goat Serum Sigma
Normal Pig Serum Sigma
Normal Rabbit Serum Sigma
Paraffin Wax Lamb
Potassium Dihydrogen Orthophosphate Sigma
Practamount ASCO Laboratories
Sodium Chloride BDH
Sodium Citrate Sigma
Tris (Hydroxymethyl) Methylamine BDH
Tris-HCl BDH
TritonX-100 Sigma
Xylene BDH
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APPENDIX II- Constituents and Preparation of Buffers and Solutions 
Neutral Buffered Formalin
1. Dissolve 510mg disodium hydrogen orthophosphate, 325mg potassium dihydrogen 
orthophosphate and 9g sodium chloride in 900ml ddH20.
2. Add 100ml formaldehyde.
3. Adjust to pH 6.8 using hydrochloric acid.
3-Aminopropyltriethoxysilane Coated Slides
1. Wash slides in 1% extran (v/v in ddH20) for 1 hour.
2. Rinse for 2 hours in hot running water.
3. Air dry.
4. Place in 1% 3-aminopropyltriethoxysilane (v/v in acetone) for 5 minutes.
5. Rinse slides in acetone for 5 minutes.
6. Wash in running tap water for 5 minutes.
7. Dry at room temperature overnight or 60°C for 1 hour 
lOx Tris Buffered Saline ( pH 7.6 at 25°C)
1. Dissolve 87.6g sodium chloride, 60.6g Tris-HCl, and 13.9 g Tris-base in 1 litre ddH20.
2. Adjust pH to 7.6
0 .1 .  a-Chymotrypsin Solution
1. Place sections in pre-warmed Tris buffered saline at 37°C for 5 minutes.
2. Place in solution containing 300ml Tris buffered saline, 30mg a-chymotrypsin, and 300mg
calcium chloride at 37°C for 20 minutes.
3. Rinse slides with Tris buffered saline.
Sodium Citrate Solution (Pressure Cooker)
1. Dissolve 5.88g of tri-sodium citrate solution in 1965ml of distilled water
2. Add 44ml of 0.2M hydrochloric acid solution
3. Adjust pH to 6.0
4. Bring to the boil in a pressure cooker
5. Add slides in a metal rack and place lid on pressure cooker and bring to pressure
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6. Time for 3 minutes
7. Run running tap water over the pressure cooker
8. Release pressure, remove lid, and run water into the pressure cooker for 10 minutes.
9. Remove slides and place in Tris buffered saline for 5 minutes
0 .2 .  Triton-X 100
1. Place sections in pre-warmed Tris buffered saline at 37°C for 5 minutes.
2. Place in solution containing 300ml Tris buffered saline and 600pl Triton-X-100 at 37°C 
for 30 minutes.
3. Rinse slides with Tris buffered saline.
ABComplex/Alkaline Phosphatase Kit
1. Mix 1 drop avidin and 1 drop biotin with 5ml ddH20.
2. Vortex and leave for at least 30 minutes before use.
Substrate Solution For Phosphatase Staining (Imunohistochemistry)
1. Dissolve 1 Tris buffered saline tablet and 1 Fast red tablet in 10ml ddH20.
2. Filter through a 0.2pm filter.
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VEGF localisation in diabetic retinopathy
Mike Boulton, David Foreman, Gillian Williams, David McLeod
Abstract
A im —To determ ine the staining pattern o f  
vascular endothelial growth factor 
(VEGF) at different stages o f  diabetic 
retinopathy (including post-laser photo­
coagulation) and to  com pare staining in  
excised  fibrovascular and fibrocellular 
(non-diabetic) preretinal m em branes. 
M ethods—Im m unohistochem ical locali­
sation o f  VEGF, using antibodies raised  
against VEGF1SS and VEGF121>IS5 IgJ, was 
carried  out on specim ens o f  norm al 
hum an retina (n=15), diabetic retinas ((a) 
w ith no overt retinopathy (n=19), (b) with  
intraretinal vascular abnorm alities but no  
proliferative retinopathy (n=6), (c) with  
active proliferative retinopathy (n=6), (d) 
w ith no residual proliferative retinopathy  
after photocoagulation therapy (n=15)), 
excised  diabetic fibrovascular m em branes 
(n=19), and non-diabetic fibrocellular 
m em branes (n=7). The degree and pat­
tern o f  im m unostain ing was recorded. 
Results—In general, VEGF w as absent 
from  the m ajority o f  norm al retinas. 
VEGF stain ing was apparent in  m ost d ia­
betic tissues but the staining pattern was 
dependent on both the specificity  o f  the 
antibody used  and the category o f  tissue. 
Staining w ith the VEGF16S antibody was 
generally confined to endothelial cells 
and perivascular regions w hile the
VEGF, antibody was also associated
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with extravascular com ponents o f  the 
inner retina. Intensity o f  im m unostaining  
o f  diabetic eyes w as dependent on the 
severity o f  retinopathy being least in  
diabetics w ith  no overt retinopathy and  
greatest in  retinas w ith proliferative retin­
opathy. Interestingly, the intensity o f  im ­
m unostain ing in  d iabetic retinas which  
had undergone laser surgery for prolifera­
tive retinopathy w as reduced to basal lev­
els. M oderate to in tense im m unostaining  
was observed in  all fibrovascular and 
fibrocellular m em branes exam ined. 
Conclusions—This study supports a cir­
cum stantial role for VEGF in the patho­
genesis o f  both the preclinical and 
proliferative stages o f  diabetic retinopathy. 
{B rJ  Ophthalmol 1998;82:561-568)
Among the microvascular manifestations of 
diabetic retinopathy are pericyte dropout, 
basement membrane thickening, microaneu­
rysm formation, and capillary non-perfusion 
resulting in inner retinal ischaemia and 
hypoxia.1 The precise stimulus for the subse­
quent preretinal neovascularisation that char­
acterises proliferative diabetic retinopathy
(PDR) remains uncertain, but historically reti­
nal hypoxia has been proposed as the stimulus 
for release of a diffusible angiogenic factor 
which promotes neovascularisation from adja­
cent retinal vessels and rubeosis.2 While a 
number of candidate molecules have been sug­
gested for this role, including basic fibroblast 
growth factor (bFGF),3 platelet derived growth 
factor (PDGF),4 and insulin-like growth 
factor-1 (IGF-1),5 recent evidence has sup­
ported vascular endothelial growth factor 
(VEGF) as an important modulator of PDR.
VEGF is a mitogen for endothelial cells whose 
expression both in vivo and in vitro can be 
induced by hypoxia.6 Reports have demon­
strated high affinity, membrane bound VEGF 
receptors located on vascular endothelial cells7'* 
and recently on retinal pigment epithelial cells.10 
These receptors, which are autophosphorylating 
tyrosine kinases, are also upregulated by 
hypoxia." 12 In situ hybridisations against VEGF 
mRNA have shown increased retinal expression 
in human vasoproliferative retinopathies and 
also in animal models of ocular 
neovascularisation.13-17 Furthermore, VEGF lev­
els are elevated in vitreous samples from patients 
with active PDR when compared with (a) 
diabetic eyes without retinopathy, (b) diabetic 
eyes with background retinopathy,18-20 and (c) 
diabetic eyes with quiescent PDR and after suc­
cessful laser photocoagulation.18 The aim of this 
study was to compare the pattern and intensity 
of VEGF immunostaining in (a) normal human 
retina, (b) diabetic retina (with and without 
non-proliferative retinopathy or PDR), (c) laser 
photocoagulated diabetic retina with presumed 
neovascular regression, and (d) surgically ex­
cised diabetic preretinal membranes, to deter­
mine whether there is a correlation between 
VEGF protein distribution and PDR. In addi­
tion, fibrocellular membranes were included as a 
comparative control for the fibrovascular mem­
branes and two antibodies with differing specifi­
cities for VEGF were tested.
M aterials and m ethods
DONOR EYES
Donor human eyes, fixed in 10% neutral buff­
ered formalin (NBF) within 12 hours post 
mortem, were provided by the National 
Disease Research Interchange (NDRI), Phila­
delphia, USA. The anterior segment was 
removed and biomicroscopy of the posterior 
segment performed (a) to note overt features of 
retinopathy (for example, preretinal mem­
branes, cotton wool spots, haemorrhages) and 
(b) to determine the extent of any scatter 
photocoagulation. Eyes were categorised as 
follows:
Normal—15 human eyes with no known 
ophthalmic disease and no history of diabetes.
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Donor age ranged from 20 to 92 years (mean 
56 years).
Diabetic with no overt retinopathy—19 human 
eyes from diabetics with no clinical history of 
PDR and no overt features of retinopathy or 
retinal photocoagulation. Donor age ranged 
from 44 to 89 years (mean 74 years). A 
complete medical history was unavailable for 
all donors but, where available (7/18), the 
duration of diabetes was between 6 and 25 
years.
Diabetic with obvious intraretinal vascular 
changes but no evidence of PDR—six human eyes 
from diabetics with no clinical history of PDR 
and no overt features of PDR or retinal photo­
coagulation. Retinas exhibited cotton wool 
spots, haemorrhages, and/or obvious micro­
aneurysms. Donor age ranged from 55 to 96 
years (mean 71 years). A complete medical 
history was unavailable for all donors but, 
where available (3/6), the duration of diabetes 
was between 3 and 21 years.
Diabetic with PDR—six human eyes from 
diabetics defined clinically as having PDR and 
exhibiting preretinal membranes. Donor age 
ranged from 37 to 76 years (mean 58 years). 
Duration of diabetes ranged from 3 to 18 years 
(mean 9 years).
Diabetic with scatter laser photocoagulation but 
no evidence of active PDR—15 human eyes from 
diabetics specified clinically as having had 
PDR and having received scatter laser photo­
coagulation (no details were available as to 
time post laser). No preretinal membranes 
were observed. Donor age ranged from 41 to 
82 years (mean 63 years). Duration of diabetes 
ranged from 3 to 35 years (mean 17 years).
METHODS
The posterior segment of each eye was cut in 
the sagittal plane through the centre of the 
optic nerve head. Cuts were then made 
perpendicular to this line (a) on the horizontal 
midline on the nasal side and (b) two cuts were 
made at approximately 5 mm above and below 
the midline on the temporal side. A final verti­
cal cut was made parallel to the initial cut and 
approximately 3 mm lateral to the macula. Five 
pm sections were cut from a portion of retina/ 
choroid/sclera (a) approximately 3 mm lateral 
to the macula and perpendicular to the 
horizontal plane (this region was chosen owing 
to its susceptibility to retinal changes associ­
ated with diabetes) and (b) other repres­
entative areas across the retina (for example, 
areas of neovascularisation).
FIBROVASCULAR MEMBRANES 
Nineteen fibrovascular preretinal membranes 
were obtained from 19 eyes during closed 
microsurgery for sequelae of PDR at the Man­
chester Royal Eye Hospital. Membranes were 
fixed in 10% NBF immediately upon removal 
for a minimum of 12 hours before paraffin wax 
embedding.
FIBROCELLULAR MEMBRANES 
Seven non-vascularised epiretinal membranes 
were obtained from seven eyes of non-diabetic 
patients during closed microsurgery for elimi-
Boulton, Foreman, WiUiams, et al
nation of retinal traction at the Manchester 
Royal Eye Hospital. Membranes were fixed in 
10% NBF immediately upon removal for a 
minimum of 12 hours before paraffin wax 
embedding.
IMMUNOHISTOCHEMISTRY
Five pm sections (1-1.3 cm in length in the 
case of retinal specimens) were cut and 
mounted on APES coated slides. Deparaffin- 
ised sections were digested with 0.01% chymo- 
trypsin for 20 minutes at 37°C. The sections 
were incubated in 10% milk proteins (Marvel)/ 
10% normal rabbit serum (Dako) in TRIS 
buffered saline (TBS) for 60 minutes at room 
temperature. Excess blocking solution was 
removed and the sections incubated overnight 
at 4°C in either (a) polyclonal goat anti-human 
VEGFl65 (R&D Systems) raised against puri­
fied insect cell line S f  21 derived recombinant 
human VEGFI65 or (b) polyclonal goat anti­
human VEGF12I16518, (Santa Cruz Biotechnol­
ogy) raised against a peptide corresponding to 
amino acids 1-20 mapping at the amino termi­
nus of VEGF of human origin and which rec­
ognises the 121, 165, and 189 amino acid 
splice variants of VEGF; both were diluted in 
TBS to 5 pg/ml. Following two 3 minute 
washes, the sections were incubated with bioti- 
nylated rabbit anti-goat IgG (Dako) diluted to 
1/600 in TBS for 30 minutes at room tempera­
ture. The sections were subsequently incu­
bated with an avidin-biotin alkaline phos­
phatase reaction complex (Dako) and antibody 
binding visualised by incubation in fast red 
substrate solution (Sigma) resulting in the for­
mation of a red product. Immunostained 
sections were counterstained with haematoxy- 
lin.
CONTROLS FOR IMMUNOSTAINING
Negative controls included (1) omission of the 
primary antibody, (2) substitution of the 
primary antibody with an inappropriate goat 
antibody (goat anti-human colostrum whey 
(Sigma) at the same concentration as the 
primary antibody), and (3) incubation of 100 
pi (0.5 pg) of anti-VEGF165 antibody with 1 pg 
of recombinant human VEGF165 (R&D sys­
tems) overnight at 4°C before use in the above 
protocol.
ASSESSMENT OF IMMUNOSTAINING
The degree and pattern of immunostaining 
both within and between specimens as ob­
served by standard light microscopy was 
assessed and recorded by two independent 
observers but pathological status of the speci­
mens was obvious. The intensity of staining 
was graded qualitatively as background (corre­
sponding to the level of staining seen in the 
negative controls), weak, moderate, or intense 
(corresponding to the highest level of immuno- 
reactivity observed). These intensities were 
recorded as 0 ,1 ,2 , and 3 respectively. For each 
retinal specimen staining intensity was re­
corded for the choroid, RPE, photoreceptor 
inner and outer segments, outer nuclear layer, 
inner nuclear layer, retinal vessels, ganglion cell 
layer, and internal limiting membrane. For
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fibrovascular and fibrocellular membranes 
staining intensity was recorded for vessels and 
surrounding matrix.
Results
VEGF staining was apparent in most diabetic 
tissue but the staining pattern was dependent 
on both the specificity of the antibody used and 
the category of tissue (see Figs 1 and 2 and 
Tables 1 and 2). Staining with the anti- 
VEGFI65 antibody was generally confined to 
endothelial cells (whether retinal or choroidal) 
and perivascular regions whereas staining with 
the VEGF12I165jIg9 antibody was also associated 
with non-vascular components of the inner 
retina. No correlation was found between 
staining intensity/distribution and either donor 
age, postmortem time, or duration of diabetes 
(where known).
NORMAL
Immunostaining with the anti-VEGF12M65>lg9 
antibody was absent in the majority of retinas 
examined while retinal staining with the 
anti-VEGF165 antibody, although generally ab­
sent, did result in weak staining associated with 
retinal vessels (7/15) and in the RPE (3/15) 
(Fig 1A; Tables 1 and 2). Weak to moderate 
staining with the antd-VEGF165 antibody was 
also observed in the choroidal vessels (12/15). 
Staining was absent from the inner and outer 
retina in all but one specimen.
DIABETIC W ITH NO OVERT RETINOPATHY
Staining intensity with the anti-VEGFl65 anti­
body was not elevated above that observed in 
non-diabetic retinas. Ttoelve of 19 specimens 
exhibited some positive staining of endothelial 
cells of inner retinal vessels, while 9/19 were 
VEGF positive in vessel basement membranes 
(generally those diabetic retinas with thickened 
endothelial basement membranes). By con­
trast, immunostaining with the anti- 
VEGF121I65 189 antibody, albeit weak to moder­
ate, was elevated in all tissue layers examined
compared with that observed in normal retinas 
(Fig IB; Table 2). Immunostaining was most 
intense in the inner retinal and ganglion cell 
layers (13/19).
DIABETIC WITH OBVIOUS INTRARETIN AL 
VASCULAR CHANGES BUT NO EVIDENCE OF PDR 
Intensity of immunostaining with the anti- 
VEGFI65 antibody was increased in the retinal 
vessels, the choroid, and the ganglion cell layer 
compared with that observed in normal retinas 
and diabetic retinas with no overt retinopathy 
(staining in the other retinal layers remained 
unchanged) (Figs 1C and 2A). Variable immu­
nostaining ranging from weak to intense was 
observed in both the retinal vessels and choroid 
with a close correlation between intense 
choroidal staining and moderate to intense 
staining around retinal vessels. Intensity of 
immunostaining with the anti-VEGF121jl65>Ig9 
antibody in this group was elevated compared 
with that observed in non-diabetic retinas but 
not increased compared with that observed for 
diabetic retina with no overt retinopathy (Fig
ID).
DIABETIC WITH PDR
Intense immunostaining with the anti-VEGF165 
antibody of the inner retinal vessels was seen in 
all diabetic retinas (6/6) with active neovascu- 
lar PDR membranes on their surfaces (Fig
IE). Equally intense staining was observed 
within die membranes themselves (Fig IE). 
While immunoreactivity for VEGF was found 
around choroidal vessels in all these PDR reti­
nas, with staining ranging from weak to 
intense, the RPE layer and outer retina were 
generally VEGF165 negative. The immuno­
staining pattern with the anti-VEGF121jl65;lg9 
antibody showed a similar moderate to high 
intensity staining of retinal vessels but, in addi­
tion, there was increased staining in the outer 
nuclear layer, inner retina, ganglion cell layer, 
and internal limiting membrane (ILM) com­
pared with the other tissue groups (Fig IF).
Table 1 M ean (SD) intensity of immunostaining of the retina!choroid using an anti-VEGF,a antibody
Tissue layer
Tissue category
Choroidal
vessels RPE Outer retina Inner retina
Retinal
vessels
Ganglion cell 
layer ILM
Normal (n=12) 
Diabetic:
1.6 (0.3) 0.3 (0.2) 0 0.3 (0.2) 0.9 (0.2) 0.1 (0.1) 0
N o overt retinopathy (n=19) 1.6 (0.2) 0.1 (0.1) 0 0.4 (0.2) 1.2 (0.2) 0.2 (0.1) 0.1 (0.1)
Vascular abnormalities (n=6) 2.3 (0.3) 0.5 (0.3) 0.2 (0.2) 0.3 (0.2) 2.2 (0.5) 1.0 (0.4) 0.3 (0.2)
PD R (n=6) 2.2 (0.4) 0.4 (0.3) 0.6 (0.2) 0.6 (0.2) 3.0 (0) 0.6 (0.2) 0.6 (0.2)
Laser, no PDR (n=15) 1.7 (0.3) 0.1 (0.1) 0.3 (0.1) 0.3 (0.1) 1.0 (0.3) 0.2 (0.1) 0.1 (0.1)
0 = background, 1 = weak, 2 = moderate, 3 = intense.
Table 2 Mean (SD) intensity of immunostaining of the retina!choroid using an anti- VEGFI2UUI„ antibody
Tissue layer
Choroidal Retinal Ganglion cell
Tissue category vessels RPE Outer retina Inner retina vessels layer IL M
Normal (n=12) 0.3 (0.1) 0.5 (0.4) 0.2 (0.1) 0.2 (0.1) 0.3 (0.1) 0.4 (0.2) 0.3 (0.2)
Diabetic:
N o overt retinopathy (n=19) 0.7 (0.2) 1.3 (0.2) 0.8 (0.2) 1.6 (0.2) 1.0 (0.2) 1.9 (0.2) 1.5 (0.2)
Vascular abnormalities (n=6) 0.5 (0.3) 0.8 (0.4) 0.3 (0.3) 1.2 (0.5) 1.1 (0.4) 1.7 (0.4) 1.3 (0.4)
PD R (n=6) 1.0 (0.5) 1.8 (0.4) 1.5 (0.4) 1.8 (0.3) 2.2 (0.3) 2.0 (0.4) 1.8 (0.4)
Laser, no PDR (n=15) 0.7 (0.2) 1.2 (0.3) 1.2 (0.3) 1.1 (0.2) 1.0 (0.2) 1.2 (0.2) 1.0 (0.2)
0 = background, 1 = weak, 2 = moderate, 3 = intense.
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F i g u r e  2  P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  V E G F  i m m u n o s t a i n i n g  o f  P D R  r e t i n a  a n d  e x c i s e d  m e m b r a n e s .  I n t e n s e  i m m u n o s t a i n i n g  f o r  V E G F i s  
l o c a l i s e d  t o  t h e  v a s c u l a t u r e  ( A )  w h i l e  V E G F l2l i a  im  i m m u n o s t a i n i n g  i s  o b s e r v e d  i n  b o t h  v a s c u l a r  a n d  e x t r a v a s c u l a r  t i s s u e  ( B ) .  M o d e r a t e  t o  i n t e n s e  
s t a i n i n g  c a n  b e  o b s e r v e d  i n  a l l  s p e c i m e n s  o f  e x c i s e d  f i b r o v a s c u l a r  ( C )  a n d  f i b r o c e l l u l a r  ( D )  e p i r e t i n a l  m e m b r a n e s .  I m m u n o r e a c t i v i t y  f o r  V E G F  w a s  
a b o l i s h e d  i n  c o n t r o l  s e c t i o n s  o f  P D R  r e t i n a  a n d  m e m b r a n e s  p r o c e s s e d  w i t h  o m i s s i o n  o f  t h e  p r i m a r y  a n t i b o d y  ( E )  o r  p r i o r  i n c u b a t i o n  o f  t h e  a n t i b o d y  w i t h  
V E G F .  M a g n i f i c a t i o n ,  A ,  B  x 2 0 0 ;  C - F  x 7 0 .
No correlation was observed between VEGF 
positive glial staining and active neovasculari­
sation.
DIABETIC WITH SCATTER LASER 
PHOTOCOAGULATION BUT NO EVIDENCE OF PDR 
The intensity of immunostaining in diabetic 
retinas that had undergone apparently success­
ful laser therapy (that is, those with no prereti­
nal neovascularisation) was similar to that 
observed for diabetic retinas with no overt 
retinopathy (Fig 1G, H). This was true for 
both antibodies used. In many laser treated 
retinas (11/15) a total absence of immunoreac­
tivity was observed within inner retinal vessels, 
even those with thickened basement mem­
branes. This was especially apparent in those 
vessels located near laser burns. Staining
F i g u r e  I  P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  V E G F  i m m u n o s t a i n i n g  o f  n o r m a l  r e t i n a  ( A ) ,  d i a b e t i c  r e t i n a  w i t h  n o  o b v i o u s  r e t i n o p a t h y  ( B ) ,  d i a b e t i c  r e t i n a  
w i t h  o b v i o u s  i n t r a r e t i n a l  v a s c u l a r  c h a n g e s  b u t  n o  e v i d e n c e  o f  P D R  ( C ,  D ) ,  d i a b e t i c  r e t i n a  w i t h  P D R  ( E ,  F ) ,  a n d  d i a b e t i c  r e t i n a  a f t e r  l a s e r  t r e a t m e n t  f o r  
P D R  ( G ,  H ) .  S e c t i o n s  w e r e  i m m u n o s t a i n e d  w i t h  e i t h e r  a n  a n t i b o d y  r a i s e d  a g a i n s t  V E G F , „  ( A ,  C ,  E ,  G )  o r  V E G F , , ,  , 6 s m  ( B ,  D ,  F ,  H ) .  I m m u n o s t a i n i n g  
w a s  g r e a t e s t  i n  d i a b e t i c  r e t i n a s  w i t h  P D R  f o r  b o t h  a n t i b o d i e s  t e s t e d ,  m i n i m a l  i n  n o r m a l  r e t i n a s ,  a n d  i n t e r m e d i a t e  i n  d i a b e t i c  r e t i n a s  w i t h o u t  P D R .  I t  w a s  
i n t e r e s t i n g  t o  n o t e  t h a t  i m m u n o s t a i n i n g  i n  l a s e r e d  d i a b e t i c  r e t i n a s  w i t h  n o  c u r r e n t  e v i d e n c e  o f  P D R  w a s  g r e a t l y  r e d u c e d  c o m p a r e d  w i t h  t h e  s t a i n i n g  
i n t e n s i t y  i n  r e t i n a s  w i t h  P D R .  M a g n i f i c a t i o n ,  A - E ,  G  x 9 0 ;  F , H x 7 0 .
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intensity was also reduced/absent in the outer 
nuclear layer, inner retina, ganglion cell layer, 
and ILM compared with diabetic retinas with 
PDR.
FIBROVASCULAR MEMBRANES
A similar staining pattern was observed for 
both anti-VEGF antibodies used. In general, 
two immunostaining profiles for VEGF were 
observed in the preretinal diabetic 
membranes; those in which staining was 
essentially confined to the vascular component 
(9/19) and those in which moderate to intense 
staining was also found in areas of acellular 
matrix (10/19) (Fig 2B, C). Staining of vessels 
was variable both between and within speci­
mens, with those vessels at the periphery gen­
erally staining more intensely than those in the 
centre of the membrane. In addition, staining 
of extracellular matrix was variable but also 
tended to be highest at the periphery. Staining 
of non-vascular cells was weak and variable, 
being present in only 7/19 membranes.
FIBROCELLULAR MEMBRANES
VEGF staining was observed in all seven fibro­
cellular membranes; the staining profile was 
similar for both anti-VEGF antibodies. Stain­
ing was associated with pigmented cells, 
non-pigmented cells and surrounding matrix 
(Fig 2D). The intensity of staining was highly 
variable both within and between membranes 
and ranged from weak to intense. Intensity of 
staining in the matrix was generally greater 
than that found in the cellular areas.
CONTROLS
Immunoreactivity for VEGF was abolished in 
sections processed with omission or substitu­
tion of the primary antibody (Fig 2E) and 
considerably reduced by prior incubation of 
the antibody with recombinant VEGF165 (Fig 
2F).
D iscussion
We have demonstrated changes in the profile 
and intensity of VEGF staining dependent 
upon the severity of diabetic retinopathy. The 
most intense staining correlated with active 
neovascularisation and was present in both 
preretinal vessels and associated inner retinal 
vessels. Interestingly, the elevation of immu­
nostaining for VEGFI21j165 lg9 in diabetic retinas 
with no overt retinopathy infers that VEGF 
may play a role in both the preclinical and the 
proliferative stages of diabetic retinopathy.
Lutty and co-workers detected VEGF im­
munoreactivity within some smooth muscle 
cells of retinal arterioles and in the pericytes and 
some endothelial cells of retinal capillaries in 
non-diabetic human retinas.21 Furthermore, 
they noted a significantly increased immunore­
activity in the contractile elements of retinal ves­
sels, in the endothelium of human diabetic 
retina and in and around the choroidal vessels, 
results consistent with those presented here. 
Immunohistochemical staining for VEGF has 
also been shown to be markedly increased in the
Boulton, Foreman, Williams, et al
retina of streptozotocin treated diabetic rats, 
with positive staining located in and around the 
inner retinal capillaries.22 However, in areas of 
non-perfused human diabetic retina and in rab­
bit and primate models of ocular angiogenesis, 
in situ hybridisation studies have shown hypoxia 
induced VEGF expression not in the compo­
nent cells of retinal vessels but in the inner and 
outer nuclear layers or the ganglion cell 
layers.1314 This distribution is in agreement with 
immunostaining of VEGF within Muller cells 
and in the ganglion cell layer in oxygen induced 
neovascularisation models in rat retina23 24 and 
in diabetic retina.25 We could only observe 
significant staining in these extravascular re­
gions with one of the anti-VEGF antibodies 
used—that is, VEGF,2I I65 189. This difference in 
specificity may reflect either (a) the availability 
of the appropriate epitope or (b) differential 
expression of VEGF isoforms within the retina. 
The generation of antibodies against the 121 
and 189 VEGF isoforms may help address this 
question.
Rather than defining the sites of potential 
VEGF synthesis, the increase in staining for 
VEGF protein in diabetic retinal vessels dem­
onstrated in our study, especially in eyes with 
neovascularisation, may reflect the localisation 
of sites of action or accumulation of the factor. 
Since VEGF binds to hypoxia inducible 
receptors found on endothelial cells, such cells 
surrounding non-perfused areas of diabetic 
inner retina may be likely to manifest in­
creased VEGF binding. In addition, VEGF, 
especially the larger splice variants 
(VEGFI89 20J ,  binds to heparin26 and increased 
staining in and around retinal vessels may to 
some extent reflect binding to heparan sul­
phate associated with basement membrane 
thickening in diabetes.
We have demonstrated that VEGF protein 
increases in diabetic eyes and that staining is 
greatest in PDR. The role of VEGF in preclini­
cal retinopathy is unclear but may relate to vas­
cular permeability. Raised VEGF levels are 
known to raise vascular permeability,27'29 a fea­
ture prominent in background and preprolif- 
erative diabetic retinopathy.1 These observa­
tions suggest that VEGF is elevated in the 
diabetic retina in the absence of hypoxia and 
extensive retinal ischaemia inferring that other 
mechanisms (for example, hyperglycaemia) 
may upregulate VEGF. However, it should be 
noted that in this, as in other,25 studies it is dif­
ficult to determine the degree of retinal ischae­
mia, if any, in postmortem diabetic retinas with 
preproliferative retinopathy. While vascular 
permeability has been suggested as being a 
critical step in angiogenesis,30 VEGF itself is 
also likely to directly affect other cellular events 
associated with neovascularisation.3132 These 
observations are supported by Tolentino et al 
who reported that intravitreal injection of 
VEGF into primates resulted in leaky vessels, 
progressively dilated and tortuous vessels, 
microaneurysms, haemorrhage, and capillary 
closure.33
Our observation that high levels of VEGF 
are associated with the periphery of preretinal 
vessels is further support that VEGF plays an
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important role in the progression of preretinal 
neovascularisation. The intense staining of 
acellular matrix in many of the membranes 
may also reflect the matrix binding properties 
of VEGF. VEGF present in PDR membranes 
may derive from the retina but may also be 
synthesised by the cells within the membrane. 
We observed staining for VEGF within 
non-vascular cells in some membranes, while 
mRNA for VEGF has been found in diabetic 
membranes.20 Vitreous fluid from patients with 
active retinal neovascularisation has previously 
been shown to contain high concentrations of 
VEGF.18 Independent of its origin, membrane 
and vitreous associated VEGF may propel the 
neovascular response resulting in membrane 
growth.
VEGF immunoreactivity in epiretinal mem­
branes is in agreement with Chen and 
colleagues.34 It is difficult to explain the 
presence of VEGF but it may reflect the 
hypoxic nature of this avascular tissue or that 
VEGF is modulating non-vascular cells; RPE 
cells10 and fibrocellular membranes34 are 
known to express VEGF receptors.
Scatter laser photocoagulation induces re­
gression of active diabetic neovascularisation. 
We have shown that immunostaining for 
VEGF is reduced in diabetic retinas that have 
no overt preretinal neovascularisation follow­
ing laser therapy. This is in close agreement 
with Aiello et al who found decreased vitreous 
levels of VEGF in patients after laser therapy.18 
It is possible that a reduction in retinal ischae- 
mia after laser treatment reduces the produc­
tion of VEGF suppressing neovascularisation 
and leading to regression and quiescence.
An expanding body of evidence, to which 
these results contribute, now suggests that 
VEGF may be Michaelson’s ischaemia in­
duced ocular angiogenic factor. However, it is 
unlikely that VEGF functions in isolation. 
Other angiogenic factor levels have been found 
to be elevated in diabetic retina, fibrovascular 
membranes, and vitreous including bFGF, 
IGF-1, TGF-P, PDGF, and placenta growth 
factor (P1GF).35 36 Thus, VEGF may work syn- 
ergistically with other factors; repeated intra- 
vitreal injection of VEGF into primates pro­
duces vascular abnormalities associated only 
with background retinopathy33 inferring that 
additional growth factors are required to initi­
ate preretinal neovascularisation. Further­
more, VEGF may play a largely ignored, but 
important, role in modifying vascular perme­
ability during the early stages of preprolifera- 
tive retinopathy. Studies which determine the 
biological effects of VEGF and its interactions 
with other growth factors should increase our 
understanding of the vasoproliferative retino­
pathies and provide opportunities for new 
therapeutic interventions for these blinding 
conditions.
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Immunolocalisation of the VEGF receptors 
FLT-13 KDR, and FLT-4 in diabetic retinopathy
Gillian Smith, David McLeod, David Foreman, Mike Boulton
A bstract
A im —To determ in e the spatial and tem ­
poral changes in  the staining pattern o f  
the VEGF receptors FLT-1, KDR, and the 
putative receptor FLT-4 during the patho­
genesis o f  diabetic retinopathy.
M ethods—Im m unohistochem ical locali­
sation  o f  VEGF receptors, using antibod­
ies  against FLT-1, FLT-4, and KDR, was 
carried  out on specim ens o f  norm al 
hum an retina (n=10), d iabetic retinas (a) 
w ith no overt retinopathy (n=12), (b) with 
intraretinal vascular abnorm alities but no 
proliferative retinopathy (n=5), (c) with  
active proliferative retinopathy (n=6), and 
(d) w ith no residual proliferative retin­
opathy after scatter photocoagulation  
therapy (n=14), and surgically excised  
diabetic fibrovascular m em branes (n = ll) .  
T he degree and pattern o f  im m unostain­
ing  was recorded.
Results—FLT-1 stain ing was apparent in  
the retinas from  both non-diabetic and 
diabetic retinas; weak to m oderate stain­
ing was generally confined to the inner 
nuclear layer, the ganglion cell layer, and  
the retinal vessels during all stages o f  the 
disease process. Staining o f  the retinal 
vessels was raised in  diabetic tissue com ­
pared w ith non-d iabetic tissue. The pre­
retinal vessels o f  the diabetic subjects 
stained  m oderately to intensely for FLT-1. 
In contrast w ith FLT-1 staining m inim al 
im m unostain ing for KDR was dem on­
strated in  the non-diabetic eyes and the 
unlasered eyes; however, weak staining for 
KDR w as observed in  the inner nuclear 
layer and the ganglion cell layer o f  the 
unlasered eyes w ith d iabetic changes. In 
those retinas w ith  preretinal neovascu­
larisation  KDR im m unoreactivity was 
m oderate to in tense in  the intra- and pre­
retinal vessels. However, in  the excised  
m em branes, w here the vessels m ay have 
been in  a quiescent state, the levels o f  
KDR w ere weak to m oderate. After appar­
ently successfu l laser treatm ent KDR  
sta in in g  w as reduced in  the intraretinal 
vessels. M in im al FLT-4 staining was ob­
served throughout norm al eyes while weak 
to m oderate FLT-4 staining was generally 
confined to the inner nuclear layer and the 
ganglion cell layer o f  the unlasered dia­
betic eyes. Weak to m oderate levels o f  
FLT-4 sta in in g  w ere observed in  the intra­
retinal vessels except after apparently 
successfu l laser treatm ent where reduced 
levels o f  staining were observed. Weak to
moderate staining was observed in  the 
preretinal vessels.
Conclusions—This study supports a role 
for FLT-1, KDR, and possibly FLT-4 in  the 
pathogenesis o f  diabetic retinopathy; how­
ever, their specific roles in  the progression  
o f the disease m ay differ.
{B rJ Ophthalmol 1999;83:486-494)
Proliferative diabetic retinopathy (PDR), the 
archetypical vasoproliferative retinopathy 
(VPR), is characterised by preretinal neovascu­
larisation and fibrosis, ultimately leading to 
vitreous haemorrhage and traction retinal 
detachment.1 A number of growth factors have 
been implicated in PDR of which vascular 
endothelial growth factor (VEGF) is consid­
ered to be of major importance since (a) it is a 
diffusible factor,2"4 (b) it increases vascular 
permeability,2"5 (c) it modulates angio­
genesis,2-4 (d) it stimulates endothelial cell 
proliferation2"4 6 and migration,6 (e) it is up- 
regulated in response to hypoxia,7-5 and (f) 
agents which inhibit the binding of VEGF to 
its receptors have been demonstrated to reduce 
neovascularisation.1011 In situ hybridisation, 
northern blotting, and immunohistochemistry 
have demonstrated increased expression of 
VEGF in animal models for VPRs8 912 and in 
diabetic human retinas.813-16
VEGF is believed to act through high affinity 
receptors located on endothelial cells.2 3 6 
These receptors are autophosphorylating type 
III tyrosine kinases and consist of KDR 
(FLK-1 in mouse, TKrC in rats, Quekl and 2 
putative avian5) and FLT-1 receptors.2 3 Both 
receptors are characterised by the presence of 
seven immunoglobulin-like domains in their 
extracellular region2 and are expressed during 
embryogenesis where they appear to play an 
important role in endothelial growth and 
differentiation during vasculogenesis and 
angiogenesis.1718 FLT-1 is believed to regulate 
metabolic activity including vascular perme­
ability while KDR is considered to modulate 
angiogenic responses (for example, endothelial 
cell migration and proliferation). The 
importance of FLT1 is further inferred by the 
recent demonstration that placenta growth 
factor (P1GF) is associated with diabetic 
retinopathy;19 P1GF acts through the FLT1 
receptor.20 A third tyrosine kinase receptor may 
be important in VEGF recognition by en­
dothelial cells; FLT-4, which has a similar 
structure to FLT-1 and KDR, is expressed in 
the placenta and in several mouse tissues dur­
ing embryogenesis.2122
Although there are a large number of reports 
documenting upregulation of VEGF mRNA
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and protein in the VPRs there is very little 
information on the profile of VEGF receptors. 
In this study we used immunohistochemistry 
to detect FLT-1, KDR, and FLT-4 protein in 
(a) normal hum an retinas, (b) diabetic retinas 
with various stages of retinopathy, and (c) in 
preretinal fibrovascular membranes excised 
during diabetic vitrectomy.
M aterials and m ethods
DONOR EYES
A total of 47 eyes enucleated and fixed in 10% 
neutral buffered formalin, within 10 hours post 
mortem, were obtained from the National Dis­
ease Research Interchange (NDRI), Philadel­
phia, USA. Each eye was dissected into an 
anterior and posterior segment. A complete 
medical history was not available for all donors 
but details were available regarding glycaemic 
management. Of the 37 diabetic donors 25 had 
been injecting insulin for at least 6 months 
(mean age 62 years) and 12 were not receiving 
insulin treatment but did use oral hyperglycae- 
mic drugs (mean age 65 years). Examination of 
the posterior segment was performed by an 
ophthalmologist (DM) using a Zeiss Stemi SV8 
zoom dissecting microscope with Schott light 
source (a) to note overt features of retinopathy 
(for example, the presence of preretinal mem­
branes, cotton wool spots, microaneurysms,
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F i g u r e  1 P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  F L T - 1  i m m u n o s t a i n i n g  o f  n o n - d i a b e t i c  r e t i n a  ( A ) ,  d i a b e t i c  r e t i n a  w i t h  n o  
o b v i o u s  r e t i n o p a t h y  ( B ) ,  d i a b e t i c  r e t i n a  w i t h  o b v i o u s  i n t r a r e t i n a l  v a s c u l a r  c h a n g e s  b u t  n o  e v i d e n c e  o f  P D R  ( C ) ,  t h e  s a m e  
r e t i n a  s t a i n e d  w i t h  G F A P  ( D ) ,  d i a b e t i c  r e t i n a  w i t h  P D R  ( E ,  F , G ) ,  d i a b e t i c  r e t i n a  p o s t  l a s e r  b u t  w i t h  n o  r e s i d u a l  P D R  
( H ) .  I m m u n o s t a i n i n g  f o r  F L T - 1  w a s  g r e a t e s t  i n  t h e  d i a b e t i c  t i s s u e  c o m p a r e d  w i t h  n o n - d i a b e t i c  t i s s u e .  I n c r e a s e d  s t a i n i n g  
w a s  g e n e r a l l y  c o n f i n e d  t o  t h e  i n n e r  n u c l e a r  l a y e r  a n d  t h e  g a n g l i o n  c e l l  l a y e r .  M a g n i f i c a t i o n  A ,  G  x 9 4 ;  B , C , E x l l 8 ; D  
x ! 5 6 ;  F  x 3 7 8 ;  H  x 2 3 6 .
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etc) and (b) to determine the extent of any 
scatter photocoagulation.
Eyes were categorised as follows:
Normal— 10 hum an eyes with no known 
ophthalmic disease, no history of diabetes, and 
no abnormalities on biomicroscopy. Donors 
ranged in age from 34 to 89 years (mean 69 
years).
Diabetic with no overt retinopathy— 12 human 
eyes from diabetic donors with no clinical his­
tory and no overt biomicroscopic features of 
retinopathy or retinal photocoagulation. Do­
nors ranged in age from 57 to 89 years (mean 
77 years), five had been injecting insulin and 
seven had not. A complete medical history was 
unavailable for all donors but, in those where 
medical histories were known (10/12), the 
duration of diabetes was between 6 and 10 
years (mean 7.3 years).
Diabetic with intraretinal changes but no 
evidence of PDR—five hum an eyes from dia­
betic donors with intraretinal changes on 
biomicroscopy bu t no clinical history or overt 
features of PD R  or retinal photocoagulation. 
Retinas exhibited cotton wool spots and/or 
obvious microaneurysms or haemorrhages. 
D onors ranged in age from 62 to 96 years 
(mean 74 years), three had been injecting insu­
lin and two had not. A complete medical 
history was known for four donors, the 
duration of diabetes being between 3 and 21 
years (mean 13 years).
Diabetic with preretinal PDR—six human eyes 
from diabetic donors defined clinically as hav­
ing PD R  and exhibiting preretinal membranes 
when examined by biomicroscopy. All eyes had 
previously received laser photocoagulation. 
D onors ranged in age from 37 to 76 years 
(mean 58 years), all had been injecting insulin. 
D uration of diabetes ranged from 3-29 years 
(mean 14.3 years).
Diabetic with scatter laser photocoagulation but 
no evidence of residual PDR— 14 hum an eyes
from diabetic donors defined clinically as hav­
ing had PDR and having received scatter laser 
photocoagulation. No preretinal membranes 
could be observed when retinas were examined 
by biomicroscopy. Donors ranged in age from 
40 to 82 years (mean 57 years), 11 had been 
injecting insulin and three had not. A complete 
medical history was known for 13 donors, the 
duration of diabetes being between 10 and 35 
years (mean 20 years).
The posterior segment of each eye was cut in 
the sagittal plane through the centre of the optic 
nerve head. Cuts were then made perpendicu­
lar to this line (a) on the horizontal midline on 
the nasal side and (b) at approximately 5 mm 
above and below the midline on the temporal 
side. A final vertical cut was made parallel to the 
initial cut and approximately 3 mm temporal to 
the macula. For this study tissue was wax 
embedded and 5 pm sections were cut from a 
portion of retina/choroid/sclera (a) approxi­
mately 3 mm lateral to the macula and perpen­
dicular to the horizontal plane (this region was 
chosen because of its susceptibility to retinal 
changes associated with diabetes) and (b) other 
representative areas across the retina (for exam­
ple, areas of neovascularisation).
Fibrovascular membranes— 11 fibrovascular 
preretinal membranes excised at vitreous 
surgery from eyes with PD R were obtained 
from the Manchester Royal Eye Hospital. 
Membranes were fixed in 10% neutral buffered 
formalin immediately upon removal and for a 
minimum of 12 hours before wax embedding.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was undertaken as 
previously described.'” The 5 pm sections were 
cut and mounted on APES (Sigma) coated 
slides. Sections were dewaxed and rehydrated. 
They were blocked for 60 minutes with 10% 
milk protein (Marvel)/normal goat serum 
(Sigma) before incubation overnight at 4°C
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F i g u r e  2  P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  F L T - 1  
i m m u n o s t a i n i n g  o f  a n  e x c i s e d  f i b r o v a s c u l a r  m e m b r a n e  ( A ) .  
I m m u n o r e a c t i v i t y  f o r  F L T - 1  w a s  a b o l i s h e d  i n  a  c o n t r o l  
s p e c i m e n  o f  e x c i s e d  m e m b r a n e  p r o c e s s e d  w i t h  o m i s s i o n  o f  
t h e  p r i m a r y  a n t i b o d y  ( B )  a n d  G F A P  s t a i n i n g  o f  t h e  s a m e  
e x c i s e d  m e m b r a n e  ( C ) .  I n t e n s e  s t a i n i n g  w a s  o b s e r v e d  
a r o u n d  t h e  v e s s e l s  i n  e x c i s e d  m e m b r a n e s .  M a g n i f i c a t i o n  A ,  
B ,  C  x 6 0 .
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with either (a) a polyclonal rabbit antibody 
raised against a peptide corresponding to 
amino acids 1312-1328 mapping at the 
carboxy term inus of FLT of human cell origin 
and reacting with FLT of mouse, rat, and 
hum an cell origin (R&D Systems) diluted to 1 
pg/ml in TRIS buffered saline (TBS), (b) a 
polyclonal rabbit antibody raised against a 
G ST  fusion protein containing FLK-1 se­
quences corresponding to amino acids 1158— 
1345 mapping at the carboxy terminal of 
FLK-1 of mouse origin (that is, the murine 
form of KDR) and reacting with FLK-1 of 
mouse, rat, and hum an cell origin (R&D 
Systems) diluted to 2 pg/ml in TBS, or (c) a 
polyclonal rabbit antibody raised against a 
peptide corresponding to amino acids 1279- 
1298 mapping at the carboxy terminus of 
FLT-4 of hum an origin and reacting with 
FLT-4 of hum an origin (R&D Systems) 
diluted to 1 pg/ml in TBS. A selection of slides 
were also stained for polyclonal rabbit antiglial 
fibrillary acidic protein (GFAP) antibody 
isolated from hum an spinal cord, directed 
against the 56 kD GFAP protein and reacting
with GFAP of bovine, rat, and human origin 
(Euro-Diagnostica), diluted 1/50 in TBS. 
Negative controls were incubated with 0.2% 
goat serum in place of the primary antibody or 
substitution of the primary antibody with an 
inappropriate rabbit IgG at the same concen­
tration as the primary antibody. Sections were 
washed three times with TBS and then 
incubated for 30 minutes with biotinylated 
goat anti-rabbit IgG (Sigma) and then incu­
bated for 30 minutes with an avidin-biotin 
alkaline phosphatase reaction mixture (Dako 
Ltd). The sections were washed three times 
with TBS and then incubated with Fast Red 
TR/naphthol AS-MX substrate (Sigma). 
When the red colour had sufficiently developed 
the slides were washed in distilled water and 
counterstained with Mayer’s haematoxylin.
ASSESSMENT OF IMMUNOSTAINING 
The degree and pattern of immunostaining 
both within and between specimens was 
assessed by standard light microscopy by two 
masked observers (both of whom obtained 
similar results). The intensity of staining was
F i g u r e  3 P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  KDR i m m u n o s t a i n i n g  o f  n o n - d i a b e t i c  r e t i n a  (A), d i a b e t i c  r e t i n a  w i t h  PDR 
(B, C ), t h e  s a m e  r e t i n a  s t a i n e d  w i t h  GFAP (D ), a n d  d i a b e t i c  r e t i n a  p o s t  l a s e r  b u t  w i t h  n o  r e s i d u a l  PDR (E). 
I m m u n o s t a i n i n g  f o r  K D R  w a s  g r e a t e s t  i n  t h e  d i a b e t i c  t i s s u e  w i t h  PDR a n d  w a s  m i n i m a l  i n  m o s t  o t h e r  d i a b e t i c  t i s s u e .  
I n t e r e s t i n g l y ,  i m m u n o s t a i n i n g  i n  t h e  d i a b e t i c  r e t i n a s  w h i c h  h a d  u n d e r g o n e  a p p a r e n t l y  s u c c e s s f u l  l a s e r  t r e a t m e n t  w a s  r e d u c e d  
c o m p a r e d  w i t h  t h e  s t a i n i n g  i n t e n s i t y  i n  t h e  r e t i n a s  w i t h  PDR. I m m u n o r e a c t i v i t y  f o r  KDR w a s  a b o l i s h e d  i n  a  c o n t r o l  
s p e c i m e n  o f  PDR r e t i n a  p r o c e s s e d  w i t h  o m i s s i o n  o f  t h e  p r i m a r y  a n t i b o d y  ( F ) . M a g n i f i c a t i o n  =  A, C, D x l 56; B x60;E  
x!18 ;F x78 .
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graded qualitatively as background (corre­
sponding to the level of staining seen in the 
negative controls), weak, moderate, or intense 
(corresponding to the highest level of immuno- 
reactivity), each of these being recorded as 0 ,1 , 
2, and 3 respectively. For each retinal specimen 
staining intensity was recorded for choroid, 
RPE, photoreceptors, outer retina, inner 
retina, ganglion cell layer, and retinal vessels. 
For the fibrovascular membranes staining 
intensity was recorded for the vessels and the 
surrounding matrix. An average score was then 
calculated for each retinal layer within each 
group.
Results
Staining was observed in both non-diabetic 
and diabetic vascular and extravascular retinal 
tissue; increased immunostaining was observed 
in preretinal and intraretinal vessels of diabetic 
tissue compared with non-diabetic tissue (see 
Figs 1-4 and Tables 1-3). For all receptors 
variable staining of the vessels within each 
retina was observed with some vessels staining 
positive and some staining negative. In  some 
instances staining was associated with both
endothelial cells and the perivascular region of 
the vessels. The variability in staining within 
retinas of the same group did not show a corre­
lation with donor age, the type of glycaemic 
control in the case of the diabetic groups, or 
time post mortem.
FLT-1 IMMUNO REACTIVITY
Staining intensity for FLT-1 was generally 
weak or absent in the choroidal vessels, the 
RPE, and the photoreceptors. Weak staining 
was observed in the outer nuclear layer of most 
tissue categories but staining intensity tended 
to be elevated in diabetic eyes with vascular 
abnormalities and in those which had been 
successfully lasered. Weak to moderate staining 
was observed in the inner nuclear layer and 
weak to intense staining was observed in the 
ganglion cell layer of all the tissue categories 
including the non-diabetic eyes (Fig 1A-C; 
E -H ; Table 1). The pattern of staining in the 
ganglion cell layer appeared to be associated 
with the Muller cell feet as it co-localised with 
positive GFAP staining (Fig ID ). While weak 
staining was observed in the retinal vessels of 
the non-diabetic eyes and the diabetic eyes
A B
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F i g u r e  4  P h o t o m i c r o g r a p h s  d e m o n s t r a t i n g  F L T - 4  s t a i n i n g  o f  n o r m a l  r e t i n a  ( A ) ,  d i a b e t i c  r e t i n a  w i t h  o b v i o u s  v a s c u l a r  
i n t r a r e t i n a l  c h a n g e s  b u t  n o  e v i d e n c e  o f  P D R  ( B ) ,  d i a b e t i c  r e t i n a  w i t h  P D R  ( C ,  D )  a n d  t h e  s a m e  r e t i n a  s t a i n e d  w i t h  
G F A P  ( E ) .  I m m u n o s t a i n i n g  f o r  F L T - 4  w a s  r a i s e d  i n  d i a b e t i c  t i s s u e  c o m p a r e d  w i t h  n o n - d i a b e t i c  t i s s u e .  I m m u n o s t a i n i n g  
w a s  i n t e r m e d i a t e  i n  t h e  P D R  s p e c i m e n s .  I m m u n o r e a c t i v i t y  f o r  F L T - 4  w a s  a b o l i s h e d  i n  a  c o n t r o l  s p e c i m e n  o f  P D R  r e t i n a  
p r o c e s s e d  w i t h  o m i s s i o n  o f  t h e  p r i m a r y  a n t i b o d y  ( F ) .  M a g n i f i c a t i o n  A ,  D  x ! 5 6 ; B  x l  1 8 ; C  x 9 4 ; E ,  F  x 6 0 .
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Table 1 Mean intensity (SD) o f FLT-1 staining in the retina/choroid
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Membrane
Photo Outer Inner nuclear Ganglion Retinal Membrane extravascular
Choroid RPE receptors nuclear layer layer cell layer vessels vessels matrix
Non-diabetic (n=10)
No overt retinopathy (n=12)
Intraretinal changes (n=5)
PDR (n=6)
Laser, no residual PDR (n=14)
PDR excised membranes (n= l 1)
0 .70(0 .46) 1.10(0.83) 0.60(0.80) 0.20(0.40) 1.10(0.94) 1.50(1.12) 1.0 (1.0)
0 .92(0 .64) 0 .58(0 .86) 0.42(0.49) 0 .33(0.47) 1.42(0.49) 1.92(0.86) 1.25(0.92)
0 .60(0 .80) 0 .80(0 .75) 0.80(1.17) 1.20(1.17) 1.60(0.80) 2.20(0.75) 1.60(1.02)
1.0 (0) 0.17 (0.37) 0 (0 ) 1.0(0.82) 1.17 (0.69) 2.0(0.82) 1.50 (1.12) 2.50 (0.50) 1.17 (0.37)
0.57 (0.49) 0.93 (1.03) 0.21 (0.56) 1.50(0.63) 1.50 (0.63) 1.86 (0.74) 1.71 (0.45)
1.55 (0.78) 1.09 (0.79)
0=background staining; l=weak staining; 2=moderate staining; 3=intense staining.
without vascular changes, staining was moder­
ate in all the other categories of diabetic tissue 
(Fig 1A-C; E-H; Table 1). The highest inten­
sity of FLT-1 staining in the intraretinal vessels 
was associated with successful laser treatment 
with most (13/14) retinas staining. In all tissue 
categories staining tended to be confined to 
small and venous vessels in the superficial lay­
ers, although in 5/14 lasered retinas and in 2/6 
retinas with PDR (both of which had previ­
ously been lasered) staining of the arterial ves­
sels was observed. The most intense staining 
for FLT1 was observed in the vessels of 
preretinal membranes of the diabetic subjects 
who had PDR (Table 1). In this tissue category 
staining of the intraretinal vessels was associ­
ated both with the membranes and across the 
retina (Fig IE, F, G) Staining was moderate in 
the excised membranes but staining tended to 
be confined to a proportion of the vessels 
within each membrane with 4/11 of the mem­
branes demonstrating staining both around the 
vessels and in the adjacent matrix (Fig 2A). 
Weak staining was associated with the non- 
vascular components of the membranes and 
staining with GPAP antibody confirmed that 
some of the perivascular and extravascular 
staining was glial cell in origin (Fig 2C).
KDR IMMUNO REACTIVITY
KDR immunoreactivity was generally minimal 
or absent in the choroidal vessels, the RPE, and 
the retinal layers of all the categories (Fig 3A); 
however, weak staining was observed in the 
inner nuclear layer and the ganglion cell layer 
of the unlasered eyes with obvious diabetic
changes. Minimal to weak staining of the 
retinal vessels was observed in most categories 
but it became moderate to intense in the retinal 
vessels of diabetics with PDR with all (6/6) of 
the retinas staining (Fig 3B, C; Table 2). In 4/6 
diabetic retinas with PDR staining of the intra­
retinal vessels was associated with the mem­
branes but in 2/4 of these staining was also 
observed in vessels across the retina. In all cat­
egories staining tended to be associated with 
small and venous vessels (with one exception 
which was a non-diabetic eye) and was always 
observed in the superficial retinal layers. Mod­
erate staining of the preretinal vessels was 
observed in most of the membranes (Fig 3B,
C). In some instances staining was observed in 
the perivascular region and extravascular re­
gion and staining with GFAP antibody con­
firmed this to be glial cell in origin (Fig 3D). In 
those retinas which had undergone apparently 
successful laser treatment staining was reduced 
(Fig 3E; Table 2). In the excised membranes 
staining tended to be confined to a proportion 
of the vessels within each membrane with 2/11 
of the membranes demonstrating staining both 
around the vessels and in the adjacent matrix. 
Weak or absent staining was associated with 
the non-vascular components of the mem­
branes and staining with GFAP antibody con­
firmed that some of the perivascular and 
extravascular staining was glial cell in origin.
FLT-4 IMMUNOREACTIVITY 
FLT-4 staining was absent or weak in the 
choroidal vessels, the RPE, the photoreceptors, 
and the outer nuclear layer in both non­
Table 2 Mean intensity (SD) of K D R  staining in the retinal choroid
Choroid RPE
Photo
receptors
Outer
nuclear layer
Inner nuclear 
layer
Ganglion cell 
layer
Retinal
vessels
Membrane
vessels
Membrane
extravascular
matrix
Non-diabetic (n=10)
No overt retinopathy (n=12) 
Intraretinal changes (n=5)
PDR (n=6)
Laser, no residual PDR (n=14) 
PDR excised membranes (n= 11)
0.40 (0.49) 
0.08 (0.28) 
0.20 (0.40) 
0.67 (0.75) 
0.07 (0.26)
0.20 (0.40) 
0 (0 )
0 (0 )
0 (0 )
0.07 (0.26)
0.10 (0.30) 
0.25 (0.43) 
0.40 (0.80) 
0 (0 )
0.07 (0.26)
0.10 (0.30) 
0 (0 )
0 (0 )
0 (0 )
0 (0 )
0.60 (0.66) 
0.75 (0.60) 
1.40 (1.20) 
0.50 (1.12) 
0.71 (0.45)
0.40 (0.49) 
0.75 (0.43) 
1.40 (0.80) 
0.17 (0.37) 
0.29 (0.45)
0.20 (0.40) 
0.75 (0.92) 
0.40 (0.49) 
2.33 (0.75) 
0.50 (0.82)
2.0 (1.15) 
1.55 (1.23)
0.67 ( l . I I )  
0.55 (0.66)
0=background staining; l=weak staining; 2=moderate staining; 3=intense staining.
Table 3 Mean intensity (SD) of FLT-4 staining in the retina!choroid
Choroid RPE
Photo
receptors
Outer
nuclear layer
Inner nuclear 
layer
Ganglion 
cell layer
Retinal
vessels
Membrane
vessels
Membrane
extravascular
matrix
Non-diabetic (n=10)
No overt retinopathy (n=12) 
Intraretinal changes (n=5)
PDR (n=6)
Laser, no residual PDR (n=14) 
PDR excised membranes (n= l 1)
0.30 (0.46) 
0.42 (0.49) 
0.20 (0.40) 
1.0 (0.82) 
0.57 (0.62)
0 (0 )
0.08 (0.28) 
0.20 (0.40) 
0.17 (0.37) 
0.29 (0.45)
0 (0 )
0.33 (0.75) 
0.60 (0.80) 
0 (0 )
0.21 (0.56)
0.10 (0.30) 
0(0)
0 (0 )
0 (0 )
0.21 (0.41)
0.90 (0.94) 
1.50 (0.76) 
1.80(1.17) 
0.33 (0.47) 
0.86 (0.64)
0.50 (0.67) 
1.83 (0.80) 
2.0 (1.10) 
1.0 (0.82) 
0.79 (0.56)
0.70 (1.0) 
1.0(0.71) 
1.20 (1.47) 
1.50 (1.12) 
0.93 (0.80)
1.50 (1.26) 
1.73 (0.96)
0.33 (0.47) 
0.18 (0.39)
0=background staining; l=weak staining; 2=moderate staining; 3—intense staining.
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diabetic retinas (Fig 4A) and diabetic retinas 
(Fig 4B, C, D). In the inner nuclear layer and 
the ganglion layer FLT-4 immunoreactivity was 
only raised in the unlasered eyes, after laser 
treatment the levels reduced (Table 3). Stain­
ing with GFAP antibody confirmed that FLT-4 
staining was associated with glial cells of the 
retina (Fig 4E). In the retinal vessels FLT-4 
staining was low except in the PDR specimens 
where staining was weak to moderate (Fig 4C,
D). In this tissue category staining in the intra­
retinal vessels was associated with the mem­
branes in 3/6 retinas but staining in 2/3 of these 
was also observed in vessels across the retina. 
In all tissue categories staining tended to be 
associated with small and venous vessels of the 
superficial retinal layers although arterial stain­
ing was demonstrated in a small number of 
retinas. Weak to moderate staining was also 
observed in the preretinal vessels of the excised 
membranes. Staining tended to be associated 
with a proportion of vessels within each mem­
brane with 2/11 of the membranes demonstrat­
ing staining both around the vessels and in the 
adjacent matrix. Minimal staining was associ­
ated with the non-vascular components of the 
membranes and staining with GFAP antibody 
confirmed that some of the perivascular and 
extravascular staining was glial cell in origin.
D iscu ssion
The data presented in this study demonstrate 
(a) immunolocalisation of FLT-1, KDR, and 
FLT-4 receptors to retinal tissue and (b) 
upregulation of these receptors in diabetic 
retinopathy. These observations add further 
support for a role for VEGF family members in 
the initiation and progression of PDR.
Binding sites for VEGF have previously been 
demonstrated to be associated with vascular 
endothelial cells during the development of the 
vasculature,17 23-25 during pathological angio­
genesis—for example, in healing wounds, in skin 
diseases, in hypersensitivity reactions, and in 
carcinomas,25 26-29 and from in vitro studies.7 30-37 
These observations advance a regulatory role for 
VEGF and its receptors in angiogenesis occur­
ring both during normal vascular development 
and in various pathologies.
The observation in this study that KDR is 
greatly elevated in both intra- and preretinal 
vessels in PDR tissue and minimal in normal 
retina and the quiescent vessels of lasered dia­
betic retina with no evidence of PDR is in 
agreement with the view that KDR is involved 
in pathological angiogenesis. These findings 
correlate with the findings of various 
workers3*-40 who reported high levels of VEGF 
in the vitreous of patients with active PDR. By 
contrast, FLT-1 was observed in both non­
diabetic and diabetic vascular and avascular 
retinal tissue. The presence of FLT-1 in 
non-diabetic tissue may reflect its involvement 
in metabolic control—for example, control of 
vessel permeability and endothelial cell main­
tenance. Upregulation of FLT1 in diabetic 
vessels, particularly those undergoing active 
neovascularisation, indicates that the receptor 
plays a role in PDR. Firstly, it may induce vas­
cular leakage; FLT-1 is known to promote
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vascular permeability.5 Secondly, it has been 
suggested that it may participate in VEGF 
induced mitogenesis by heterodimer formation 
with KDR.41 Thirdly, FLT-1 may regulate 
VEGF induced angiogenesis; a soluble form of 
FLT-1 can complex with the extracellular 
region of KDR and act as a negative regulator 
of VEGF action.37 Fourthly, P1GF which is 
associated with PDR acts through the FLT1 
receptor.20 FLT-4 represents a third putative 
receptor for the VEGF family which shares 
structural similarities with FLT-1 and KDR; it 
is believed to be a receptor for VEGF-C.42 
FLT-4 immunolocalisation was minimal in 
non-diabetic eyes but was upregulated in 
diabetic tissue, especially in the inner nuclear 
layer, the ganglion cell layer, and intraretinal 
and preretinal vessels. These observations sug­
gest that FLT-4 may have a role in the 
pathogenesis of diabetic retinopathy.
Several ocular cell types, in addition to 
vascular endothelial cells33 43 44 and peri­
cytes,7 45 express VEGF receptors. VEGF 
receptors have been identified on cultured cor­
neal cells,46 cultured lens epithelial cells,47 48 
and cultured RPE cells.48 49 Increased levels of 
VEGF mRNA and protein have previously 
been demonstrated in retinal disorders in the 
cell bodies of the inner nuclear layer, the 
ganglion cell layer, and the outer nuclear 
layer.8 9131516 Studies on the developing retinal 
vasculature have also demonstrated VEGF 
mRNA and protein in the retinal glial cells.50 51 
Chen and co-workers demonstrated intense 
VEGF staining in both vascular and extravas­
cular epiretinal membranes.49 They also dem­
onstrated FLT-1 but not KDR expression by 
glial cells in the epiretinal membranes and in 
cultured retinal glial cells. In our study we also 
demonstrated increased immunoreactivity for 
FLT-1, FLT-4, and, to a lesser extent, KDR in 
the glial cells of the retina which was 
particularly associated with the end feet of the 
Muller cells. Thus, these observations demon­
strate that VEGF may act through its receptors 
via both autocrine and paracrine mechanisms. 
It may be that one of the functions of the reti­
nal glial cells is as early detectors of the hypoxic 
environment occurring during the earlier 
stages of diabetic retinopathy. This could 
explain why in our study FLT-1, FLT-4, and to 
a lesser extent KDR, were associated with the 
glial cells before proliferation had occurred. 
These cells may respond to hypoxia by upregu- 
lating their receptors and secreting VEGF 
which acts on the endothelial cells. The 
sustained production of VEGF would eventu­
ally lead to an angiogenic response. Sustained 
production of VEGF may be maintained by a 
positive feedback mechanism to the receptors 
on the glial cells and the endothelial cells which 
could explain why increased levels of FLT-1 
were observed in the glial cells of the eyes with 
PDR. An interesting observation was that in 
some of the membranes GFAP staining was 
observed both around the vessels and in the 
surrounding matrix which corresponded to 
receptor immunoreactivity. It may be that these 
particular membranes were undergoing active
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neovascularisation or that there may have been 
hypoxic regions within these membranes.
VEGF receptor expression appears to be 
regulated by various stimuli including growth 
factors and cytokines’ and, as mentioned 
above, hypoxia.7 ” 74 44 45 Takagi et al suggested 
that hypoxia may be responsible for increasing 
KDR/FLK expression indirectly via adenosine 
receptors on endothelial cells44; adenosine is 
hypoxia inducible in some tissues and it is 
known to stimulate angiogenesis and cellular 
proliferation.
In conclusion, this study confirms the 
presence of VEGF family receptors in the dia­
betic retina and indicates that while KDR 
appears to be involved principally with the 
angiogenic process (that is, PDR), FLT-1 may 
have a role in both normal endothelial cell 
homeostasis and in all stages of diabetic retin­
opathy. Therefore, any agent directed against 
VEGF or FLT-1 could have a detrimental 
effect on the normal structure and functioning 
of endothelial cells and vessels. A more attrac­
tive alternative would be to produce anti- 
angiogenic molecule (s) with low toxicity di­
rected against KDR. One study by Strawn and 
co-workers found anti-angiogenesis com­
pounds that can inhibit FLK-1/KDR tyrosine 
kinase activity as well as endothelial cell 
mitogenesis and blood vessel formation in the 
chorioallantoic membrane.52 Further studies 
are necessary (a) to determine whether the 
receptors are active, (b) to ascertain the stimu­
lus for upregulation of the receptors, and (c) to 
determine whether inhibition of receptor acti­
vation is the therapy of choice in preretinal 
angiogenesis.
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Loss of the Antiangiogenic Pigment Epithelium-Derived 
Factor in Patients With Angiogenic Eye Disease
Joachim Spranger,1,2 Martin Osterhoff,1,2 Manja Reimann,1’2 Matthias Mohlig,1,2 Michael Ristow,1,2 
Mary Kay Francis,3 Vincent C ristofalo,3 Hans-Peter Hammes,4 Gillian Smith,5 Michael Boulton,5 and 
Andreas F.H. Pfeiffer1,2
Retinal neovascularization characterizes proliferative 
diabetic retinopathy (PDR). Pigment epithelium-derived 
factor (PEDF) has been shown to be a major antiangio­
genic growth factor in the mammalian eye. PEDF expres­
sion is suppressed by hypoxia, and changes in PEDF have 
been correlated to the development of retinal neovascu­
larization in animal models of hypoxic eye disease. How­
ever, whether this concept of a reduced angiogenesis 
inhibitor holds true in humans is as yet unclear. In this 
study, we analyzed the in vivo regulation of PEDF in 
patients with and without hypoxic eye disease. We used 
immunoblots to measure PEDF in ocular fluids obtained 
from 64 nondiabetic and diabetic patients. In addition, 
immunohistochemistry of PEDF was carried out in spec­
imens of normal human retinas and retinas with various 
degrees of diabetic retinopathy. The PEDF concentra­
tions in patients with PDR (i* < 0.001) or extensive 
nondiabetic retinal neovascularization caused by reti- 
nal-vein occlusion (P < 0.001) were lower than in 
control patients. Levels of PEDF were replenished in 
PDR patients with previous retinal scatter photocoagu­
lation compared with PDR patients without previous 
photocoagulation (P = 0.01). Immunohistochemistry 
revealed an interstitial staining pattern as expected for 
a secreted protein, with an intense staining in retinas of 
patients without proliferative eye disease. However, in 
patients with PDR, little or no staining was detectable. 
Our data strongly support the concept that retinal 
angiogenesis is induced by loss of the major angiogene­
sis inhibitor in the eye, PEDF, in combination with an 
increased expression of angiogenic growth factors such 
as vascular endothelial growth factor. Our findings sug­
gest that substitution of angiogenesis inhibitors may be
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The control of retinal angiogenesis is of critical importance for the preservation of vision. Reti­nal neovascularization characterizes prolifera­tive diabetic retinopathy (PDR), which is still one of the most common causes of blindness worldwide. 
Retinal ischemia induces intraocular neovascularization, 
presumably by stimulating the expression of angiogenic 
growth factors and by inhibiting the release of antiangio­
genic cytokines (1,2). Vitreal levels of angiogenic growth 
factors have been shown to be directly associated with the 
degree of retinal angiogenesis (3,4). 'Die ability to monitor 
and grade retinal angiogenesis within the eye as well as the 
ability to aspirate vitreous, which is known to contain 
retina-derived growth factors in direct association to the 
stage of retinal angiogenesis, makes the eye an ideal 
setting in which to investigate the delicate balance of new 
vessel growth and the influence of specific growth factors 
in vivo in humans.
Pigment epithelium-derived factor (PEDF) protects cer­
ebellar granule cells against neurotoxic agents (5) and is 
also called early population doubling level cDNA-1 (EPC- 
1), reflecting its upregulation during cell cycle arrest (G0) 
in young but not in senescent cultured fibroblasts (6). 
Recently, PEDF has been shown to be a highly effective 
inhibitor of angiogenesis in animal and cell culture mod­
els. The production of PEDF was decreased by hypoxia
(7), which is also a central pathogenic stimulus in PDR. 
Immunoneutralization of PEDF diminished the ability of 
cadaveric human vitreous to inhibit migration of endothe­
lial cells, thereby demonstrating that a loss of PEDF is 
functionally important in mediating angiogenic properties 
of human vitreous ex vivo. Most importantly, systemically 
administered PEDF prevented aberrant blood vessel 
growth in a murine model of ischemia-induced retinopathy
(8). However, no information is yet available about the 
presence and regulation of PEDF in vivo in humans, 
particularly in hypoxia-induced proliferative retinopathy. 
If PEDF is involved in the control of retinal angiogenesis in 
humans, one would expect that PEDF is decreased in the 
ocular fluids of patients with hypoxia-induced proliferative 
retinopathy and that PEDF levels increase after at least
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partially successfu l therapy, such as retinal photocoagula- 
tion. In this study, w e attempted to ascertain whether 
intraocular concentrations o f PEDF correlated with the 
gree of retinal neovascularization by m easuring PEDF in 
the ocular fluid o f  64 patients. We also investigated  
whether retinal scatter photocoagulation is capable of 
replenishing PEDF in the ocular fluid o f  patients with 
PDR. Spatial and temporal changes in the expression of 
retinal PEDF were determined by im munohistochem ical 
localization o f PEDF in the human retinas o f  patients with 
different degrees o f diabetic retinopathy.
RESEARCH DESIGN AND METHODS
Vitreous was obtained from 64 patients (32 women and 32 men). Patients 
without proliferative retinal disease (control subjects: n  = 19, 6 women and 13 
men, mean age 70 ±  3 years) were compared with patients with PDR (n = 37, 
17 women and 20 men, mean age 61 ±  2 years, 6 patients with type 1 diabetes, 
31 with type 2 diabetes, HbA1(. 7.8 ±  0.1%) and patients with extensive 
nondiabetic neovascularizing eye disease caused by central-vein occlusion 
(Rubeosis; n = 8, 2 women and 6 men, mean age 71 ± 3 years, no diabetes). 
A total of 27 patients with PDR had retinal photocoagulation before vitrec­
tomy (PDR + previous retinal photocoagulation [PRP]), whereas 10 patients 
with PDR had no previous photocoagulation (PDR -  PRP). PDR was 
considered to be active if there was extensive retinal neovascularization 
represented by perfused, multibranching preretinal capillaries and to be 
quiescent if mainly nonperfused or gliotic vessels were p resen t Altogether, 15 
patients with PDR had active neovascularization, whereas 22 patients had 
quiescent retinal angiogenesis. A total of 13 patients with PDR + PRP had new 
vessels elsewhere (NVE), 3 had new vessels on the disk (NVD), and 11 had 
NVE + NVD. Five patients with PDR -  PRP had NVE, four had NVD, and one 
had NVE and NVD. Age, HbAlr, and duration of diabetes did not differ 
significantly between patients with PDR + PRP and PDR -  PRP (age 61 ± 4 
and 61 ± 2 years, HbAlr 7.6 ± 0.3 and 8.2 ±  0.4%, duration of diabetes 18.3 ± 
2 and 17 ± 4 years, respectively). Undiluted samples of human vitreous were 
obtained during pars plana vitrectomy. Samples were aspirated under stan­
dardized conditions directly above the retina at the beginning of surgery and 
prepared as previously described (2). Ocular neovascular activity was deter­
mined by fluorescein photography, via slit lamp examination, or by the 
surgeon at the time of surgery.
Specimens for immunohistochemistry were obtained from the National 
Disease Research Interchange (NDRI), Philadelphia, Pennsylvania. Eyes were 
enucleated and fixed in 10% neutral buffered formalin within 10 h post 
mortem. Examination of the posterior segment was performed by an experi­
enced ophthalmologist using a Zeiss Stemi SV8 zoom dissecting microscope. 
Eyes were categorized as follows (n =  5 for each group): normal (A); diabetic 
without ocular abnormalities (B ); diabetic with intraretinal changes but no 
evidence of PDR (C); diabetic with PDR (£>); and diabetic with scatter laser 
photocoagulation and no evidence of residual PDR (£')• Samples were 
prepared, and criteria for categorization were chosen as previously described
(9).
Classification of specimen was performed before the experimental part of 
the study. The study was approved by the Ethical Committee of the University 
of Bochum, and informed consent was obtained from all patients included. 
W estern blot. PEDF was quantified by Western blotting using polyclonal 
PEDF-speciflc antibodies (anti-PEDF), which were raised as previously de­
scribed (10). Blots were analyzed automatically by a digital imaging system 
with standardized imaging values, thereby obtaining observer-independent 
quantification of the band intensities. The samples were compared with 
defined quantities of purified human PEDF, which was run as an internal 
standard on every gel. The internal standard was engineered by transfecting a 
human PEDF cDNA (with a 6xHis tag cloned into CEP4) (Invitrogen) into 
human embryonic kidney cells as previously described (7). Recombinant 
PEDF was enriched from the conditioned media with the QIAexpress system 
(Qiagen, Hildesheim, Germany) and quantified using the Bradford assay (11). 
Im m unohistochem istry. Primary antibody (anti-PEDF, 1:300 dilution) was 
incubated for 60 min. Detection was performed with an alkaline phosphatase- 
based system (LASB + ; Dako, Glostrup, Denmark). Staining procedures were 
performed under standardized conditions, and sections were counterstained 
with Mayer’s hematoxylin. Negative controls were incubated without primary 
antibody or with primary antibody after preabsorbtion with recombinant 
PEDF. The intensity of staining was graded qualitatively as background (0), 
weak (1), moderate (2 ), or intense (3) by a blinded investigator without
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FIG. 1. W estern blots with a polyclonal PEDF/EPC-1 antibody. Lanes  
1-3 rep re sen t a typical standard  curve w ith a  d ilu tion  o f  recom binant 
PEDF ( lane 1, undiluted; lane 2, 1:2 d ilu tion; lane 3, 1:4 d ilu tion). M, 
m olecular size m arker. A: The PEDF bands in  lanes 1—3  w ere reduced 
o r  d isappeared  a fte r  p reincubation  o f  the  antibody  w ith recom binant 
PEDF ( lanes 4 —6), thereby  dem onstrating  th e  specificity  o f  the reac­
tion. B: W estern b lo t o f  v itrea l sam ples o f  con tro l sub jec t (C ), pa tien ts  
w ith PDR (D ), and pa tien ts  w ith severe in tra o cu la r  neovascularization  
(R ubeosis irid is) caused by central-vein  occlusion (R ).
knowledge of the clinical data. An average score of staining was calculated 
within each group.
S ta tis tica l analysis. Data are reported as the mean ±  SE. The Mann Whitney 
U  test was used to compare quantitative data with unequal distributions. The 
correlation between variables was calculated by linear regression analysis of 
untransformed values. A level of P  < 0.05 was considered significant.
RESULTS
Vitreal levels o f PEDF were determined by immunoblot 
(Fig. 1). We detected a protein band o f  50 kDa correspond­
ing to the predicted molecular m ass o f  PEDF. The band 
disappeared or was diminished after preincubation of the 
antibody with a previously enriched recombinant PEDF, 
thereby demonstrating specificity o f the reaction. Recom­
binant PEDF occurred as a single band on a SDS-poly- 
acrylamide gel as investigated by Ponceau S staining after 
immobilization on a nitrocellulose filter.
V itre a l P E D F  le v e ls  a r e  d e c re a s e d  in  PDR. The intraoc­
ular levels of PEDF were determined by Western blot 
analysis and then quantified based on an internal standard 
of purified human recombinant PEDF (Fig. 2). The results 
suggest that the PEDF levels were significantly decreased  
in patients with PDR (20 ±  0.5 nmol/1, n = 37; P <  0.001) 
and patients with central-vein occlusion resulting in exten­
sive neovascularization (17.6 ±  0.3 nmol/1, n =  8; P < 
0.0001) compared with control subjects (23.7 ±  0.7 nmol/1, 
n — 19). Furthermore, patients with quiescent PDR had 
unchanged PEDF levels (22 ±  0.6 nmol/1, n  =  22; P  =  0.06) 
compared with control subjects, whereas patients with 
active PDR (17.2 ±  0.5 nmol/1, n =  15) had PEDF levels 
comparable with those o f patients with Rubeosis. PEDF 
levels of patients with active PDR were significantly lower 
than those o f control subjects (P <  0.0001) and patients 
with quiescent PDR (P <  0.0001).
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FIG. 2. Levels of vitreal PEDF in patients with proliferating eye 
disease. PEDF levels in intraocular samples from numerous patients 
were determined by Western blot analysis and compared with a stan­
dard concentration of purified human recombinant PEDF. The influ­
ence of intraocular activity was investigated by comparing levels of 
intraocular PEDF in patients with different degrees of neovascular 
activity; control subjects without angiogenesis, patients with quiescent 
PDR, patients with active PDR, and nondiabetic patients with exten­
sive retinal neovascularization caused by central-vein occlusion (Ru­
beosis).
Photocoagulatioii replenishes intraocular levels o f  
PEDF. Previous photocoagulation was associated with 
reduced neovascular activity (Fig. 3). Although 70% of the 
patients without prior photocoagulation (PDR — PRP) 
suffered from active angiogenesis, only 30% of the patients 
with PDR + PRP had active neovascularization. Patients 
with PDR + PRP had higher concentrations of PEDF (n = 
27, 20.9 ± 0.7 nmol/1; P = 0.01) compared with patients 
with PDR -  PRP (n = 10, 17.7 ± 0.3 nmol/1). However, 
PDR concentrations of patients with previous photocoag­
ulation were still clearly below levels of control patients 
(P = 0.007).
PEDF levels are associated with the localization of 
retinal neovascularization. Taking all patients into ac­
count, levels of PEDF correlated significantly with the 
localization of retinal neovascularization. Patients with 
NVE and NVD (18 ± 0.4 nmol/1, n = 20) had decreased 
levels compared with control patients without prolifera­
tion (23.7 ± 0.7 nmol/1, n = 19; P < 0.001) and patients 
with NVE only (21 ± 1 nmol/1, n = 18; P = 0.02) (Fig. 4). 
Patients with NVE or NVD only (19 ± 1 nmol/1, n = 7) had 
lower levels than control patients (P = 0.053 and P = 
0.002, respectively). We found no correlation between 
vitreal levels of PEDF and sex, duration of diabetes, 
HbAlc, or age of the patients.
PEDF-specific immunohistochemistry o f human reti­
nas with different stages o f diabetic retinopathy. To
obtain data about spatial and temporal changes of PEDF 
expression in the course of diabetic retinopathy, 25 spec­
imens of human retina were examined by immunohisto- 
chemistry. Our results revealed an interstitial accumulation 
of PEDF in the eyes of control subjects (Fig. 5A), patients
with diabetes without ocular abnormalities (Fig. 5J3), and 
patients with nonproliferative diabetic retinopathy 
(NPDR) (Fig. 5C), thereby confirming the murine staining 
pattern previously described (7). We qualitatively assessed 
the staining for each section (as described in r e s e a r c h  
d e s ig n  a n d  m e th o d s ) ,  and our results show that intraretinal 
intensity of staining was nearly abolished in patients with 
PDR (mean 0.4 [range 0-1]) (Fig. 5D) compared with 
control subjects (2.2 [1-3]), patients with diabetes without 
ocular disease (1.6 [1-2]), and patients with NPDR (1.2 
[1-2]), despite unchanged intensity of unspecific staining 
of the fibrous tissue. Patients with previous scatter photo­
coagulation resulting in quiescent PDR had weak intrareti­
nal immunochemical staining that was, on average, slightly 
more intense (1.0 [0-2]) (Fig. 5E) than that of patients 
with active PDR.
Taken together, our results demonstrate a significant 
intraocular loss of the angiogenesis inhibitor PEDF in 
patients with neovascularizing eye disease such as PDR. 
Intraocular levels of PEDF strongly correlate with the 
degree of retinal neovascularization. In addition, we dem­
onstrate that retinal scatter photocoagulation, the treat­
ment of choice for patients with diabetic retinopathy, 
replenishes concentrations of PEDF in the eye. Changes of 
vitreal levels are confirmed by immunohistochemistry, 
which reveals an interstitial staining pattern as expected 
for a secreted protein.
DISCUSSION
The switch to an angiogenic phenotype of proliferating 
tissues requires both upregulation of angiogenic stimula­
tors and downregulation of angiogenesis inhibitors. An 
elevated expression of angiogenic growth factors such as 
vascular endothelial growth factor (VEGF) in patients with 
retinal neovascularization has been previously demon-
35  -i
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FIG. 3. Levels of vitreal PEDF depend on previous photocoagulation. 
PEDF levels were determined as described in Fig. 2 for patients with 
PDR — PRP, PDR + PRP, and Rubeosis, as well as nondiabetic patients 
with extensive retinal neovascularization due to central vein occlusion 
(control subjects).
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FIG. 4. Concentrations of PEDF in human vitreous depending on 
localization of neovasularization. PEDF levels were determined as 
described in Fig. 2. Levels of PEDF correlate with the localization of 
retinal neovascularization. We compared patients without retinal an- 
giogenesis (control subjects), patients with NVD, those with NVE, and 
those with both NVE and NVD.
strated (4). Additionally, decreased expression of VEGF 
was observed in patients with reduced neovascular activ­
ity after panretinal photocoagulation (2). The question  
targeted by this study was whether a loss o f angiostatic 
growth factors such as PEDF is critical in the developm ent 
of retinal neovascularization in vivo in humans. We found 
PEDF concentrations in ocular fluid to be low er in patients 
with active neovascularization than in control subjects 
without retinal angiogenesis. The vitreal data are con­
firmed by the results o f im munohistochemistry showing  
almost no staining in patients with active proliferation  
compared with a strong intraretinal staining in control 
patients. These results demonstrate regulation o f  the ma­
jor intraocular angiogenesis inhibitor PEDF in vivo de­
pending on the stage o f retinal ischemia. The data support 
the concept that induction o f angiogenesis in the human 
eye requires not only elevation o f angiogenic growth 
factors such as VEGF (4) but also a decrease in angiogen­
esis inhibitors such as PEDF (1,7). PEDF has been pro­
posed to be an age-dependent regulated protein (10). 
However, our data do not support this concept, although 
the number of control patients in our study may be too  
small to definitively answer this question.
We found that intraocular PEDF levels w ere reduced in 
nondiabetic patients with severe retinal ischem ia caused  
by central-vein occlusion. Therefore, hypoxia rather than 
hyperglycemia promotes intraocular reduction o f  PEDF in 
humans. Our immunohistochemical findings sh ow  a small 
reduction in staining intensity in diabetic patients without 
retinal alterations and in diabetic patients with nonprolif­
erative abnormalities (such as m icroaneurysm s) com ­
pared with control subjects. These results suggest that 
glycemic control might also influence the expression of 
PEDF in the eye. Because o f technical reasons in regard to
2644
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quantification of immunohistochemistry in general, w e 
cannot fully exclude small differences in the expression of 
PEDF in NPDR compared with control patients. Even such  
small differences might be relevant in the early stages of 
diabetic retinopathy, as suggested by data showing PEDF- 
dependent functional changes of retinal vessels (L.P. Aiello, 
Boston, MA; personal communication).
An important observation of this study was that patients 
with quiescent retinal neovascularization who mostly had 
retinal photocoagulation before intraretinal surgery had 
higher levels o f PEDF compared with patients with active 
neovascularization without previous photocoagulation. 
Retinal photocoagulation induces regression of retinal 
neovascularization and has been shown to be associated  
with a reduction in the incidence of severe visual loss and 
retinal neovascularization (12). In our study group, pa­
tients with previous photocoagulation had reduced neo­
vascular activity compared with patients without prior 
photocoagulation, suggesting that the positive effects o f  
retinal photocoagulation are mediated at least in part by 
the reestablishment o f near-normal PEDF levels. Presum­
ably, a reduction in retinal ischemia after photocoagula-
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FIG. 5. PEDF protein expression in retinal samples from patients with 
different stages of diabetic retinopathy. Human retinas were examined 
by immunohistochemistry for PEDF expression. Staining patterns for 
representative sections are shown for control subjects (A), patients 
with diabetes without ocular abnormalities (B), and patients with 
NPDR (C) compared with patients with PDR (D) and patients with 
quiescent PDR after retinal photocoagulation (JE). Specificity of reac­
tion was demonstrated by the absence of staining after incubating 
sections with the primary antibody that was preabsorbed with the 
recombinant antigen (F).
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tion increases expression of angiogenesis inhibitors such 
as PEDF, thereby further suppressing neovascular activity. 
Indeed, PEDF expression was initially induced by hyper- 
oxia in neonatal mice (7). However, the patients in our 
study still exhibited intraocular proliferative activity re­
quiring intraocular surgery. PEDF concentrations of pa­
tients after retinal scatter photocoagulation remained 
below those of control patients, thereby possibly explain­
ing further existing proliferative activity in the subjects 
investigated.
A receptor for PEDF has not yet been identified, al­
though radio-ligand binding studies in retinoblastoma cells 
and cerebellar granule neurons suggest a PEDF-specific 
receptor (13). Until now there has been no information 
about binding properties of putative receptors on vascular 
cells, putative binding proteins, or specific biological ac­
tivities on different vascular cell types. Intraocular levels 
in mice are as high as 90 nmol/I. Despite these comparably 
high levels, systemically administered PEDF was able to 
completely inhibit aberrant retinal angiogenesis in a model 
of ischemia-induced proliferative retinopathy (8). This 
clearly indicates that increasing PEDF levels in the murine 
eye by systemic substitution is therapeutically effective. 
Our results with a loss of PEDF in humans strongly 
suggest that a similar PEDF-based treatment might be a 
promising therapeutic approach in patients with neovas- 
cularizing eye disease. Clearly, further investigations are 
needed to identify the exact mechanisms of PEDF release, 
PEDF-induced biological effects, and possible PEDF bind­
ing to putative binding proteins in the vitreous, such as 
that described for IGFs.
In conclusion, PEDF meets the criteria hypothesized for 
an ischemia-suppressed antiangiogenic factor (1). This 
principle, with obvious therapeutic impact, has been con­
firmed in animal studies (8). Here we suggest that the loss 
of a nuyor angiogenesis inhibitor in the eye, PEDF, has a 
central role in vivo in humans in mediating the angiogenic 
response of retinal ischemia, such as that seen in PDR and 
other ischemic retinal disorders. In addition to the previ­
ously observed changes in angiogenic growth factors such 
as VEGF, our data support the hypothesis that an imbal­
ance in the angiogenic ratio between angiogenic and 
antiangiogenic growth factors contributes significantly to 
the development of retinal neovascularization. Our data 
might potentially induce further investigations into the 
effectiveness of PEDF substitution in humans. Further 
characterization of ischemia-regulated PEDF expression 
and its biological effects should offer hopeful new thera­
peutic approaches to prevent blindness in patients with 
neovascularizing eye disease.
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EXTENDED REPORT
Vascular endothelial growth factor C promotes survival of 
retinal vascular endothelial cells via vascular endothelial 
growth factor receptor-2
Bojun Zhao, Gill Smith, Jun Cai, Aihua Ma, Mike Boulton
Br J Ophthalmol 2007 ;91:538-545. doi: 10.113 6 /b jo .2 0 0 6 .101543
Aim: To determine vascular endothelial growth factor C (VEGF-C) expression in retinal endothelial cells, its 
antiapoptotic potential and  its putative role in diabetic retinopathy.
Method: Cultured retinal endothelial cells and pericytes were exposed to tumour necrosis factor (TNF)a and 
VEGF-C expression determined by reverse transcriptase-polymerase chain reaction. Secreted VEGF-C 
protein levels in conditioned media from endothelial cells were examined by western blotting analysis. The 
ability of VEGF-C to prevent apoptosis induced by TNFa or hyperglycaemia in endothelial cells was assessed 
by flow cytometry. The expression of VEGF-C in diabetic retinopathy was studied by immunohistochemistry of 
retinal tissue.
Result: VEGF-C was expressed by both vascular endothelial cells and pericytes. TNFa up regulated both 
VEGF-C and vascular endothelial growth factor receptor-2 (VEGFRJ-2 expression in endothelial cells in a  
dose-dependent manner, but had no effect on VEGFR-3. Flow cytometry results showed that VEGF-C 
prevented endothelial cell apoptosis induced by TNFa and hyperglycaemia and that the antiapoptotic effect 
was mainly via VEGFR-2. In pericytes, the expression of VEGF-C mRNA remained stable on exogenous TNFa 
treatment. VEGF-C immunostaining was increased in retinal vessels in specimens with diabetes compared 
with retinal specimens from controls without diabetes.
Conclusion: In retinal endothelial cells, TNFa stimulates the expression of VEGF-C, which in turn protects 
endothelial cells from apoptosis induced by TNFa or hyperglycaemia via VEGFR-2 and thus helps sustain 
retinal neovascularisation.
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Vascular endothelial growth factor A (VEGF-A) plays a key part in diabetic retinopathy by increasing retinal vascular permeability and inducing neovascularisation. However, 
the inhibition of VEGF-A only partially decreases neovascular­
isation and vessel hyperpermeability,1 suggesting that other 
VEGF family members may also be involved in this process.2 3
VEGF-C is a member of the VEGF family that displays a high 
degree of homology with VEGF-A.4 The VEGF-C precursor 
binds only vascular endothelial growth factor receptor 
(VEGFR)-3, whereas the fully processed VEGF-C ligand can 
bind and activate both VEGFR-2 and VEGFR-3.5 VEGF-C 
stimulates proliferation and migration of blood vascular 
endothelial cells5 and promotes release of nitric oxide and 
plasminogen activator from endothelial cells.6 7 In animal 
models, VEGF-C induces angiogenesis and increases vascular 
permeability.7 * Furthermore, high expression of the VEGF-C 
protein and gene has been found in different vascularised 
tumour tissues.*"" The activation of both VEGFR-2 and VEGFR- 
3 has been implicated in angiogenesis,12 13 and VEGFR-3 is 
present in different vascular beds including the retinal 
vasculature.1415
The pathogenesis of diabetic retinopathy may be correlated 
with chronic subclinical inflammation,16 and anti-inflammatory 
drugs have been shown to prevent early diabetic retinopathy via 
tumour necrosis factor (TNF)a suppression.17 TNFa has been 
found in human retinas with proliferative eye diseases18"20 and 
in animal models of retinal neovascularisation.21 Furthermore, 
hyperglycaemia also plays an important part in the onset and 
progression of diabetic retinopathy by inducing apoptosis of 
vascular cells, advanced glycation end product deposition and 
up regulation of angiogenic factors.22-24
This paper reports that VEGF-C can promote survival of 
retinal endothelial cells and that this can be regulated by both 
TNFa and hyperglycaemia.
MATERIALS AND METHODS 
R eagents
Recombinant TNFa, an anti-VEGFR-2 neutralising antibody, 
recombinant VEGF-C wild type (which binds both VEGFR-2 
and VEGFR-3) and VEGF-C (Cysl56Ser; a selective agonist of 
VEGFR-3) were obtained from R&D Systems Europe 
(Abingdon, UK). Anti-VEGF-C antibody was from Santa Cruz 
(UK). For immunohistochemistry, an affinity-purified goat 
polyclonal antibody raised against the carboxy terminus of the 
VEGF-C precursor of human origin (c-20) was obtained from 
Autogen Bioclear (Caine, Wiltshire, UK). TRIzol was from 
Invitrogen (Glasgow, UK), and polymerase chain reaction 
(PCR) Reddy Mix and Master Mix Kit were purchased from 
Abgene (UK). Vybrant apoptosis Assay Kit was from Molecular 
Probes (UK). All other materials were from Sigma unless 
otherwise stated.
Cell culture
Primary cultures of bovine microvascular retinal endothelial 
cells (MECs) and pericytes were isolated as described pre­
viously.25 Endothelial cells were maintained in an endothelial
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
MEC, microvascular retinal endothelial cell; PCR, polymerase chain 
reaction; PDR, proliferative diabetic retinopathy; RT-PCR, reverse 
transcriptase-polymerase chain reaction; siRNA, small interfering RNA; 
TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor; 
VEGFR, vascular endothelial growth factor receptor
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cell basal medium with growth supplement (TCS Works, 
Buckingham, UK). Cells were characterised by their cobble­
stone appearance and expression of factor VIII antigen.” 
Pericytes were cultured in Eagle's minimal essential medium 
(GibcoBRL, Paisley, UK) containing 10% fetal calf serum. 
Pericytes were identified and distinguished from endothelial 
cells by their size, irregular morphology and negative staining 
for factor VIII.” Both cell types were used between passages 1 
and 3 for all experiments.
To ensure cross species recognition of VEGFRs, primary 
cultures from human donor eyes were obtained from the Bristol 
Eye Bank, Bristol, UK, and used in accordance with the tenets 
of the Declaration of Helsinki. The cultures were isolated and 
maintained as described above and used for the apoptosis 
studies within five passages.
TNFa treatm ent
For gene and protein expression studies, cells were treated with 
different concentrations of TNFa for up to 6 h. For time- 
dependent studies of TNFa treatment, cells were incubated 
with 10 ng/ml TNFa at different time points.
Reverse transcrip tase-p o lym erase  chain  reaction
To investigate gene expression of VEGF-C and its receptors, 
total RNA was isolated from endothelial cells and pericytes 
exposed to different experimental conditions, using the 
isolation kit TRIzol, and then analysed by reverse transcrip­
tase-polymerase chain reaction (RT-PCR) using the First Strand 
Synthesis Kit and PCR ReddyMix according to the manufac­
turer's protocol. Equal quantities of total RNA were used from 
different samples. The primers for VEGF-C were according to 
the sequences of bovine VEGF-C from GenBank. The oligonu­
cleotide primers for amplification of VEGF-C cDNA were 5'- 
GAA CAA GGC TTA TGC AGG CAA AG -3' and 5 '-CCA CAT 
CTG TAG ACG GAC ACA C-3'. The resultant PCR product was 
348 bp long. The primers for VEGFR-2 were from Berisha et al26 
and VEGFR-3 was from Pepper et al.* Glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) was used as the internal 
control. The sequences were 5'-TGT TCC AGT ATG ATT CCA 
CCC-3' and 5'-TCC ACC ACC CTG TTG CTG TA-3', and gave an 
850 bp amplimer. The cDNA was amplified using the PCR 
Master Mix, each cycle consisting of 20 s at 94*t, 30 s at 55°C 
for amplifying VEGF-C and GAPDH cDNA, 5I t  for VEGFR-2 
cDNA, 5 6 t for VEGFR-3 cDNA and 60 s at 7 2 t .  All the 
samples were amplified in a linear amplification range 
established using a serial cDNA dilution and varying the 
number of cycles. PCR products were electrophoresed on to a 
1.2% agarose gel containing ethidium bromide and visualised 
under ultraviolet light. The relative intensities of the bands 
were quantified by densitometric analysis.
Im m unoprecipitation and w estern  b lotting
To measure VEGF-C protein, preconfluent MECs were starved 
overnight in basal medium containing 1% fetal calf serum, after 
which either 1 or 10 ng/ml TNFa was added to the basal 
medium. De novo protein synthesis was blocked by the addition 
of 3.6 pM cycloheximide. Cells were exposed to different 
conditions for 24 h, the conditioned media was collected and 
centrifuged to remove cell debris. The protein concentrations 
were determined by the BCA protein assay (Pierce, UK). The 
medium with equal quantity of proteins was immunoprecipi- 
tated by incubation with an anti-VEGF-C antibody, and then 
protein A/G-agarose (Santa Cruz Biotechnology, USA). The 
immunoprecipitates were subjected to sodium dodecyl sul- 
phate-polyacrylamide gel electrophoresis and proteins trans­
ferred on to nitrocellulose membranes. The membranes were 
probed with an anti-VEGF-C antibody followed by incubation
5 3 9
with secondary antibody conjugated with horseradish peroxide. 
The enhanced chemiluminescence reaction system (Santa Cruz, 
UK) was used to visualise the bands.
A poptosis a ssa y
Apoptosis was evaluated using the Vybrant Apoptosis Assay Kit 
based on annexin-V binding to phosphatidylserine exposed on 
the outer leaflet of the plasma membrane lipid bilayer of cells. 
MECs were treated with either 100 ng/ml TNFa or 30 mM 
glucose in the presence or absence of 200 ng/ml VEGF-C for 
48 h in culture medium. The cells from different treatments 
were subjected to the apoptosis assay according to the 
manufacturer's instructions. The samples were analysed using 
a fluorescent activated cell sorting 440 Flow Cytometer (Becton 
Dickinson, Oxford, UK). Viable cells were double-negative 
stained, early apoptotic cells stained positive for annexin V and 
negative for propidium iodide, whereas, late apoptotic/necrotic 
cells were double-positive stained for annexin V and propidium 
iodide. To define the role of VEGFR-2 in the anti-apoptotic 
effect of VEGF-C, 60 ng/ml anti-VEGFR-2 antibody was added 
to the culture medium for 1 h before incubation with 100 ng/ml 
TNFa and 200 ng/ml VEGF-C, or 30 mM glucose and 200 ng/ml 
VEGF-C. Anti-VEGFR-2 antibody alone acted as a control. To 
observe whether VEGFR-3 had an anti-apoptotic function, 
200 ng/ml VEGF-C (Cysl56Ser; a selective agonist of VEGFR-3) 
was administrated together with 100 ng/ml TNFa for 48 h.
To block the basal secretion of VEGF-C, cells were transfected 
with either VEGF-C small interfering RNA (siRNA) or 
scrambled siRNA for 72 h and then incubated with 100 ng/ml 
TNFa for 48 h. siRNA duplexes were designed and synthesised 
by Dharmacon Research (Lafayette, Colorado, USA) to target 
the bovine sequence of VEGF-C 5'-ACA GAG ATC TTA AGA 
AGT A-3'. The premade siRNA (scramble II; Dharmacon) was 
used as a negative control. Cells were transfected with siRNA 
duplexes using DharmaFECT 1 (Dharmacon) at a final RNA 
concentration of 100 nmol/1 according to the manufacturer's 
protocol. To determine the efficiency of transfection, the 
medium from parallel samples was collected and subjected to 
immunoprecipitation and western blotting after 24-h of 
incubation.
Im m unohistochem istry
A total of 47 eyes enucleated and fixed in 10% neutral-buffered 
formalin within 10 h after death were obtained from the 
National Disease Research Interchange, Philadelphia, USA. All 
procedures were performed according to the Declaration of 
Helsinki. Eyes were categorised by an ophthalmologist based on 
fundus appearance as normal (no known ophthalmic disease, 
no history of diabetes, no abnormalities on biomicroscopy), 
diabetic with no overt retinopathy, diabetic with intraretinal 
changes but no evidence of proliferative diabetic retinopathy 
(PDR), diabetic with preretinal PDR and diabetic with scatter 
laser photocoagulation but no evidence of residual PDR.14
Immunohistochemistry was performed on 5 pm sections as 
described previously.14 Sections were incubated overnight at 4 t  
with a polyclonal VEGF-C antibody (2 pg/ml). The negative 
control was the substitution of the primary antibody with an 
inappropriate rabbit IgG. After washing, sections were incu­
bated for 30 min with biotinylated rabbit anti-goat IgG, then 
for a further 30 min with alkaline phosphatase reaction 
mixture (Dako) and incubated with Fast Red TR/naphthol 
AS-MX substrate. Slides were counterstained with Mayer's 
haematoxylin. The degree and pattern of immunostaining was 
assessed by two blinded observers. The intensity of staining was 
graded qualitatively as background, weak, moderate or intense 
(corresponding to the highest level of immunoreactivity).
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Figure 1 The regulation of vascular endothelial growth factor-C (VEGF-C) mRNA expression by tumour necrosis factor (TNF)a in microvascular endothelial 
cells and pericytes. (A) Dose-response of mRNA induction of VEGF-C by TNFa in microvascular retinal endothelial cells (MECs). MECs were stimulated with 
the indicated concentrations of TNFa for 6 h. (B) Time dependence of VEGF-C mRNA induction by TNFa. MECs were stimulated with TNFa (10 ng/ml) for 
0 -2 4  h. (C) Expression of VEGF-C mRNA in bovine retinal pericytes after exposure to different concentrations of TNFa for 6 h. The isolated total RNA from 
different treatments was subjected to reverse transcriptase-polymerase chain reaction and polymerase chain reaction products were analysed by agarose 
gel electrophoresis. Band intensities were quantified by laser densitometry. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was the internal control. 
Representative results from three separate experiments a re  shown. Vertical bars represent mean (standard error of the mean); **p<0.01, indicating 
significant difference between treatment and controls.
S ta tistica l a n a ly s is
The results represent the m ean of at least three separate 
experiments. Statistical analysis was carried out using an 
unpaired Student's t test. Significance was defined as p<0.05. 
All numerical results are expressed as m ean (standard error of 
the mean).
RESULTS
R egulation  of VEGF C mRNA e x p re s s io n  by  TNFa in 
m ic ro v ascu la r e n d o th e lia l cells a n d  p e r ic y te s
RT-PCR analysis showed that VEGF-C mRNA was expressed in 
MECs. TNFa stimulated the expression of VEGF-C mRNA in a 
dose-dependent manner, w ith a maxim al 4.6 (0.5)-fold 
increase with 10 ng/ml TNFa (fig 1A). Stimulation of cells 
with 10 ng/ml TNFa increased VEGF-C mRNA expression in a 
time-dependent m anner w ith a m axim um  at 6 h. Beyond 6 h, 
VEGF-C expression decreased, but even after 24 h stimulation, 
the expression of VEGF-C mRNA was still higher than  that 
with no stimulation (fig IB). Pericytes expressed VEGF-C 
mRNA, but TNFa had no regulatory effect on this expression 
(fig 1C).
In c re a se d  e x p re ss io n  of VEGFR-2, bu t no t VEGFR-3 
mRNA in MECs c h a llen g e d  w ith TNFa
RT-PCR results showed that MECs expressed both VEGFR-2 
and VEGFR-3 mRNA (fig 2). TNFa induced an increase of 
VEGFR-2 mRNA in a dose-dependent manner. The levels of 
VEGFR-2 mRNA began to increase at 1 ng/ml TNFa and 
reached a maximum level at 50 ng/ml TNFa (fig 2A). By 
contrast, the expression of VEGFR-3 was not modified by 
exposure to TNFa (fig 2B). The expression of VEGFR-2 and 
VEGFR-3 mRNA was not detectable in pericytes (data not 
shown).
TNFu in c re ase s  VEGF C p ro te in  sy n th es is  a n d  sec re tio n  
in MECs
Western blotting showed that the secreted peptide was present 
at high amounts, with a m aximum 4.1 (0.4)-fold increase in the 
medium under TNFa conditions compared with the medium of 
control cultures (fig 3A). Treatment with cycloheximide 
considerably reduced the am ount of VEGF-C in the conditioned 
medium. This result indicates that increased am ounts of VEGF- 
C released by MECs in response to TNFa treatm ent are due to
www.bjophtbalmol.com
Downloaded from bjo.bmj.com on 26 September 2007
VEGF-C p rom otes en d o th e lia l cell survival 541
A
VEGFR-2
GAPDH
S 50
jo  25
0 0.1 1 10 50  100
TNFa (ng/ml)
VEGFR-3
GAPDH
20
10m m
0 0.1 1 10 50
TNFa (ng/ml)
Figure 2 Tumour necrosis factor (TNF)a stimulates the expression of 
vascular endothelial growth factor receptor (VEGFR)-2 mRNA, but not 
VEGFR-3 in microvascular retinal endothelial cells (MECs). Total RNA was 
isolated 6 h after stimulation by different concentrations of TNFa. Reverse 
transcriptase-polymerase chain reaction w as performed and polymerase 
chain reaction products were analysed by agarose gel electrophoresis. The 
signal intensity was determined by densitometry, and the amount of 
VEGFR-2/VEGFR-3 was normalised for the amount of glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) present. Representative results from a t 
least three separate experiments are shown. Vertical bars represent mean 
(standard error of the mean); *p<0.05  and **p<0.01, indicating 
significant difference between treatment and controls. (A) Expression of 
VEGFR-2 mRNA; (B) expression of VEGFR-3 mRNA.
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Figure 3 Western blotting analysis of de novo vascular endothelial 
growth factor-C (VEGF-C) protein synthesis. (A) Microvascular retinal 
endothelial cells (MECs) were treated with 1 or 10 ng/ml tumour necrosis 
factor (TNF)-a for 24 h. (B) MECs were treated with 10 ng/ml TNFa and 
3 .6 pM cyclohexamide (CHX) for 24 h, and 10 ng/ml TNFa alone was the 
control. Conditioned media were immunoprecipitated using a  polyclonal 
antibody raised to VEGF-C and the immunoprecipitates electrophoresed by 
12% sodium dodecyl sulphate-polyacrylamiae gel electrophoresis, followed 
by blotting on a  nitrocellulose membrane. Positive bands were visualised by 
an enhanced chemiluminescence reaction detection system. Band intensity 
for VEGF-C was quantified by laser densitometry from a t least three 
separate experiments. Vertical bars represent mean (standard error of the 
mean); **p<0.01, indicating significant difference between treatment and 
controls.
increased protein synthesis rather than  an increased release of 
VEGF-C from cell storage (fig 3B)
VEGF C p rev en ts  TNFa an d  h y p e rg ly c a e m ia - in d u c e d  
ap o p to s is  in MECs an d  th is e ffec t occu rs  m ain ly  v ia 
VEGFR-2
Flow cytometry showed that TNFa induced apoptosis/necrosis 
and that this was markedly inhibited by VEGF-C. The cell 
population at the late stage of apoptosis/necrosis reduced from 
56.5% (1.38%) to 28.1% (0.7%) w hen VEGF-C was present 
(fig 4A-C). The apoptolic/necrotic population increased to 82.7% 
(2.8%) after exposure to TNFa in cells treated with VEGF-C 
siRNA compared with 57.9% (1.72%) in cells treated with 
scrambled siRNA (fig 4D,E). The efficiency of knockdown of 
VEGF-C expression in culture m edium  with RNAi was confirmed 
using immunoprecipitation and western blotting (fig 4L).
To identify which of the two VEGF-C receptors was 
responsible for the anti-apoptotic effect of VEGF-C, VEGFR-2 
was blocked by neutralising antibody or cells were treated with 
a VEGFR-3 agonist. After neutralising VEGFR-2, the protective 
effect of VEGF-C on TNFa-induced apoptosis was considerably
reduced. The population of apoptotic/necrotic cells was 
increased from 28.1% (0.7%) to 53.2% (1.41%) (fig 4C,F). 
VEGFR-2-neutralising antibody alone had no effect on promot­
ing apoptosis/necrosis (fig 4G). After addition of VEGF-C 
(Cysl56Ser), there was no protective effect on TNFa-induced 
apoptosis. The population of apoptotic/necrotic cells was 55.7% 
(2.1%), and showed no statistically significant change from 
cells treated with TNFa alone (fig 4B,H). After addition of 
VEGF-C, the percentage of apoptosis/necrosis induced by high 
glucose was reduced from 47.1% (1.6%) to 23.6% (1.2%) 
(fig 41,J) and this rescue effect was abolished when VEGFR-2 
was blocked by its neutralising antibody (fig 4K). Results were 
similar for both hum an and bovine MECs.
E xpression  of VEGF-C in d iab e tic  re tin o p a th y
Weak to moderate staining for VEGF-C was observed in the 
vessels of non-diabetic retinas and in retinas without overt 
retinopathy; staining was increased (moderate to intense) 
compared with non-diabetic retinas once intraretinal changes 
became obvious (4 of 5 eyes) and markedly increased in PDR 
retinas (6 of 6 eyes; table 1, fig 5). Intense staining was also
www.biophthalmol.com
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Figure 4  (A—K) Vascular endothelial 
growth factor (VEGF)-C prevents tumour 
necrosis factor (TNF)ot-induced apoptosis via 
vascular endothelial growth factor receptor 
(VEGFR)-2. Microvascular retinal endothelial 
cell (MECs) were given different treatments 
for 48 h. The cells were then stained with 
annexin V-fluorescein isothiocyanate 
conjugate (FITC) containing propidium 
iodide (PI). Data show two-parameter 
analysis of fluorescence intensity of annexin 
V and PI. Annexin V/PI-negative cells were 
counted as viable cells (lower left quadrant). 
All measurements were performed in 
triplicate. Representative results from at least 
three separate experiments are shown. (A) 
Control; (B) TNFa; (C) TNFa+VEGF-C; (D) 
TNFa+VEGF-C siRNA; (E) TNFa+scrambled 
siRNA; (F) TNFa+VEGF-C+anfi-VEGFR-2 
antibody; (G) anti-VEGFR-2-neutralising 
antibody alone; (H) TNFa+VEGF-C 
(Cys156Ser); (I) high glucose; (J) high 
glucose+VEGF-C; (K) high glucose+VEGF- 
C+anti-VEGFR-2 antibody. Numbers in the 
quadrant are the percentage of FiTC+/PI+ 
cells. (L) Knockdown of the expression of 
VEGF-C in culture medium from small 
interfering (si)RNA-treated MECs. Culture 
medium mom either VEGF-C siRNA or 
scrambled siRNA-treated cells was collected 
after 24  h of incubation and equal quantity 
of proteins was subjected to 
immunoprecipitation and western blotting. 
Positive bands were auantified by laser 
densitometry from at least three separate 
experiments. Vertical bars represent mean 
(standard error of the mean); ^ < 0 . 0 1 ,  
indicating significant difference between 
VEGF-C siRNA treatment and scrambled 
siRNA.
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observed in the vessels of preretinal mem branes. After laser 
treatment, the levels of VEGF-C in the retinal vessels were 
reduced to weak staining in 11 of 14 eyes. In addition, increased 
staining was observed in the ganglion cell layer of diabetic 
retinas both with and w ithout intraretinal changes as compared 
with the minimal staining in non-diabetic retinas. Staining was 
weak or absent in the choroidal vessels, the RPE, the 
photoreceptors, and the outer and inner retinal layers 
(table 1). The variability of staining w ithin retinas of the same 
group did not show a correlation w ith donor age, the type of 
glycaemic control in the case of the diabetic groups or time after 
death.
DISCUSSION
In this study, we showed that TNFa strongly up regulates the 
expression of VEGF-C in MECs and that this induction is both
543
time dependent and dose dependent. The dose-response study 
showed that the stimulatory effect of TNFa was produced at a 
concentration as low as 0.1 ng/ml, which is w ithin the range of 
TNFa concentrations in vitreous fluid from patients with active 
PDR." VEGFR-2 was also up regulated by TNFa, whereas the 
expression of VEGFR-3 mRNA remained stable with various 
TNFa treatments, suggesting that in our experimental system 
VEGF-C may exert its angiogenic effect mainly via increasing 
VEGFR-2 rather than VEGFR-3. This increase in VEGFR-2 may 
also be important in enhancing VEGF-A-induced angiogenesis. 
After blockade of VEGFR-2, the antiapoptotic effect of VEGF-C 
was abrogated, whereas the activation of VEGFR-3 by VEGF-C 
(Cysl56Ser) did not attenuate TNFa-induced apoptosis show­
ing that VEGFR-2 is the dom inant receptor for VEGF-C action 
in MECs. Our data support the observations that VEGF-C, 
which was originally thought to be a potent inducer of
Figure 5 Immunolocalisation of vascular endothelial growth factor (VEGF)-C in the diabetic retina. VEGF-C staining is shown for representative retinal 
sections. W eak to moderate VEGF-C immunostaining w as localised to non-diabetic retina (A) and diabetic retina with no obvious intraretinal vascular 
changes (B). By contrast, moderate to intense VEGF-C staining was observed in the diabetic retina with obvious intraretinal vascular changes but no 
evidence of proliferative diabetic retinopathy (PDR; C) and in the diabetic retina with PDR (D). After laser treatment, the only weak immunostaining for VEGF- 
C was observed (E). Immunostaining was raised in later-stage diabetic retinopathy and was generally confined to the intraretinal vessels (IRV).
Immunoreactivity was abolished in the control retina processed with omission of primary antibody (F). Magnification x200. PRM, polynomial regularisation 
method.
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Table 1 Mean (SD) intensity of vascular endothelial growth factor-C in the retina and choroids
Outer nuclear Inner nuclear Ganglion cell
Choroid RPE layer layer layer Retinal vessels
Non-diabetic (n ■ 14) 0.6  (0.8) 0.1 (0.4) 0 .4  (0.8) 0 (0 ) 0.1 (0.4) 0.3 (0.4) 1.1 (1.2)
No overt retinopathy (n ■ 12) 0.8 (0.6) 0.1 (0.3) 0 .3  (0.7) 0 (0 ) 0.1 (0.3) 1.2 (1.0) 1.6(1.1)
Intraretinal changes (n»5) 0 .8  (0.8) 0 (0 ) 0 .6  (0.9) 0.2 (0.5) 0.6 (0.9) 1.2 (1.1) 2.4 (0.9)
PDR (n -6 ) 0 .8  (0.8) 0.3 (0.5) 0 .3  (0.5) 0 .2  (0.4) 0.3 (0.5) 0.3 (0.5) 2.5 (0.5)
Laser, no residual PDR (n«14) 0 .6  (0.6) 0 (0 ) 0 .4  (0.6) 0 .4  (0.9) 0.3 (0.5) 0.4 (0.5) 0.8 (1.2)
PDR, proliferative diabetic retinopathy; RPE,retinal pigment epithelium. 
0, background; 1, mild; 2, moderate; 3, intense staining.
lymphangiogenesis,” “ may also act as a survival factor to 
suppress apoptosis in vascular endothelial cells. VEGF-C has 
been shown to be important in vascular angiogenesis in other 
vascular beds,7 ” and the response can be robust and 
indistinguishable from that observed using VEGF-A.’0 ” The 
existence of VEGF-C in human retinas and the expression of 
VEGF-C in the retinal vasculature that increases in diabetic 
retinopathy further support a role for VEGF-C in diabetic 
retinopathy. Interestingly, laser photocoagulation, a proved 
treatment for reversing neovascularisation in PDR, resulted in a 
marked reduction in VEGF-C protein expression.
Our data showed that mRNA coding for VEGF-C was present 
not only in endothelial cells but also in pericytes. However, the 
regulatory effects differ between the two principal types of 
microvascular cells. The VEGF-C gene remained constitutively 
expressed in pericytes on adding various concentrations of 
TNFa, but VEGF-C is unlikely to signal in an autocrine fashion 
as only VEGFR-1 is expressed in pericytes” TNFa is a 
macrophage/monocyte-derived pluripotent mediator. Whether 
TNFa plays a part in angiogenesis may be highly dependent on 
its concentration.M TNFa has been shown to be a powerful 
activator of angiogenesis in vivo in several animal models when 
used at appropriate doses.”"’7 Previous studies show that high 
glucose or advanced glycation end products induce the 
expression of proinflammatory cytokines, including TNFa from 
monocytes and macrophages,’* ” and TNFa may have an 
important role in mediating angiogenesis in diabetic retino­
pathy.'*"20 The angiogenic effect of TNFa may be due to the 
generation of secondary mediators."41
In conclusion, increased expression of VEGF-C protein in the 
retinal vasculature of diabetic retinopathy suggests that VEGF- 
C may have an important role in its pathogenesis.
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